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Abstract 
Thymine DNA glycosylase (TDG) is an essential DNA repair enzyme mediating excision 
of uracil and thymine mispaired with guanine within CpG contexts.  Unrepaired, these 
lesions result in G:C to A:T transitions which are major contributors to genome 
instability.  Interestingly, TDG interacts functionally with transcriptional regulators and 
participates in directed cytosine demethylation at promoters.  TDG is subject to multiple 
post-translational modifications (PTM) and we undertook an analysis of how these 
regulate TDG function.   
Initially, we examined TDG regulation by small ubiquitin-like modifier (SUMO) and 
identified a novel SUMO binding motif (SBM1, residues 144-148).  We hypothesized 
that SBM1, along with SBM2 (319-322), would facilitate non-covalent SUMO 
interactions upon conjugation of SUMO (sumoylation) to lysine 341, altering TDG 
conformation and function.  Biochemical and cell based analyses supported our 
hypothesis, showing SUMO interactions allosterically regulate TDG protein-protein and 
substrate interactions, altering TDG subnuclear localization and enzymatic function.  
Furthermore, sumoylation drastically reduced acetylation of TDG occurring at lysines 70, 
94, 95, and 98.   
Secondly, we examined TDG regulation by phosphorylation and demonstrated that 
serines 96 and 99 are phosphorylated by protein kinase C α in vivo.  Biochemical analysis 
of covalently modified recombinant TDG showed that acetylation and phosphorylation of 
TDG are mutually exclusive and both are suppressed by TDG-DNA interactions. 
Furthermore, acetylated TDG did not interact stably with DNA or efficiently excise 
thymine from G:T mispairs, while phosphorylated TDG was indistinguishable from 
unmodified protein.   
iv 
 
Lastly, we examined TDG regulation in aging cells.  Immunostaining showed TDG 
redistributed from nucleus to cytoplasm in aged cells.  Interestingly, treatment with 
histone deacetylase inhibitors resulted in similar redistribution and immunoblotting 
indicated that an increase in TDG modification consistent with sumoylation or 
monoubiquitination had occurred.  Similar results were obtained by exposing cells to 
oxidative stress.  Analysis of a sumoylation-minus mutant of TDG identified sumoylation 
as an important regulator of TDG localization.  Interestingly, we found extensive 
colocalization of TDG with sites of active transcription which was reduced by phorbol 
ester treatments which surprisingly promoted entry into heterochromatic regions from 
which TDG is generally excluded.  
Together, these findings suggest that TDG function may be regulated by PTM, 
consequently affecting genome stability and expression. 
 
Keywords:  thymine DNA glycosylase (TDG), DNA repair, base excision repair (BER), 
5-methylcytosine, spontaneous hydrolytic deamination, epigenetic modification, 
carcinogenesis, acetylation, phosphorylation, sumoylation. 
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Chapter 1:  Introduction 
1.1 Overview 
Maintenance of genomic stability is crucial to ensure the fidelity of information contained 
within nucleotide sequences comprising genes and corresponding regulatory regions.  The 
integrity of the genome is constantly undermined by DNA damage that occurs via distinct 
mechanisms, which potentially generate harmful mutations.  This is problematic as 
precise regulation of gene expression is critical for normal development and homeostasis.  
Gene expression is dynamic process, tightly regulated and highly responsive to the 
cellular milieu.  Occurring at every stage of the process, regulation of gene expression 
may be facilitated by proteins, RNA, and regulatory regions of the gene.  Which of these 
is the predominant regulator of gene expression has been explored in studies performed 
on a mouse model of Down syndrome in which mice bear a copy of human chromosome 
21.  Despite being regulated by mouse proteins/RNAs in the mouse cellular milieu, the 
human chromosome 21 recruited transcription factors, directed modification of chromatin 
structure, and expressed genes as they would be in human cells rather than they were on 
the mouse equivalent chromosome.  This strongly suggested that the predominant 
regulator of gene expression is the primary sequence of the gene itself rather than the 
local gene regulatory proteins, RNA, and cellular context that expression occurs within 
(337).  This finding highlights the importance of ensuring stability of the primary genome 
sequence. 
There are four major sources of DNA damage.  First, DNA is an inherently unstable 
molecule and decays over time, predominantly through spontaneous hydrolysis creating 
abasic sites and deamination products  (202).  Secondly, metabolism produces highly 
reactive byproducts which create diverse types of DNA damage (67, 286).   Thirdly, 
mutations may also arise due to deletion or misincorporation of DNA bases during 
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replication or DNA repair.  Lastly, exogenous agents such as industrial chemical vinyl 
chloride may also damage DNA (11, 31, 329).  It is estimated that there are as many as 
105 spontaneous nucleotide damage events per day in each cell (202).  A large body of 
evidence indicates that DNA damage causes mutations which are associated with genetic 
diseases, aging, and carcinogenesis (20, 43, 250).  To ensure stable maintenance and 
inheritance of genetic material, several DNA repair pathways have evolved to repair 
DNA lesions.  The pathway tasked with correcting the products of oxidative stress is the 
base excision repair (BER) pathway.  BER is initiated by DNA glycosylase specific for 
the damaged base, and the context in which it is found.  The substrate specificity of most 
glycosylases is overlapping, creating redundancy between the glycosylases which results 
in subtle effects in cell culture and animal models when an individual glycosylase is 
deficient.  BER enzyme Thymine DNA glycosylase (TDG) however, is an important 
mediator of genome stability that is unique amongst glycosylases as mice deficient in 
TDG do not develop past mid-gestation (M. Tini, unpublished), indicating that TDG, 
unlike any other glycosylase studied to date, has a non-redundant role in cell function [M. 
Tini, unpublished, (44, 60, 83, 128)]. 
TDG is subject to multiple post-translational modifications (PTMs).  PTMs such as 
phosphorylation and acetylation have long been recognized as crucial modulators of cell 
signaling and operate through diverse mechanisms to regulate protein function.  PTM can 
act on substrate proteins to alter electrostatic charge, affecting conformation or enzymatic 
function.  This may lead to changes in affinities for protein and non-protein partners, 
resulting in altered association with protein complexes.  PTM have also been shown to be 
important regulators of subcellular localization.  The focus of this thesis is an examination 
of how multiple PTM may act in concert to regulate protein function to affect genome 
stability and gene expression.  Specifically, we focus on how PTM act to regulate TDG 
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function through modulation of subcellular localization, enzymatic function, and 
intra/intermolecular interactions.   
Mechanisms of DNA damage  
Watson and Crick were the first to correctly elucidate the structure of DNA as a double 
helix comprising two anti-parallel polynucleotide strands made continuous by linkage of 
the phosphate backbone and the two strands are held together by hydrogen bonding 
between the DNA bases adenine (A), thymine (T), cytosine (C), and guanine (G) such 
that pairing is always between A and T (A:T) or G and C (G:C) (333) (Figure 1.1.A).  
This simple arrangement represents a powerful mechanism for storage and propagation of 
biological information.  Agents which damage DNA do so via diverse chemical reactions 
resulting in alterations to the DNA molecular structure preventing its normal metabolism 
and replication fidelity.  Additional sources of damage may arise due to inherent 
instability of the DNA molecule itself, resulting in spontaneous damage such as 
hydrolytic deamination of cytosine and 5-meC (Figure 1.1.B).  Because of its centrality to 
biological function, DNA damage may potentially affect all biological processes directly 
or indirectly.   
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Figure 1.1.  DNA structure.  A.  The structure of unmodified DNA showing correct 
pairing between adenine (A) and thymine (T); cytosine (C) and guanine (G).  B.  DNA 
damage via hydrolytic deamination of cytosine and 5-methyl-cytosine (5-meC) produces 
uracil (U) and thymine lesions respectively.   
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Hundreds of distinct DNA damage products have been documented making a 
comprehensive discussion of each beyond the scope of this thesis.  However, DNA 
damaging agents may be categorized in four ways.  First, environmental toxins, ranging 
from sunlight and ionizing radiation to food and industrial chemicals, have been shown to 
interact with DNA and produce genotoxic lesions which may be carcinogenic (106, 111, 
194, 339).  Some of these DNA adducts have been proposed to useful biomarkers for 
exposure to environmental toxins as well as risk of carcinogenesis (295, 322).  Secondly, 
cellular metabolism, including oxidative respiration and lipid peroxidation, produces 
reactive oxygen species such as superoxide anions, hydroxyl radicals, and hydrogen 
peroxide.  These are powerful mediators of DNA damage and account for over 100 
different types of DNA damage (41, 150).  Thirdly, DNA is prone to spontaneous 
degradation over time arising from base hydrolysis producing abasic sites, or from 
hydrolytic deamination of bases.  For example, deamination of cytosine, 5-
methylcytosine, guanine, and adenine produces uracil, thymine, xanthine, and 
hypoxanthine, respectively (41, 234, 263).  Mutations may also arise due to deletion or 
misincorporation of DNA bases during replication or DNA repair potentially altering 
coding or gene regulatory sequences.  These may alter regulation of gene expression or 
mRNA processing and may result in the production of aberrant gene products (63, 347) 
[see Table 1.1, adapted from Dalhus et al., 2009 (63)].  
Physical breakage of the DNA double-helix, or DNA double strand breaks (DSBs), may 
be created by ionizing radiation, x-rays, industrial chemicals, reactive oxygen species, 
excessive base excision repair (see below), replication of single strand DNA breaks, 
uncapped telomeres, stalled/collapsed replication forks, as well as through natural process 
related to immunological function.   
Consequences of DNA damage 
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The cell has multiple strategies for responding to DNA damage.  Initial responses to 
damage which may interfere with cellular processes may include initiation of transient 
cell cycle arrest (16, 107, 110, 293, 321).  Specific points for cell cycle arrest are cell 
cycle stages G1, S, G2, and M and may include inhibition of transcription, DNA 
replication, and chromosome segregation.  During this time, cellular DNA repair 
mechanisms attempt to correct the damage (357).  If exposure to DNA damage is too 
severe to allow re-entry into the cell cycle, pre-programmed cell death may occur, or 
alternatively, the cell may enter a type of permanent cell cycle arrest termed senescence 
(1, 95, 190, 196).   When DNA damage persists, it may result in alterations to normal 
DNA sequences which can be incorporated into the genome as mutations.  Mutations in 
different contexts have been shown to contribute to aging and diseases including cancer 
in humans (121, 122, 142, 207).  It is important to note that DNA damage may also be a 
source of biological diversity and its occurrence over time, leads to greater allelic 
diversity and robustness of species.  Without some level of genome instability there 
would be no genetic diversity and the resulting genetic monoculture becomes highly 
susceptible to catastrophic events such as outbreaks of disease (76).     
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DNA repair pathways 
DNA repair occurs through a number of multi-protein pathways: homologous 
recombination (HR), non-homologous end joining (NHEJ), DNA mismatch repair 
(MMR), nucleotide excision repair (NER) (including transcription coupled repair), and 
base excision repair (BER).   An alternative mechanism is available which utilizes a 
single protein to enact repair.  The basic mechanisms underlying these pathways are 
briefly discussed below with emphasis on base excision repair, which is the focus of this 
thesis.  
Direct DNA damage reversal 
Alkylating agents contained in tobacco smoke and grilled food (69, 71) and endogenous 
enzymes (163, 202, 284) induce formation of a variety of methyl-DNA lesions, of which 
O6-methyl-guanine are the most carcinogenic (52, 72, 163, 164, 210, 251, 273, 349).  
DNA-alkyltransferases are capable of reversing this damage through removal of the alkyl 
group in a one step reaction.  For example, O6-methylguanine methyltransferase (MGMT) 
removes aberrant methyl groups from O6-methyl-guanine and O6-methyl-thymine base 
lesions which are then transferred to an internal cysteine residue in a one step reaction 
which results in inactivation of MGMT (204).  Following inactivation, MGMT is 
ubiquitinated and degraded (300, 345).  Some products of alkylation damage are also 
repaired by the nucleotide excision repair pathway (described below) which competes 
with alkyltransferases to repair alkylated bases (285).  In the case of O6-methyl-guanine, 
the lesion is not efficiently repaired by the nucleotide excision repair system because the 
excised methyl-base is easily mistaken for a normal base and may be replaced into the 
position from which it was just excised, causing futile rounds of repair which continue 
until replication allows pairing with cytosine or thymine (62, 80, 165).  The irreversible 
strategy used by MGMT ensures forward progression of the repair step although 
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degradation of MGMT in the final step of repair limits the robustness of MGMT-
mediated repair to the number of molecules of MGMT available.  Once these are 
degraded, new MGMT proteins must be expressed.  The alkylating/methylating 
chemotherapeutic temozolomide is used to capitalize on this limitation as treatment with 
pharmacological doses of temozolomide produces large amounts of MGMT substrate 
DNA damage.  Repair of these lesions exhaust MGMT-mediated repair by depleting the 
cellular compliment of MGMT.  The following rounds of futile mismatch repair then 
contribute to DNA fragmentation and cytotoxicity (62, 80, 139, 165, 252, 309).  Larger 
adducts, such as ethylated guanine, do not fit into the substrate pocket of MGMT and are 
mainly repaired by nucleotide excision repair (see below) (34, 312). 
Homologous recombination and non-homologous end joining 
DNA double strand breaks (DSBs) may be created by ionizing radiation, x-rays, industrial 
chemicals, reactive oxygen species, excessive base excision repair (see below), 
replication of single strand DNA breaks, uncapped telomeres, stalled/collapsed 
replication forks, as well as through class switch recombination – a natural process related 
to immunological function (183, 318).  DSBs are repaired by either homologous 
recombination (HR) or non-homologous end joining (NHEJ) (19).   
Homologous recombination is initiated by alterations in chromatin (chromatin is 
discussed below) structure at DSB sites which activate Mre11/Rad50/Nbs1 (MRN) 
complex.  The MRN complex concurrently binds the ends of the DSB and activates ataxia 
telangiectasia mutated (ATM) kinase, directing it toward the site of breakage.  There, 
ATM, ataxia telangiectasia and Rad3 related (ATR), and DNA protein kinase catalytic 
subunit (DNA-PKCS) phosphorylate histone variant H2AX, marking the DSB.  At the 
DSB ends the MRN complex mediates 5’-3’ strand trimming, leaving 3’ overhangs 
suitable for DNA recombination.  The 3’ overhang is populated by replication protein A 
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(RPA) which recruits RAD51-related proteins XRCC2, XRCC3, RAD51B, RAD51C, 
and RAD51D, forming a filamentous structure.  The sister chromatid is positioned for 
recombination by cohesions and the filamentous RAD51 proteins direct recombination to 
matching sequences.     
Non-homologous end joining is initiated by Ku70/80 heterodimers which bind and align 
the broken DNA ends (46, 331).  Ku70/80 then recruits DNA-PKCS to the DSB site and 
activates its kinase function (348).  Together, DNA-PKCS and Artemis proteins promote 
processing of the DNA ends to produce ends compatible for ligation (218).  Lastly, 
XRCC4 ligates the aligned compatible ends, returning continuity of the strand (113).    
HR is mostly error free due to the presence of an undamaged template whereas NHEJ 
often results in a small gain or loss of nucleotides during end processing to create 
ligatable DNA end fragments (219, 220)  
The pathway chosen for repair of DSBs is highly dependent on which stage of the cell 
cycle the break was detected.  HR is preferred during S and G2 stages of the cell cycle 
when there is a second, undamaged copy of the DNA sequence available due to the 
presence of a sister chromatid.  Otherwise, during G0, G1, and early S-phase NHEJ is 
preferred (86).  Interestingly, the type of break also contributes to the decision of which 
pathway is chosen for repair.  For example, repair of DSBs caused by ionizing radiation 
in G1 are not be repaired by NHEJ.  Instead repair is delayed until S or G2 so that HR 
may take place after DNA replication (12).  The decision to use HR or NHEJ is 
influenced by cell cycle dependent post-translational modification of proteins which may 
direct progression of repair.  For example, CtIP/Sae2 is a substrate for phosphorylation by 
cyclin dependent kinases active during S and G2 and favors initiation of HR over NHEJ 
(152, 287). 
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DNA mismatch repair 
DNA mismatch repair (MMR) primarily addresses mismatches created during DNA 
replication and missed by replication-associated proofreading mechanisms (186).  These 
damages may take the form of single base mismatches and single base loops, or insertion 
and deletion loops (92, 232).  Dysfunction in MMR may lead to microsatellite instability 
and dramatic increases in mutation rates leading to carcinogenesis, particularly hereditary 
nonpolyposis colon cancer (HNPCC) in which 60% of cases examined show germline 
mutations in MMR proteins mutL homolog 1(MLH1) and mutS homolog 2 (MSH2) (94, 
157, 315).   
MMR is initiated by MutSα (consisting of MSH2-MSH6) and MutSβ (consisting of 
MSH2-MSH3) which contact DNA and, along with MutLα (consisting of MLH1 and 
postmeiotic segregation increased 2 (PMS2)) (51), form sliding clamps that scan along 
DNA until they recognize mispaired or DNA bases or loops.  MutSα preferentially 
recognizes single base mismatches or single base loops, whereas MutSβ recognizes 
insertions and deletion loops of 2-8 bases (99, 223, 282).  Once a lesion is identified 
MSH3 or MSH6 along with proliferating cell nuclear antigen (PCNA) (58) direct repair 
toward the damaged strand and a long stretch of the damaged strand is degraded by a 3’-
5’ exonuclease then resynthesized correctly by DNA polymerase δ and PCNA (208).    
Nucleotide excision repair and transcription coupled repair 
Nucleotide excision repair (NER) allows processing of a diverse set of DNA-helix 
distorting lesions.  When used to correct DNA damage during transcription, the process is 
termed transcription-coupled repair (TCR) while all non-transcription-associated NER is 
referred to as global genome (GG) NER (242).  NER is initiated upon detection of a 
disrupted base-pair causing distortion of the DNA helix by the xeroderma pigmentosum, 
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complementation group C-RAD23 homolog B (XPC-hHR23B) complex (303).  Non-
helix-distorting lesions generally are not addressed by NER but by base excision repair 
(see below) (308).  Initiation of TCR occurs when a lesion is sufficient to stop RNA 
polymerase from proceeding at which point it is temporarily stopped by excision repair 
cross-complementing rodent repair deficiency, complementation group 6 (CSB/ERCC6) 
and excision repair cross-complementing rodent repair deficiency, complementation 
group 8 (CSA/ERCC8) proteins to allow NER to proceed.  After stabilizing the paused 
polymerase, CSA and CSB recruit proteins which contribute to NER (85).  From this 
point, NER and TCR follow the same pathway.  Using the helicase activity of its 
xeroderma pigmentosum group B complementing (XPB) and xeroderma pigmentosum D 
(XPD) subunits, the TFIIH transcription factor unwinds approximately 30 base pairs 
surrounding the lesion, at which point xeroderma pigmentosum complementation group 
A (XPA) verifies that repair is needed (38).  If this does not occur, then the NER process 
is halted and reversed (303).  If DNA damage is still detected, replication protein A 
(RPA) then binds the undamaged strand, stabilizing the open DNA helix.  Excision repair 
cross-complementing rodent repair deficiency, complementation group 5 (ERCC5/XPG) 
and excision repair cross-complementing rodent repair deficiency, complementation 
group 1 (ERCC1/XPF) endonucleases then cleave the damaged strand, excising 24-32 
bases containing the damaged base.  The normal DNA replication machinery then 
completes repair by filling in the gap using the undamaged strand as a template.      
Base excision repair  
The process of correcting more subtle, non-helix-distorting mismatches occurs 
predominantly through the base excision repair (BER) pathway (Figure 1.1) (reviewed by 
Hoeijmakers, 2001) (143) and is initiated by lesion-specific DNA glycosylases.  The 
substrate specificities of the glycosylases are partially overlapping so that most lesions 
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may be corrected by more than one glycosylase.  This redundancy, along with the ability 
of TCR (see above) to repair some lesions addressed by BER, is credited with the non-
lethal phenotypes seen in mouse models of glycosylase deficiency (204, 336), with the 
notable exception of TDG (see below) (M. Tini, unpublished).  The glycosylases may be 
divided into two types - monofunctional and bifunctional.  Monofunctional glycosylases 
such as TDG (see below) lack lyase activity which is provided by DNA polymerase β.  
Lyase activity refers to the ability to catalytically break specific chemical bonds (in this 
case, referring to the DNA phosphate backbone) by means other than hydrolysis and 
oxidation, often forming or breaking a double bond in the process.  Bifunctional 
glycosylases such as hOGG1 possess lyase activity and after base excision, cleave the 
phosphate backbone 3’ of the abasic site.  Abasic sites may also occur spontaneously and 
are unstable (98), producing cytotoxic DNA single stranded breaks upon degradation 
(203).  Abasic sites also hinder DNA- and RNA-polymerases, potentially impeding 
replication or transcription or promoting error-prone bypass synthesis (335).  DNA single 
strand breaks are also prone to forming double-strand breaks which are also cytotoxic.  
Additional risk of DNA double-strand break production is created from abasic sites 
arising closely together on opposite DNA strands.  Whether produced by glycosylases or 
arising spontaneously, abasic sites are mostly processed by apurinic/apyrimidinic (AP) 
endonuclease 1 (APE) which prepares the 3’ end of the phosphate backbone so that it 
becomes substrate for DNA polymerase.  In mammalian cells, APE is the major AP 
endonuclease, processing 95% of the AP-site incision activity present (49, 68).  
Additionally, APE is essential for cellular proliferation and embryonic development in 
mice, and mice heterozygous for APE exhibit phenotypes associated with oxidative stress 
(90, 235, 343).  The BER pathway also addresses damage produced by x-rays which can 
contribute to DNA damage directly by causing single strand breaks, or by reaction with 
water to create free radicals which then create a variety of lesions including single strand 
breaks (27, 116, 135, 332).  In certain scenarios where single strand breaks are produced 
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as a by-product of radiation, repair is initiated by PARP which is activated by the 
presence of the breaks and along with polynucleotide kinase (PNK) and X-ray repair 
complementing defective repair in Chinese hamster cells 1(XRCC1) prepares the DNA 
ends for new DNA synthesis (3, 147).  The resulting DNA lesions are predominantly 
addressed by the short-patch BER pathway and to a lesser extent by the long-patch BER 
pathway, a decision which may partially depend on the availability of ATP at the time of 
repair (268).  The short-patch pathway is completed by DNA polβ which removes the 
remaining phosphate backbone and inserts a new nucleotide, followed by DNA ligase 3 
which returns continuity to the strand, completing repair.  XRCC1, which has no 
enzymatic activity, interacts with many BER core proteins also participates in these final 
steps and is thought to play a role as a scaffold protein in BER (147).  Long-patch repair 
is completed by PCNA and DNA polβ/ε which synthesize a patch of new bases (2-10 
bases) over the lesion after which FEN1 cleaves the displaced strand and DNA ligase 1 
reseals the phosphate backbone, returning continuity to the strand.   In cases where the 
BER lesion blocks transcription, the lesion is addressed by TCR and the NER pathway 
(see above). 
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Figure 1.2.  The base excision repair (BER) pathway.  Upon recognition of an aberrant 
base, the glycosylase binds and excises the mispaired base, generating a cytotoxic abasic 
site (step I) (206).  Abasic sites may also be generated through spontaneous hydrolysis.  
The abasic site is then processed by apurinic/apyrimidinic (AP) endonuclease 1 (APE) 
which prepares the 3’ end of the phosphate backbone so that it may be processed by DNA 
polymerase (step II).  BER may also be initiated by DNA single strand breaks (SSBs) 
which activate Poly(ADP-ribose) polymerase (PARP).  PARP, X-ray repair 
complementing defective repair in Chinese hamster cells 1(XRCC1), and polynucleotide 
kinase (PNK) bind the SSB and prepare the DNA ends for new DNA synthesis (step III).  
The resulting single nucleotide gap may be processed by the short patch (predominant) or 
long-patch (minor) pathways.  In the short-patch pathway DNA polymerase β in complex 
with XRCC1 cleaves the phosphate backbone 5’ of the abasic site, removing the 
remaining piece of the base-free phosphate backbone (step IV), and then replaces the 
missing base (step V).  Finally, DNA ligase 3 in complex with XRCC1 returns continuity 
to the strand (step VI) (184).  In the long-patch pathway the single nucleotide gap is 
processed by DNA pol δ/ε and PCNA which synthesize a short (2-10 bases) stretch of 
new DNA around the gap (step VII) after which FEN1 endonuclease cleaves the DNA 
flap displaced by synthesis (step VIII) and DNA ligase 1 reseals the phosphate backbone, 
returning continuity to the strand and completing repair (step IX).  Adapted from 
Hoeijmakers, 2001(143).  
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Posttranslational regulation of the mammalian DNA base excision repair pathway 
The BER pathways as described above, and many other DNA repair pathways, are 
affected by a series of protein complexes which assemble sequentially on the site of the 
DNA lesion being repaired (140).  These complexes may include scaffolding proteins 
such as XRCC1 (281), which has been implicated in coordinating the entire BER pathway 
(42, 66, 224, 228, 325), or chromatin modifiers such as the CREB binding protein and its 
related family member p300 (CBP/p300), which have been identified as potentially acting 
at sites of DNA damage to acetylate histone tails and promote access for DNA repair 
proteins to chromatinized DNA (316).  As each step of the pathway is completed, the 
resulting product is passed from the processing enzymes on to either the next protein 
complex or within the same complex, until the lesion has been repaired (338).   
The repair proteins are subject to PTM which may act to modulate enzymatic activity, 
alter protein-protein interactions (316), and affect stability of the modified DNA repair 
proteins (118, 127).  In this way, the DNA repair response may be tailored to specific 
cellular conditions such as exposure to DNA damaging oxidative stress (150) or to 
normal process such as cell cycle progression (118, 127) and transcription (22).  Table 1.2 
[adapted from Almeida et al., 2007 (3) and Fan et al., 2005 (78)] describes some 
examples of BER proteins which are subject to PTM and where known, indicates the 
effect these modifications may have on protein function.  Although this thesis focuses on 
BER, regulation of DNA repair by PTM occurs in many of the other pathways outlined 
above.  For example, NHEJ proteins Ku70 and Ku80 are subject to sumoylation and 
ubiquitination respectively (18) and in response to DNA DSB ATM dimers 
autophosphorylate, releasing monomers which propagate the γH2AX mark, assisting in 
DNA repair and cell cycle checkpoint activation (193). 
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TDG, thymine DNA glycosylase; NEIL2, nei like 2; UNG2, uracil-DNA glycosylase; AAG, alkyladenine 
DNA glycosylase; OGG1, 8-oxoguanine DNA glycosylase; MYH, adenine DNA glycosylase; MPG, N-
methylpurine-DNA glycosylase; APE, apurinic/apyrimidinic endonuclease 1; MGMT, O-6-
methylguanine-DNA methyltransferase; Msh2/6 (Mutsα), the Msh2-Msh6dimer; XRCC1, X-ray repair 
complementing defective repair in Chinese hamster cells 1; PARP, Poly-(ADP-ribose) polymerase; FEN1, 
flap structure-specific endonuclease 1; WRN, Werner syndrome, RecQ helicase-like; DNA pol β, 
polymerase beta; PCNA, proliferating cell nuclear antigen.  References - 1: (243, 316), 2: (243), 3: (128, 
244), 4: (21), 5: (212), 6: (83), 7: (199), 8: (156), 9: (64), 10: (117, 265), 11: (199), 12: (22, 23), 13: (169), 
14: (88, 216), 15: (40), 16: (299), 17: (55), 18: (215), 19: (131), 20: (166), 21: (105), 22: (227), 23: (87, 
130), 24: (138), 25: (28), 26: (52, 163, 164, 273, 349), 27: (167, 341), 28: (129), 29: (75), 30: (181, 216), 
31: (24), 32: (70), 33: (168), 34: (274), 35: (124, 141), 36: (149, 296). 
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Transcription occurs within a chromatin context 
The mammalian genome consists of approximately 2.7-3 billion bases (mouse and human 
respectively) and approximately 22,000 genes (56, 192).  Eukaryotic genomes are 
packaged with specialized protein (histones) into a higher order structure (chromatin) that 
protects the genome and permits regulated access to genetic information. Regulation of 
transcription is critical for viability and misregulation of the transcriptional program lead 
to disease and carcinogenesis (1, 2, 8, 14, 29, 32, 33, 37, 43, 45, 47, 53, 59, 74, 79, 85, 96, 
97, 101, 102, 256, 259, 270, 283).  Agents such as α-amanitin amatoxin which may be 
found in the Amanita genus of mushrooms such as the Death cap mushroom (Amanita 
phalloides) inhibit the critical transcriptional mediator RNA polymerase II, and are lethal 
(39).   
Chromatin is composed of a core histone octamer consisting of 2 units each of histones 
H2A, H2B, H3, and H4.  Around this core particle 146 bp of duplex DNA is tightly 
wrapped (214).  This unit is repeated every 200 bp in eukaryotic genomes and appears as 
approximately 11 nm “beads on a string” when imaged by electron microscopy 
(euchromatin) (233).  Further compaction into higher order structures may be achieved 
through inclusion of the linker histone H1 (heterochromatin) (241) as well as inter-
nucleosomal interactions and through chromatin binding proteins.  Euchromatin is 
generally permissive for transcription while heterochromatin is generally repressive 
(340). 
Interestingly, the core histone particles possess outward facing tails which are substrates 
for PTM.  These include acetylation, phosphorylation, methylation, sumoylation, and 
ubiquitination (182).  Histone tails may also be irreversibly modified by proteolytic 
cleavage (73).  These modifications can act to alter histone-DNA interactions (182).  For 
example, acetylation of histone tails has been associated with reducing histone-DNA 
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interactions and promoting a euchromatic state which increases access to the constituent 
DNA sequences (115, 226, 294, 323, 324).  Histone tails also serve as docking sites for 
chromatin modifiers, and reversible PTM of specific residues in histone tails can regulate 
binding of these factors.  In turn, these proteins direct further alterations in local 
chromatin structure cascading to regulate genomic organization.  The complex regulation 
of chromatin structure achieved through histone tail PTM and histone binding proteins, 
can serve to regulate histone-DNA interactions and DNA metabolism (84, 189, 288, 302). 
Four families of ATP-dependent chromatin remodeling complexes have been identified 
that function to improve access of trans-acting factors to chromosomal DNA.  The 
families are named SWI/SNF, INO80, ISWI, and Mi-2/CHD (10).  The mechanism of 
action for these complexes is still under investigation, but may include actions as drastic 
as complete removal of local histone octamers to more subtle manipulations involving 
creation of small loops of DNA lifted from the surface of the core octamer (57, 119, 145, 
209) and in either case, may be associated with epigenetic marks that favor continuity of 
promoter states (255).    
A useful intellectual framework for conceptualizing the relationship between histone 
post-translational modification, chromatin organization, and DNA metabolism has been 
described by the histone code hypothesis (189, 289, 302, 319).  This hypothesis proposes 
that histone PTM may be written and read by the cell, resulting in a dynamic exchange of 
information from chromatin to the cell and vice versa.  This information is transmitted 
through numerous chromatin modifiers as described above and collectively these PTM, 
their mediators and effectors of chromatin remodeling are thought to facilitate a 
mechanism for exquisite and dynamic regulation of genome structure, stability, 
replication, and metabolism.  Accordingly, misregulation of chromatin state through 
aberrant PTM of histone tails or misdirection of ATP-dependent chromatin remodeling 
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complexes is a common feature of malignancies and gene expression studies have shown 
that this can potentially affect expression of thousands of genes (53, 120, 176, 280). 
Transcription is directed by the coordinated action of three classes of transcriptional 
regulators which act to coordinate transcription temporally, spatially, and quantitatively.  
These include the basal transcription apparatus, sequence specific transcription factors, 
and the transcriptional coactivators/repressors (61).  When the chromatin state is 
permissive for transcription factor binding, sequence specific transcription factors such as 
nuclear receptors may recognize and bind to their cognate gene regulatory regions, this 
promotes assembly of a preinitiation complex (PIC) which consists of the multimeric 
RNA pol II (PolII) enzyme and the basal or general transcription factors TFIIA, TFIIB, 
TFIID, TFIIE, TFIIF, and TFIIH bound to promoter DNA (278, 313).  For high levels of 
induced transcriptional activation or repression,  the sequence specific transcription 
factors also recruit transcriptional coactivators and corepressors, which are often multi-
protein complexes possessing enzymatic activities facilitating covalent modification of 
chromatin and transcription factors (247).  These multiple protein complexes assemble 
sequentially, some acting as bridging factors which facilite binding of subsequent factors.  
For example, the transcriptional coactivator steroid receptor coactivators-1, -2, and -3 
(SRC1, 2, 3) interact with steroid receptors in a hormone dependent manner and 
dramatically increases steroid receptor-dependent transcription (50, 262, 326, 327).  The 
SRC coactivators possess several interaction domains, including triple LXXLL motifs 
necessary for association with steriod receptors (65, 134, 327), and two activation 
domains, AD1 and AD2, which mediate interactions with the transcriptional coactivators 
CBP/p300 (CBP/p300 are discussed below), and the coactivator associated 
methyltransferase 1 (CARM1)/protein arginine N-methyltransferase (PRMT1), 
respectively.  Interestingly, CBP/p300 are histone acetyltransferases; CARM1 and 
PRMT1 are histone methyltransferases (4, 35, 151, 178, 217, 266, 304, 350); and 
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SRC1and SRC3 contain putative histone acetyltransferase (HAT) domains  (298).  These 
multiple interaction surfaces allow formation of multi-protein complexes and the 
accompanying enzymatic activities facilitate local chromatin remodeling, transcription 
factor recruitment, and assembly of RNA polymerase II, resulting in dynamic regulation 
of transcription in a gene specific manner (279, 346, 354). 
Interestingly, increasing evidence indicates a role for DNA repair pathways in chromatin 
remodeling and transcriptional regulation.  For example, demethylation of dimethylated 
histone H3, lysine 9 during estrogen-induced gene activation was shown to cause local 
oxidative DNA damage resulting in recruitment of OGG1 as well as DNA topoisomerase 
II β which contributed to chromatin remodeling essential for induction of estrogen-
dependent transcription (267).  Additionally, evidence indicates that during signal-
dependent transcriptional activation by nuclear receptors as well as other DNA-binding 
transcription factors, DNA topoisomerase II β generates DNA double-stranded breaks in 
gene promoter regions, initiating a signal which activates PARP-1 function and 
subsequent histone H1-HMGB exchange proximal to the break (160).  These observations 
link the DNA double-strand break repair, chromatin remodeling, and transcriptional 
machinery in a signal cascade generally facilitating induced gene expression.  It is 
interesting to note that this implies that a broad induction of numerous, potentially 
cytotoxic, DNA lesions occurs during transcriptional activation.  DNA repair signaling 
pathways may also participate in cross-talk with transcriptional pathways in order to 
facilitate coordination between cellular processes.  For example, after binding to 
mutagenic O(6)-alkylguanine direct DNA damage reversal protein MGMT undergoes a 
conformational change which exposes an internal estrogen receptor α (ERα) binding site.  
Binding between MGMT and ERα prevents ERα interaction with its transcriptional 
coactivator SRC1 and represses estrogen regulated transcription and cell growth, slowing 
DNA metabolism when its integrity has been compromised (310).  BER protein APE also 
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participates widely in transcriptional activation through its redox activity, acting to 
regulate the redox state of transcription factors such as Fos-Jun heterodimers, Jun-Jun 
homodimers, Hela cell AP-1 proteins, NF-kappa B, Myb, and ATF/CREB family 
members, stimulating their DNA binding activity and promoting transactivation (342).  
Conversely, APE has also been shown to negatively regulate some negative Ca2+ 
responsive elements (nCaREs) (260). Interestingly, the DNA repair and redox functions 
of APE are biochemically independent, indicating that the APE DNA damage response 
does not have to be active for transcriptional regulation to occur (342).  Additional 
mechanisms linking DNA repair and transcription exist; another is discussed below, 
although a complete discussion of this topic is beyond the scope of this thesis. 
Cytosine methylation regulates gene expression and contributes to genome 
instability  
Cytosine may be methylated at the 5’ site (5-meC) and approximately 3-4% of cytosines 
in mammalian genomes are methylated resulting in 1% of all DNA bases being 5-meC 
(159, 271).  In differentiated vertebrate cells, 99.98% of 5-meC is found within CpG 
sequences and in stem cells 25% 5-meC may be found at CA sequences (205, 290).  
Sequence analysis shows that gene regulatory regions in nearly all constitutively 
expressed, and 60-70% of total, human genes are enriched in CpG sequences (referred to 
as CpG islands) (276, 360).  Although the majority of CpGs in mammals are methylated 
(153), 91.8% of CpG islands exhibit low levels of methylation (less than 20%), while 
4.8% show intermediate methylation (20-80%), and only 3.4% are highly methylated 
(greater than 80%).  In contrast, 5-meC is largely found within repetitive DNA sequences 
such as Alu repeats and at non-island CpGs within coding and non-coding regions (205).    
Methylation of cytosine contributes to chromosomal organization as methyl binding 
domain (MBD) bearing proteins are recruited to methylated CpGs and subsequently 
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recruit histone deacetylases (HDACs) which deacetylate local histone tails, promoting 
chromatin condensation (26).  Accordingly, methylation in CpG island promoters is 
generally associated with gene silencing (158, 305);  however, methylation within gene 
bodies has been found in certain transcribed genes, suggesting that context may be 
important to 5-meC function in gene regulation (305).  Recently, base-pair resolution 
mapping of human fibroblast methylation sites has shown that sites of DNA-protein 
interaction correlate with reduced CpG methylation and furthermore, that large tracts of 
DNA may be partially methlylated, resulting in reduced activity of genes 5’ of these 
methylated cytosines, indicating that methylated cytosines are generally refractory to 
protein binding and suggesting that they promote formation of a chromatin structure 
inhibitory to DNA metabolism (205).     
Although CpG methylation is a powerful gene-silencing mechanism  (175), it also 
contributes to genome instability by promoting spontaneous hydrolytic deamination of 
cytosine which generates thymine (292).  Unmethylated cytosine also undergoes 
deamination at lower rates and generates uracil.  Left unrepaired, the resulting G:U and 
G:T mispairs these mispairs will give rise to G:C to A:T transitions upon replication.  
Such alterations to genomic coding sequences may alter gene regulatory regions as well 
as coding sequences.  Analysis of cytosine methylation in non-pathologic human tissue 
samples has uncovered variations in methylation significantly correlating to age and 
exposure to environmental toxins such as cigarette smoke (54).  High resolution mapping 
of DNA methylation in lung cancers has shown that misregulation of this epigenetic mark 
is a common feature of human cancers and can potentially affect expression of thousands 
of genes (276, 277).  
The p53 tumor suppressor gene is an ideal mutation reporter to investigate the role of 
DNA damage in carcinogenesis (272).  Mutations of the p53 gene are one of the most 
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common characteristics of human cancers (144, 261, 328) occurring in approximately 
50% of all cancers.  The majority of these (approximately 90%) are single point missense 
mutations which inactivate the p53 protein DNA binding domain, preventing it from 
enacting a transcriptional program which causes cell cycle arrest and apoptosis (269, 328, 
330).  Other cancers show altered p53 expression and nuclear localization  (236).  The 
IARC p53 mutation database is a repository for mutations found in the human p53 gene 
which have been found in tumor tissue samples.  Examination of this database shows that 
almost one half of mutations in colon and rectal tumors are attributable to G:C to A:T 
transitions at CpG sequences.  This grows to over 60% when all G:C to A:T transitions 
are considered (269).    
Measurements of the spontaneous rates of deamination of cytosine and 5-methylcytosine 
in double stranded DNA have shown that 5-methylcytosine undergoes spontaneous 
deamination at a rate 2-3 times higher than cytosine with average rates of 2.6 x 10-13/s and 
5.8 x 10-13/s for 5-methylcytosine and cytosine respectively (292).  These rates are 
consistent with a role for spontaneous hydrolytic deamination of cytosine and 5-
methylcytosine as major contributors to genome instability and carcinogenesis (202, 292).  
Importantly however, observations indicate that CpGs are 12-42 fold more prone to 
mutation than other nucleotide sequences as measured in cells, rates much higher than can 
be accounted for by spontaneous processes alone (59, 177, 297, 306).  This may be due to 
inefficient repair G:T mispairs (36, 201) and/or malfunction of enzyme-mediated 
deamination mechanisms which have been reported to play a role in transcriptional 
regulation (172, 238).        
Thymine DNA Glycosylase is a multifunctional DNA repair enzyme 
There are two known enzymes possessing an activity which excises mispaired thymine 
and uracil in a CpG context – thymine DNA glycosylase (TDG) and methyl binding 
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domain protein 4 (MBD4).  Although TDG and MBD4 process similar lesions by 
initiating the DNA base excision repair pathway (see above), they lack sequence 
homology (13, 81, 136, 137, 249, 311, 352).  TDG has orthologs in bacteria, yeast, 
insects, frogs, and vertebrates (5, 93, 125, 126).  Sequence analysis shows that TDG 
posses a highly conserved central region containing the active site, and more divergent 
amino and carboxy-terminal regions (Fig 1.3, adapted from Cortazar et al. (2007)) (60).  
Structural studies have shown that this highly conserved TDG central region forms a 
relatively large substrate pocket (Fig 1.4) (13).  Accordingly, TDG processes a large 
number of aberrant bases in addition to oxidative damage of cytosine and methylcytosine, 
including the products of base damage due to alkylation, halogenation, and lipid 
peroxidation (17, 82, 123, 245, 352).  Interestingly, TDG also processes halogenated 
bases such as 5-fluorouracil, contributing to the DNA-directed cytotoxicity of this 
chemotherapeutic agent (187).  Crystallographic analysis of the TDG core, along with 
kinetic studies of both core and full-length proteins have shown that the amino terminus is 
critical for full TDG glycosylase function as it forms hydrogen bonds with guanine bases 
which are essential for mispair recognition specificity and mediating tight DNA 
interactions necessary to process thymine mispairs (222).  Without this region, TDG 
binds less stably to DNA and loses the ability to excise thymine from G:T mispairs while 
retaining G:U processing activity (244, 301).  For the purposes of this thesis, we have 
used mouse TDG (or mTDG).  Human and mouse TDG are biochemically 
indistinguishable and highly conserved both in sequence and structure (See multiple 
sequence alignment Fig. S.3.1).  In NIH 3T3 mouse fibroblast cells MBD4 largely 
associates with transcriptionally silent heterochromatic regions of the genome while TDG 
is largely associated with euchromatic, or transcriptionally active regions (316) 
suggesting that TDG, rather than MBD4 is the predominant protein responsible for 
maintenance of transcriptionally active regions of the genome.  A small portion of TDG 
has also been shown to associate with heterochromatin in complex with DNA 
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methyltransferase 3b (Dnmt3b) in P19 embryonic carcinoma stem cells  (30) and in NIH 
3T3 cells upon coexpression with DNA methyltransferase 3a (Dnmt3a)  (198), suggesting 
that TDG, in complex with these regulators of DNA methylation, may play a role in 
maintenance of these transcriptionally silent regions of the genome.   
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Figure 1.3.  Schematic of mouse (m) TDG indicating the relative organization of 
important regulatory regions and surfaces mediating specific protein-protein 
interactions.  Abbreviations: estrogen receptor α (ERα), retinoic acid receptor α 
(RARα), retinoid x receptor (RXR), CREB binding protein (CBP) – specifically CBP 
histone acetyltransferase (HAT) and CH3 domain interactions, protein kinase C α 
(PKCα), jun oncogene (C-Jun), DNA methyltransferase 3a (Dnmt3a).  Adapted from 
Cortazar et al., 2007 (60).  
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Figure 1.4.  Overview of the structure of TDG.  (A)  The hTDG catalytic domain 
(hTDGcat, residues 111–308) binds a 22-bp DNA containing a tetrahydrofuran nucleotide 
(THF), a chemically stable mimic of the natural AP product, in a 2:1 complex: one 
subunit at the abasic site (product complex) and the other at an undamaged site 
(nonspecific complex). DNA shown includes a full 22-bp duplex and part of the adjacent 
duplex joined by 3' A/T overhangs (blue arrow, see B). Overall, the two subunits are 
highly similar (rms deviation of 0.8 Å for Cα positions).  (B)  Schematic overview of the 
enzyme–DNA interactions and the dimer interface.  The 22-bp DNA is yellow with 
phosphates shown as orange circles. The adjoining DNA fragment (purple) shows 
contacts with K246 and K248 from the NS subunit. The arrows represent hydrogen bonds 
involving side-chain or main-chain (mc) atoms of the enzyme. In the product complex, 
the flipped abasic nucleotide (THF) is a red pentagon, the “opposing G” is magenta, and 
the “3′-G” is cyan. A277 intercalates the complementary strand, disrupting base-stacking 
interactions between the opposing G and its 5′ neighbor. Contacts involving N157, S273, 
and A274 for hTDGcat are topologically conserved with contacts in the eMUG product 
complex (13), and the N157, K232, S271, and S273 contacts are conserved with those in 
the UDG product complex (264).  (C)  Close-up view of the dimer interface, with the 
G·THF-bound subunit in green and the nonspecific subunit in cyan. The N termini of each 
subunit (T123) are indicated. Adapted from Maiti A et al., 2008 (222).  PDB ID: 2RBA. 
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Interestingly, TDG also associates with subnuclear structures called promyelocytic 
leukemia protein (PML) oncogenic domains (PODs) (244, 307).  PODs are subnuclear 
structures comprised mainly of promyelocytic leukemia (PML), SP100, and Daxx 
proteins (231).  PML is a necessary component for assembly of PODs and comprises their 
main structural component (191, 355).  Distinct in composition from other nuclear bodies, 
the PODs may be detected by labeling PML by methods such as immunohistochemistry 
or tagging with fluorescent proteins (244).  Interestingly, PML has been shown to bind a 
diversity of protein partners and PODs have been shown to be a site of localization and 
putative site of storage for many proteins which function in transcription and the 
maintenance of genome stability (197, 200, 356).  Interestingly, certain DNA repair 
factors such as the Rad50, MRE11 and NBS1 proteins associate dynamically with PODs, 
accumulating in these structures until DNA damage is induced, at which time they move 
into the nucleus where they presumably perform a repair function, after which they return 
to the PODs (239).  PODs may also be a site of nucleation for protein complexes, creating 
local accumulations of proteins with high effective concentrations promoting assembly of 
these multi-subunit complexes.  Additionally, proteins may be placed in close proximity 
within PODs to facilitate interactions post-translational modifications (200).  
Accordingly, numerous acetyltransferases, kinases, proteases, and transcription factors 
have been found localized to PODs and these structures are surrounded by regions of 
active transcription (112, 344).  Although deletion of the PML gene in mice results in 
viable and fertile animals, misregulation of PML by fusion with the retinoic acid receptor 
(PML-RAR) has been shown to cause promyelocytic leukemia (200).   
Interestingly, TDG has been shown to functionally interact with a number of transcription 
factors and transcriptional coactivators including estrogen receptor alpha (ERα) (48, 238), 
retinoic acid receptors (RAR and RXR) (320), thyroid transcription factor 1 (TTF1) 
(240), p53 tumor suppressor family members p53 and p73α (171), the p160 coactivator of 
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nuclear receptors SRC1 (213), serum response factor (SRF) co-activator myocardin (358), 
as well as the transcriptional coactivators and acetyltransferases CBP/p300 (316).  Finally 
a novel role for TDG has recently been reported linking TDG to the mechanism of 
reversible DNA methylation.   
Finally, a role for TDG in the regulation of transcription through demethylation of 
cytosine had been proposed by Zhu et al., who demonstrated that overexpression of TDG 
reactivated a transgene silenced by CpG methylation (359).  Recently, Metivier et al. 
identified a critical role for TDG-mediated BER when they reported that TDG plays a 
role in the cyclical DNA methylation of the transcriptionally active estrogen responsive 
pS2/TFF1 gene (238).  This process takes place when TDG is recruited to the promoter 
along with the methyltransferases (Dnmt) 3a and 3b as well as p68 and the BER proteins 
APE, DNA ligase, and DNA polymerase β.  In the presence of low concentrations of co-
factor S-adenosyl methionine (SAM) these methyltransferases promote hydrolytic 
deamination of methylated cytosine (291, 361).  Interestingly, the methyltransferase 
activity of Dnmt3a is inhibited in the presence of TDG (198).  The product of this 
targeted deamination event is a G:T mispair.    However, the presence of Dnmt3a 
promotes TDG base excision activity in vitro (198).  Accordingly, TDG recognizes and 
excises the mispaired thymine base, and through completion of the BER pathway it is 
replaced with cytosine.  This mechanism of transcriptional regulation through cyclical 
methylation has also been described for another ERα responsive gene, Wisp-2, raising the 
possibility that this may be a mechanism of transcriptional regulation on other promoters 
(238).  Importantly, this was the first mechanistic explanation to indicate that DNA 
methylation is reversible and involves BER.  Soon afterward, it was shown that BER-
mediated demethylation of cytosine also occurs in Zebrafish (275) and recently, MBD4 
was also shown to participate in cytosine demethylation facilitating transcription although 
MBD4 is capable of direct excision of methylated cytosine (172).    
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TDG is a coactivator and substrate for the CBP and p300 acetyltransferases  
CBP/p300 are coactivators that participate in transcription through various mechanisms to 
integrate signaling pathways for a large number of sequence specific transcription factors 
such as CREB , AP-1, p53, and steroid receptors (89, 148, 154, 162, 211).  For example, 
when recruited to chromatin by p53 as well as other transcription factors, CBP/p300 
acetylate histone proteins, promoting an open chromatin conformation more amenable to 
DNA metabolism (77).  CBP/p300 have also been shown to acetylate numerous non-
histone proteins (consensus sequence G/SK (9)).  For example, CBP/p300 mediated 
acetylation of sequence-specific transcription factors p53, p73, and Sp3, result in 
increased DNA binding activity  (89, 154, 155, 161, 180, 248).  CBP/p300 have also been 
shown to act as bridging proteins between sequence specific transcription factors and 
basal transcription machinery apparatus (108).  Additionally, the large surface area and 
multiple protein-protein interaction sites of CBP/p300 may facilitate use of these 
acetyltransferases as scaffolds for assembly of multi-protein complexes.  Such an 
arrangement has been observed on the β-interferon gene promoter in response to viral 
infection (237).  Some of these proteins may have additional enzymatic activities not 
limited to acetyltransferase or histone deacetylase activity seen in CBP/p300 interactors 
pCAF (254) and HDAC1 (254) respectively.   
Evidence indicates that there is a role for CBP/p300 in tumor suppression.  Breakpoints, 
microdeletions, and point mutations in the CBP and p300 genes are associated with 
Rubenstein Taybi Syndrome in humans (14, 270).  This autosomal dominant syndrome is 
characterized by physical abnormalities including skeletal deformities, mental retardation, 
and high risk for malignancy.  Somatic mutations in CBP/p300 have been found in a 
number of malignancies and translocations in the CBP and p300 genes occur in acute 
myeloid leukemia.  Additionally, CBP/p300 are targets for transforming viruses, 
36 
 
 
 
suggesting that disruption of their function permits carcinogenesis (155).  Importantly, 
mouse models lacking CBP/p300 do not survive embryogenesis (257, 258, 351), and 
those heterozygous for CBP develop hematological failures and malignancies in which 
the second CBP allele had been inactivated (185, 257). 
Intriguingly, TDG is capable of forming ternary complexes with CBP and DNA which 
are competent for base excision (316).  Additionally, TDG has been shown to be a potent 
stimulator of CBP-mediated transcription and is substrate for CBP-mediated acetylation 
on amino terminal lysine residues 70, 94, 95, and 98 (316).  Proteomics-based analysis of 
non-histone protein acetylation has shown that important mediators of longevity, 
carcinogenesis, tumor suppression, and metabolism are all substrates for acetylation (25, 
173). 
TDG interacts covalently and non-covalently with SUMO 
In addition to acetylation, TDG is also subject to modification by conjugation of the small 
ubiquitin-like modifier (SUMO) proteins (sumoylation) to lysine residue 341 (consensus 
conjugation site ψKXE) and approximately 5-50 percent of the cellular pool of mTDG is 
sumoylated at any time, depending on the tissue or cell line examined (M. Tini, 
unpublished).  This 97 amino acid protein is distantly related to ubiquitin and despite 
sharing only 18% EST cDNA and amino acid sequence identity, establishes a common 
three-dimensional structure  (15, 221).  There are four SUMO isoforms termed SUMO-1 
(referred to as SUMO), -2, -3, and -4.  Although SUMO-1 is only 50% related to SUMO-
2/3, SUMO-2/3 differ by only 3 amino-terminal residues and are functionally identical 
(133).  Interestingly, SUMO-2/3 are able to form multimeric chains while SUMO-1 does 
not (246) although SUMO-2/3 may be sumoylated by SUMO-1 (229).  TDG is subject to 
sumoylation by SUMO-1, -2, and -3 (6, 7, 128) and also possess a non-covalent SUMO-
binding activity (7, 244).  The effect of covalent modification, or noncovalent interaction, 
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with SUMO is protein-specific, and has been shown to regulate diverse biological 
processes such as subcellular localization, chromosome segregation, DNA repair, 
transcription, proteolysis (103, 133).  The mechanism underlying this regulation occurs 
through any combination of alterations to a sumoylated or SUMO-bound protein function 
through differential subcellular localization, protein-protein interactions, intramolecular 
interactions, and crosstalk between sumoylation and subsequent posttranslational covalent 
modifications (132, 133).  For example, sumoylation of RanGAP1 promotes translocation 
to the cytoplasmic fibrils of the nuclear pore complex protein through increased binding 
to RanBP2 (5).  Sumoylation of CBP/p300 causes recruitment of Daxx and HDAC6 
respectively, negatively affecting transcription (104, 188).  Sumoylation of PML assists in 
assembly of PODs and promotes recruitment of POD components Daxx, sp100, and CBP 
(8).  Additionally, sumoylation of HSF1 and HSF2 alters the ability of these proteins to 
interact with DNA (109, 128, 146). 
TDG is a phosphoprotein 
TDG was first identified as a phosphoprotein in experiments showing that phosphatase 
treatments could alter the mobility of TDG as resolved by SDS-PAGE (320).  In chapter 4 
we identify the kinase responsible for these marks as protein kinase C alpha (PKCα).  
First identified as a histone protein kinase in rats (253), the PKC family consists of 11 
family members which share a common catalytic domain recognizing the consensus 
sequence S/T-X-[R/K] (174), but distinct regulatory domains which have different 
activation requirements.  Classical PKCs (α, βI, βII, and γ) require either diacylglycerol 
or phorbol esters, calcium, and an acidic phospholipid, such as phosphatidylserine, for 
activation.  Additional PKCs δ, ε, η, and θ are classified as “novel PKCs” and require 
either diacylglycerol or phorbol esters, and an acidic phospholipid for activation, but are 
calcium independent.  The ζ, and ι/λ PKCs are classified as “atypical PKCs” and require 
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only an acidic phospholipid for activation.  In addition to specific cofactor requirements 
for activation, PKC isoforms possess distinct  tissue expression and subcellular 
localization which contributes to effective separation of biological function (334).  PKCα 
is the only PKC which is ubiquitously expressed and exhibits both cytoplasmic and 
nuclear localization (225).  Activation of PKCα with phorbol esters causes 
autophosphorylation and relocalization to lipid membranes and nuclear compartments 
(314).  Interestingly, PKCα is also activated by H2O2 (179) and products of lipid 
peroxidation, agents known to cause DNA damage that may be repaired by TDG (91, 
195).   Phosphorylation appears to be a major mediator of the DNA damage response as 
proteomic analysis has identified over 700 proteins which phosphorylated by the kinases 
ATM and ATR in response to DNA damage (230).  Furthermore, PKC phosphorylates 
BER proteins APE (150) and DNA polymerase β (317).  PKCα signaling has also been 
implicated in transcriptional control at various stages of transcription through 
phosphorylation of proteins such as PPARα (114), thyroid hormone receptor-α1 (170) 
and histones (100).  Interestingly, PKCα phosphorylation of CBP is required for 
coactivation of transcription on AP1 responsive promoters (353).   
1.2 Hypothesis and experimental aims 
The observations described above place the lysine- and serine-rich amino terminus of 
TDG in focus as a hot-spot for PTM.  Importantly, these PTM and the mediators of these 
marks have been implicated in transcriptional regulation and carcinogenesis.  
Interestingly, the TDG amino terminus also participates in mediating numerous protein-
protein interactions, including those with APE and CBP (316).  Furthermore, mechanisms 
regulating TDG enzymatic function may consequently play an integral role in regulation 
of gene expression and removal of epigenetic marks (279).    
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We hypothesize that PTM of TDG may act in concert to regulate TDG function.  In this 
thesis we aim to identify novel TDG PTM, determining the modifying enzymes as well as 
the substrate residues on TDG.  We will then determine the effect of these PTM on 
regulating TDG intramolecular and intermolecular interactions.  Furthermore, we aim to 
investigate whether these PTM play a role in regulating TDG subcellular localization.  
Importantly, we will determine the effect of these PTM on TDG substrate interactions and 
base excision activity.  Lastly, we will elucidate a possible interplay between TDG PTM 
and determine the nature of any relationship between PTM. 
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Chapter 2: SUMO-1-dependent allosteric regulation of thymine DNA glycosylase 
alters subnuclear localization and CBP/p300 recruitment 
2.1 Introduction 
In vertebrate genomes, methylation of cytosine within CpG dinucleotides constitutes an 
important mechanism regulating transcription and chromatin structure (35). CpG 
methylation also contributes to genome instability by promoting spontaneous hydrolytic 
deamination of methylated cytosines to generate thymine residues (27), which in the 
absence of DNA repair give rise to cytosine-to-thymine transition mutations believed to 
have a causative role in cancer (17). For example, these CpG mutations are the most 
prevalent genetic alterations in the p53 tumour suppressor gene detected in many human 
tumors (36). The incidence of CpG mutations is also dramatically increased in aging 
mouse tissues and, therefore, may contribute significantly to cellular aging (11).  
Thymine DNA glycosylase (TDG) is one of two enzymes mediating the excision of 
mispaired thymine (G:T) and uracil (G:U) in the CpG context (23, 32, 33). TDG 
processes thymine, uracil, 5-hydroxymethyluracil, and 3,N4-ethenocytosine mispaired 
with guanine (18) to generate an abasic site that is subsequently repaired by other base 
excision repair (BER) enzymes (41). Interestingly, TDG has also been shown to interact 
with a number of transcription factors, including Jun and members of the nuclear receptor 
family, suggesting a link between transcription and BER (7, 8, 28, 46, 47).  
Previous studies have revealed a functional association between TDG and transcriptional 
coactivators CREB-binding protein (CBP) and p300 (46). CBP/p300 are essential proteins 
that potentiate diverse transcription factor signaling pathways in part by mediating 
acetylation of chromatin and chromatin-associated proteins (16). Notably, CBP/p300-
TDG complexes are recruited to DNA in vitro and have the potential to participate in both 
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transcriptional regulation and DNA repair (46). Accordingly, TDG was shown to be both 
a potent activator of CBP/p300-dependent transcription and a substrate for CBP/p300 
acetylation (46).  
TDG is posttranslationally modified by covalent conjugation to SUMO (small ubiquitin-
like modifier) proteins (SUMO-1, -2, and -3), resulting in inhibition of DNA binding and 
altered DNA repair kinetics (20). SUMO-1 is a 97-amino-acid peptide that is covalently 
attached to proteins at lysine residues (consensus KXE), thereby affecting subcellular 
localization and molecular interactions (22). Importantly, SUMO modification plays 
important roles in transcriptional regulation and maintenance of genomic integrity (22). 
Sumoylation, in some instances, promotes localization to nuclear compartments, known 
as promyelocytic leukemia protein (PML) oncogenic domains (PODs) (6, 26, 37). The 
dynamic association of transcription and DNA repair factors with PODs suggests that 
these nuclear structures play important roles in regulating gene expression and genome 
stability (26).  
We have investigated the role of sumoylation and noncovalent SUMO-1 binding in the 
regulation of subcellular localization and biochemical properties of TDG. Our studies 
have mapped SUMO-1 binding activity to two separate SUMO binding motifs (SBMs) 
located in the amino- and carboxy-terminal regions. We show that both SBMs are 
essential for normal POD localization and activation of CBP-dependent transcription. 
Furthermore, the SBMs are regulated by DNA interactions mediated via an amino-
terminal hydrophilic domain. Interestingly, we have shown that sumoylation of TDG 
promotes intramolecular interactions that dramatically alter the biochemical properties of 
TDG, thereby preventing association with CBP and POD translocation.  
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2.2 Materials and Methods 
Plasmids 
Plasmid constructs were verified by sequencing, and details are available on request. 
GAL-CBP and TDG were expressed in pCMX mammalian expression vectors (46). 
FLAG-tagged constructs lacking the amino-terminal region of TDG were fused to the 
simian virus 40 (SV40) nuclear localization signal (NLS) to replace the natural NLS 
contained within this region. Carboxy-terminal deletions of TDG were constructed by 
directional cloning of PCR-amplified fragments into the pCMX-FLAG vector. TDG and 
CBP point mutants were constructed using the QuikChange mutagenesis kit (Stratagene) 
according to the manufacturer's directions. Cyan fluorescent protein (CFP) and yellow 
fluorescent protein (YFP) fusions of TDG and PML were constructed using the pCMX-
CFP or pCMX-YFP expression vectors. Renilla green fluorescent protein (GFP) fusion 
constructs were made using the phrGFP-N1 vector from Stratagene. Other expression 
vectors have been previously described (10, 31, 46).  
Cell culture, transfections, and heat shock treatment 
MCF-7 cells were maintained in Dulbecco's minimal essential medium containing 
penicillin-streptomycin and supplemented with 10% fetal bovine serum. Cells were 
seeded onto 24-well dishes and transfected using Lipofectamine 2000 transfection reagent 
(Invitrogen). Approximately 250 ng of luciferase-based reporter plasmid, 100 ng of Gal-
CBP, and 100 to 500 ng of pCMX-based expression vectors were used per well. 
Transfection efficiency was normalized by cotransfection of Renilla luciferase reporter 
vector phRL-SV40 (Promega). Transfection experiments were performed at least three 
times in duplicate, and results are shown with standard error plotted (standard error = 
standard deviation/sqrt of n, where n= the number of replicates). Heat shock treatments 
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(42°C) were performed on MCF-7 cells seeded on six-well dishes transfected with 
expression vectors for TDG (200 ng) and PML (100 ng). At 0, 15, or 30 min, cells were 
lysed in 300 µl Laemmli buffer containing 3 units Benzonase (Novagen), and the 
modification state of TDG was analyzed by immunoblotting with a TDG-specific 
antibody.  
Preparation of whole-cell extracts 
MCF-7 whole-cell extracts for glutathione S-transferase (GST)-based interaction assays 
were prepared from 10-cm dishes of cells transfected with 7.5 µg of TDG expression 
vector. Cell pellets were resuspended in 500 µl of lysis buffer (50 mM Tris-HCl pH 7.9, 
300 mM NaCl, 1 mM EDTA, 1 mM EGTA 10% glycerol, 0.5% Triton X-100, 1 mM 
dithiothreitol [DTT], proteinase inhibitors) and incubated on ice for 30 min. 
Subsequently, the cell lysate was diluted with 500 µl of dilution buffer (50 mM Tris-HCl 
pH 7.9, 1 mM EDTA, 1 mM EGTA, 10% glycerol, 1 mM DTT), and insoluble products 
were removed by centrifugation. Whole-cell extracts for the analysis of sumoylation were 
prepared from transfected MCF-7 cells lysed in Laemmli buffer containing Benzonase.  
Protein purification and in vitro interaction assays 
Protein purification and GST-based interaction assays using in vitro-translated and 
recombinant proteins have been previously described (46). For ethidium bromide 
treatments, in vitro-translated proteins were treated with 100 µM ethidium bromide for 20 
min at 4°C prior to use in pull-down experiments. Binding reaction mixtures and washing 
buffers also contained ethidium bromide. For interaction assays performed in the presence 
of duplex oligonucleotides containing a G:T mispair, recombinant TDG was preincubated 
with increasing amounts of the oligonucleotides for 15 min at room temperature. Whole-
cell extracts for pull-down experiments were precleared twice with 25 µl (packed bead 
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volume) of glutathione-Sepharose beads (Amersham) for 30 min at 4°C. Total protein 
concentration of the precleared lysate was determined by bicinchoninic acid assay 
(Pierce), and the relative expression of transfected proteins was determined by 
immunoblotting with a TDG-specific antibody. Subsequently, the amount of expressed 
protein in each lysate used for the pull-down was equalized by addition of untransfected 
cellular lysates. Pull-downs were performed using 3 µg of GST-SUMO and bound 
proteins detected by immunoblotting with a TDG-specific antibody. FLAG-epitope-based 
interaction assays were performed with baculovirus-expressed FLAG-CBP (400 ng) and 
recombinant sumoylated (400 ng) or mock-sumoylated HIS-TDG (400 ng). Proteins were 
incubated with 10 µl packed commercial anti-FLAG affinity matrix (Sigma-Aldrich) in 
NETN buffer (50 mM Tris-HCl pH 7.9, 100 mM NaCl, 1 mM EDTA, 10% glycerol, 0.2% 
NP-40, 1 mM DTT) in a final volume of 150 µl for 1 h (4°C). The beads were 
subsequently washed with NETN buffer, and bound proteins were fractionated by sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis and visualized by immunoblotting 
with an anti-HIS antibody. Recombinant GST-p53 (2.5 µg) was sumoylated as described 
below and bound to glutathione-Sepharose affinity matrix (25 µl packed volume). Beads 
were washed three times with NETN buffer, including one wash with NETN containing 
500 mM NaCl and subsequently resuspended in 150 µl of NETN. Binding reactions were 
carried out with 40-µl aliquots as described above. A portion of the slurry was analyzed 
by immunoblotting with anti-p53 and anti-GMP-1 monoclonal antibodies. Interaction 
assays with baculovirus-expressed FLAG-CBP (1 µg) were carried out as described 
above, but bound complexes were immunoprecipitated with CBP polyclonal antibody.  
Oligonucleotide cleavage assays 
Cleavage assays were performed essentially as previously described (32). Approximately 
25 ng of recombinant TDG or 5 µl of in vitro-translated TDG was incubated at 30°C with 
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5 ng of radiolabeled duplex oligonucleotide containing either a G:T or G:U mispair in 20 
µl of cleavage buffer (25 mM HEPES-KOH [pH 7.8], 1 mM EDTA, 0.1 mg/ml bovine 
serum albumin, and 1 mM DTT). Reactions were carried out for 30 min for recombinant 
TDG and 2 h for in vitro-translated protein. Subsequently, the DNA was precipitated, 
resuspended in 100 mM NaOH, and incubated at 90°C for 30 min. The cleavage products 
were fractionated by denaturing polyacrylamide gel electrophoresis and visualized by 
autoradiography and phosphorimaging. Assays on sumoylated TDG were carried out 
using 10 ng of duplex oligonucleotide. 
ABCD assays 
Duplex oligonucleotides containing either no mispairs or a single G:T or G:U mispair 
were generated by annealing the following complementary oligonucleotides: 5'-[biotin]- 
TAG ACA TTG CCC TCG AGG TAC CAT GGA TCC GAT GTC GAC CTC AAA 
CCT AGA CGA ATT CCG -3' and 5'-CGG AAT TCG TCT AGG TTT GAG GT[C, T, or 
U] GAC ATC GGA TCC ATG GTA CCT CGA GGG CAA TGT CTA -3'). 
Approximately 500 ng annealed oligonucleotide was incubated for 30 min at room 
temperature with 10 µl of streptavidin-coated paramagnetic beads (MagneSphere; 
Promega) and 500 ng of purified bacterially expressed TDG in avidin-biotin complex 
DNA (ABCD) buffer (50 mM Tris-HCl [pH 7.9], 150 mM NaCl, 10% glycerol, 5 mM 
MgCl2, 0.1% NP-40, and 0.5 mM DTT). Total reaction volume was 50 µl. Beads were 
washed five times with 200 µl of ABCD buffer, and bound proteins were analyzed by 
immunoblotting. In some experiments, TDG was preincubated on ice with 2 µg GST-
SUMO or GST for 30 min prior to analysis.  
Protein acetylation assays 
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Sumoylated or mock-sumoylated TDG (400 ng) was incubated with approximately 100 
ng of purified, full-length CBP in a total volume of 30 µl in acetylation buffer (20 mM 
HEPES [pH 7.8], 1 mM EDTA, 1 mM DTT, 10 mM sodium butyrate, and 10% glycerol) 
in the presence of 1.5 µM [14C]acetyl coenzyme A (AcCoA) and incubated for 30 min at 
30°C followed by electrophoresis on an 8% sodium dodecyl sulfate-polyacrylamide gel. 
The gel was subsequently fixed with a 30% methanol, 10% acetic acid solution and 
treated with amplifying solution (Amersham) before exposure to film. Western blotting 
was performed to confirm equal loading of protein and the maintenance of SUMO 
modification of TDG.  
In vitro sumoylation 
Sumoylation was performed as previously described (10). Briefly, recombinant GST-
SAE1, GST-SAE2, polyhistidine (His)-tagged UBC9 (1 µg each), and SUMO-1 (1.5 µg) 
proteins were incubated with 5 µg of His-TDG in SUMO conjugation buffer (20 mM 
HEPES [pH 7.4], 5 mM MgCl2, 1 mM creatine phosphate, 0.35 units/ml of creatine 
kinase [Roche], 1 mM ATP). Mock sumoylation reactions were performed in the absence 
of SUMO-1. Modified TDG was purified using Ni-nitrilotriacetic acid Superflow affinity 
resin (QIAGEN) and dialyzed against NETN at 4°C for 12 h. Copurified His-UBC9 was 
removed by centrifugal membrane separation using a 10-kDa molecular weight cut-off 
cellulose filter (Centricon).  
Antibodies and immunostaining 
TDG-specific antibody was raised in rabbits immunized with recombinant full-length 
TDG. Immunoglobulin G (IgG) was purified from immune sera by protein A 
chromatography. Human PML-specific monoclonal (PG-M3, sc-966), CBP-specific 
polyclonal (sc-369), and anti-p53 (DO-1, sc-126) monoclonal antibodies were obtained 
84 
 
 
 
from Santa Cruz Biotechnology. Mouse PML-specific monoclonal antibody (05-718) was 
from Upstate/Chemicon. SUMO-1-specific monoclonal antibody was purchased from 
Zymed (clone 21C7). Anti-FLAG monoclonal antibody (M2) was obtained from Sigma-
Aldrich. For immunostaining, cells were fixed with 4% formaldehyde for 15 min 
followed by a 10-min incubation with 0.1 M glycine in phosphate-buffered saline. Cells 
were then permeabilized with 0.5% Triton X-100. Alternatively, cells expressing FLAG-
tagged proteins were fixed with methanol-acetone (1:1) for 1 minute at room temperature. 
Immunostaining was performed with the appropriate primary antibody and fluorophore-
conjugated donkey secondary antibody (CY3 and fluorescein isothiocyanate [FITC]; 
Jackson ImmunoResearch Laboratories).  
Microscopy 
Epifluorescence imaging was performed on an Axiovert 200 M inverted microscope 
equipped with an Apotome (Carl Zeiss) using appropriate fluorophore-specific filter sets. 
Z-series images (x63 magnification) of 0.5-µm thickness were acquired and processed 
with Axiovision software and Adobe Photoshop.   
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2.3 Results 
SUMO-dependent translocation of TDG to PML oncogenic domains.  
Previous studies have demonstrated that TDG is acetylated by CBP/p300 and can act as a 
potent activator of CBP-dependent transcription (46). CBP is recruited to PODs by 
association with PML (12), and there is considerable evidence suggesting that these 
nuclear structures play important roles in transcription and DNA repair (9, 26, 50). We 
investigated the subnuclear localization of TDG in human breast carcinoma cells (MCF-7) 
by indirect immunofluorescence using TDG-specific antibodies and by transient 
expression of YFP-tagged TDG. YFP-TDG localized throughout the nucleoplasm with the 
exception of nucleoli (Fig. 2.1A, panel II); accentuated fluorescence was observed in 
nuclear PODs, as demonstrated by colocalization of YFP-TDG with PML (Fig. 2.1A, 
panel III). Furthermore, coexpression of YFP-TDG and PML dramatically increased POD 
localization of TDG (panels V to VIII). Since these observations suggested that TDG 
associates with PML, we determined whether a bacterially expressed GST-PML fusion 
protein bound TDG in whole-cell lysates derived from transfected MCF-7 cells. While we 
did not detect binding of TDG to GST-PML, binding to GST-SUMO-1 was readily 
observed (Fig. 2.1B). In light of the SUMO-1 binding properties of TDG, we investigated 
whether this activity is required for POD targeting. Mild hyperthermic stress causes rapid 
desumoylation of PML and another POD component, SP100, without affecting the 
structural integrity of the PODs (34). We subjected MCF-7 cells expressing YFP-TDG 
and CFP-tagged PML (CFP-PML) to heat shock at 42°C for 15 min and monitored 
protein localization in live cells by fluorescence microscopy. A dramatic loss of POD 
accumulation of YFP-TDG was observed without detectable changes in CFP-PML 
localization (Fig. 2.1C). Immunoblotting analysis of cell lysates, using a TDG-specific 
antibody, indicated that heat shock did not alter the levels of TDG sumoylation (Fig. 
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2.1C). In light of the reported desumoylation of PML and SP100 following hyperthermic 
stress (34), these observations suggest that the SUMO-1 binding activity of TDG mediates 
POD targeting.   
To rule out the potential influence of overexpression on the subcellular distribution of 
TDG, we determined whether native TDG is found in PODs by immunostaining MCF-7 
cells with purified TDG-specific rabbit IgG and commercial PML-specific mouse 
monoclonal antibodies. TDG-specific rabbit antibody raised against recombinant mouse 
TDG also recognizes human TDG (Fig. 2.1D) but does not cross-react with PML (data 
not shown). In untransfected MCF-7 cells, endogenous TDG staining was observed in a 
granular pattern throughout the nucleoplasm: a subpopulation of cells consistently 
displayed increased staining within the PODs (Fig. 2.1E, panels I to III). Similar results 
were obtained with immortalized mouse NIH 3T3 cells (Fig. 2.1E, panels IV to VI). 
These findings indicate that a small fraction of endogenous TDG localizes to the PODs, 
consistent with our transient-expression studies. 
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Figure. 2.1.  SUMO-1-dependent recruitment of TDG to PML oncogenic domains. 
(A) Subcellular localization of YFP-TDG with and without coexpression of PML. MCF-7 
cells were transfected with 300 ng of YFP-TDG expression vector alone or in 
combination with 300 ng of PML expression vector. PODs were detected by 
immunostaining fixed cells with PML-specific antibody. Fluorescence microscopy was 
performed using appropriate filters (CY3, YFP). Representative 0.5-µm optical sections 
are shown. (B) In vitro interaction of MCF-7-expressed TDG with recombinant GST-
SUMO-1 and GST-PML. Cellular lysates were incubated with GST fusion proteins, and 
bound TDG was detected by immunoblotting. (C) Hyperthermic stress releases TDG 
from PODs. Live MCF-7 cells expressing YFP-TDG and CFP-PML were imaged initially 
at 37°C and following incubation at 42°C for 15 min. Lysates of control and heat-shocked 
cells (15 and 30 min) were immunoblotted with a TDG-specific antibody to reveal 
unmodified and sumoylated (S) YFP-TDG. (D) TDG-specific antibody recognizes mouse 
and human TDG. Whole-cell extracts from MCF-7 cells transfected with empty vector 
(control) or mouse TDG expression vector were immunoblotted with purified TDG-
specific rabbit IgG. (E) Nuclear colocalization of endogenous TDG and PML. 
Untransfected MCF-7 and NIH 3T3 cells were immunostained with TDG- and PML-
specific antibodies and fluorophore-conjugated (FITC, CY3) secondary antibodies. The 
fluorescence intensity plot illustrates the coincidence of peak fluorescence for TDG 
(CY3, red) and PML (FITC, green). Measurements were obtained by performing a line 
scan across three PODs using Axiovision software. Representative 0.5-µm optical 
sections are shown.  
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Identification of POD targeting and SUMO-1 binding domains.  
In order to identify protein domains within TDG essential for POD localization, we 
generated a series of CFP-tagged amino- and carboxy-terminal deletions and examined 
their cellular localization following coexpression with PML. Our analysis indicated that 
amino-terminal residues were required for nuclear targeting of TDG (Fig. 2.2A). Deletion 
of residues 1 to 156 shifted localization predominantly to the cytoplasm, whereas deletion 
of residues 1 to 121 resulted in similar levels of nuclear and cytoplasmic fluorescence. In 
order to assess the contribution of this region to POD localization, we engineered deletion 
constructs containing the SV40 NLS. FLAG epitope-tagged amino- and carboxy-terminal 
deletions were coexpressed with YFP-PML, and subcellular localization was examined by 
immunostaining with anti-FLAG antibody. Remarkably, we found that TDG lacking the 
first 121 residues (i.e., NLS122-421) accumulated preferentially in the PODs compared to 
wild-type TDG (Fig. 2.2B, compare panels I and II). Consequently, in a large fraction of 
cells (40 to 50%) nuclear fluorescence was predominantly associated with PODs, whereas 
in the case of wild-type TDG, substantial nucleoplasmic localization was observed. A 
lysine-rich regulatory domain (LRD; residues 70 to 118) previously shown to be 
acetylated by CBP/p300 is contained within this deleted region (46). Further removal of 
residues 123 to 156 (NLS157-421) led to a dramatic decrease in the number of expressing 
cells, with the majority of the tagged protein being found in large aberrant nucleoplasmic 
foci that also contained PML. Loss of carboxy-terminal residues 346 to 421 did not affect 
POD targeting; however, further deletion to residue 307 completely abrogated TDG 
accumulation in these structures. These data suggest that both amino- and carboxy-
terminal regions of TDG contribute to POD localization. 
In light of evidence suggesting a SUMO-1-dependent mechanism in POD targeting, we 
also tested amino- and carboxy-terminal deletions of TDG produced by in vitro 
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transcription/translation for binding to GST-SUMO-1. While full-length TDG displayed 
only weak SUMO binding activity, removal of residues 1 to 121 dramatically stimulated 
binding (Fig. 2.2C). In contrast, deletion of residues 1 to 156 or 307 to 346 resulted in 
complete loss of SUMO binding activity. These findings suggest that two distinct regions 
of TDG (residues 122 to 156 and 307 to 346) are essential for SUMO-1 binding, whereas 
a third region (residues 1 to 121) containing the LRD appears to suppress binding activity. 
Notably, these domains are also involved in POD targeting, suggesting that the SUMO-1 
binding activity of TDG may be required for targeting to these nuclear structures. 
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Figure 2.2.  Deletion mapping of SUMO-1 binding and POD-targeting domains in 
mouse TDG. (A) Subcellular localization of amino- and carboxy-terminal deletions of 
TDG. CFP-tagged deletions of TDG were expressed in MCF-7 cells and analyzed by 
direct fluorescence microscopy. (B) Amino- and carboxy-terminal deletions of TDG 
(depicted in the upper panel) containing the FLAG epitope were coexpressed with YFP-
PML in MCF-7 cells. Approximately 300 ng of TDG and 500 ng of YFP-PML expression 
vectors were used. TDG was detected by immunostaining with anti-FLAG monoclonal 
antibody and CY3-conjugated secondary antibody. Representative 0.5-µm optical 
sections are shown. The location of the LRD is indicated. Note that FLAG-tagged amino-
terminal deletions include the SV40 NLS. (C) In vitro interaction of TDG with GST-
SUMO-1 is enhanced by deletion of residues 1 to 121. In vitro-translated 35S-radiolabeled 
full-length TDG and the indicated deletion mutants were used in binding assays with 
GST-SUMO-1 and GST. Bound proteins were detected by autoradiography. 
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DNA interactions regulate SUMO-1 binding activity.  
In vitro mapping studies suggested that the amino-terminal region (residues 1 to 121) 
modulated interactions with SUMO-1. In human TDG, this region has been found to be 
essential for nonspecific DNA binding and interactions with abasic sites (44). Since in 
vitro translation reaction mixtures contain plasmid DNA, we wanted to establish whether 
the DNA binding properties of the amino-terminal region could interfere with SUMO-1 
binding in vitro; therefore, we performed SUMO binding experiments in the presence of 
ethidium bromide to effectively prevent DNA binding (25). A marked stimulation in 
SUMO-1 binding from full-length TDG was observed, while binding of the 122-421 
protein was not affected (Fig. 2.3A). These data suggested that DNA binding by the 
amino-terminal region of TDG may prevent SUMO-1 recognition. 
Human TDG has been shown to bind both G:T/U-mispaired and normally paired DNA 
(19). The mouse and human TDG orthologs are highly conserved within the central 
enzymatic core and less well conserved in the amino- and carboxy-terminal regions. 
Using an electrophoretic mobility shift assay (13), we confirmed that bacterially 
expressed mouse TDG has similar DNA binding specificity and could form complexes 
with normally paired (G:C) as well as G:T/U-mispaired duplex oligonucleotides (Fig. 
2.3B). The requirement of the 1-121 region in DNA interactions was confirmed using the 
ABCD binding assay (15). In these assays, recombinant full-length TDG bound to a G:T-
mispaired oligonucleotide, while an amino-terminal-truncated protein fragment (122-421) 
did not detectably associate with DNA (Fig. 2.3C). To determine whether residues 1 to 
121 contained a modular DNA binding domain, we assayed a GST fusion protein 
containing this region for binding to G:T duplex oligonucleotide using the ABCD assay 
(data not shown). The fact that DNA binding was not observed suggests that the amino-
terminal region does not independently associate with DNA. Interestingly, the NLS122-
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421 protein displayed preferential POD localization upon coexpression with PML (Fig. 
2.2B), suggesting that loss of DNA interactions promotes POD targeting. We tested 
whether the DNA and SUMO binding activities of TDG are mutually exclusive by 
performing binding studies with GST-SUMO-1 and recombinant TDG in the presence of 
increasing amounts of duplex oligonucleotide containing a G:T mispair. A dose-
dependent reduction in SUMO binding was consistently observed in the presence of DNA 
(Fig. 2.3D); in contrast, preincubation of TDG with SUMO-1 did not affect binding to 
G:T or G:C duplex oligonucleotides (see Fig. S.2.1). 
  
95 
 
 
 
 
 
 
Figure 2.3.  The amino-terminal DNA binding domain of TDG regulates SUMO-1 
binding activity. (A) Binding of full-length in vitro-translated TDG to GST-SUMO-1 is 
sensitive to ethidium bromide. In vitro-translated 35S-radiolabeled full-length TDG or the 
122-421 truncated protein was bound to GST-SUMO-1 in the presence or absence of 
ethidium bromide. (B) Recombinant mouse TDG binds normally paired as well as G:T or 
G:U mispaired duplex oligonucleotides. An electrophoretic mobility shift assay was 
performed using the indicated radiolabeled duplex oligonucleotides. Approximately 100-
fold molar excess of the same unlabeled oligonucleotides was used as competitor DNA. 
(C) Residues 1 to 121 of mouse TDG are essential for DNA binding. A biotin-tagged 
duplex oligonucleotide (500 ng) containing a G:T mispair was bound to recombinant full-
length TDG or the 122-421 protein (500 ng each). DNA-protein complexes were isolated 
using streptavidin-Sepharose and analyzed by immunoblotting with a monoclonal 
antihistidine antibody. (D) DNA binding suppresses the SUMO-1 binding activity of 
TDG. Recombinant TDG (200 ng) was bound to GST-SUMO-1 in the presence of 
increasing amounts (70, 210, and 420 ng) of duplex oligonucleotides containing a G:T 
mispair. 
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Identification of a novel amino-terminal SUMO-1 binding motif.  
In vitro mapping studies indicated that residues 122 to 156 are required for SUMO-1 
binding; therefore, we examined the amino acid sequence within this region and identified 
four residues (IVII; amino acids 145 to 148) which are identical to the recently 
characterized SUMO-1 binding consensus motif (I/V-X-I/V-I/V) (42). Furthermore, this 
motif is flanked by an aspartic acid (i.e., DIVII) residue also present adjacent to the 
SUMO-1 binding motifs of the RanBP2/NUP358 and SUMO activating enzyme 2 (SAE2) 
proteins (42). The DIVII residues are conserved in mammalian, chicken, and Drosophila 
melanogaster TDG orthologs and are contiguous with the conserved GINPGL 
glycosylase motif (2, 18) (Fig. 2.4A). Previous structural studies using a truncated form of 
human TDG have identified a carboxy-terminal SUMO-1 binding motif (VQEV) (1) that 
is conserved in mouse, human, and chicken TDG, but not in the Drosophila ortholog (Fig. 
2.4A). In order to establish whether the putative amino- and carboxy-terminal SBMs in 
mouse TDG bind SUMO-1, we generated a series of mutant proteins with single amino 
acid substitutions and measured their ability to bind to GST-SUMO-1 (Fig. 2.4B). 
Alanine substitution mutants were generated for each residue in the DIVII motif, whereas 
a single glutamic acid-to-glutamine (E321Q) substitution in the VQEV motif was 
analyzed, as this had been previously reported to abrogate SUMO-1 binding in human 
TDG (1). Substitution of specific residues within each putative SBM independently 
abrogated SUMO-1 binding, suggesting that in the context of full-length TDG both motifs 
are essential for stable SUMO-1 interactions. Specifically, within the DIVII motif, the 
I145A and V146A substitutions produced small but consistent reductions in binding, 
whereas the D144A and I147A substitutions displayed more pronounced loss of binding. 
In contrast, the I148A substitution appeared to stimulate binding. The E321Q substitution 
in the carboxy-terminal SBM completely abrogated binding. To rule out gross effects of 
the amino acid substitutions on protein folding, we performed DNA glycosylase assays 
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using radiolabeled duplex oligonucleotides containing a single G:T mispair (see Fig. 
S.2.2). Comparable levels of base excision were observed with in vitro-translated wild-
type TDG, D144A, and E321Q, consistent with proper folding. Similar results on SUMO 
binding were obtained when we expressed the respective TDG mutants in MCF-7 cells 
and used whole-cell lysates in interaction studies (Fig. S.2.3). 
In order to determine whether the SBMs are required for binding to SUMO-1 conjugated 
to a target protein, we employed an in vitro sumoylation system (10) reconstituted with 
bacterially expressed enzymes (SAE1, SAE2, and UBC9) and SUMO-1 to sumoylate a 
purified bacterially expressed GST fusion of tumor suppressor p53 protein (39). As a 
control, mock sumoylation reactions were carried out in the absence of SUMO-1. 
Analysis of the reaction products by immunoblotting revealed the presence of a protein 
band reactive with both p53 and SUMO-1 antibodies only in the sumoylation reaction 
(Fig. 2.4C). The products of both the mock and sumoylation reactions were bound to 
glutathione affinity beads and used in interaction studies with in vitro-translated TDG and 
SBM mutants (D144A and E321Q). We observed appreciable binding of wild-type TDG 
on beads containing sumoylated GST-p53, while only marginal binding was detected with 
mock-sumoylated GST-p53 (Fig. 2.4D). The D144A mutant displayed substantially 
reduced binding, while the E321Q substitution almost completely abrogated binding. 
Since the sumoylation reaction mixtures contain GST fusions of the SAE1 and SAE2 
enzymes, we also performed binding reactions with the products of sumoylation reactions 
lacking GST-p53. In this case, binding of TDG was not detected. These findings indicate 
that the DIVII residues in TDG constitute a bona fide SBM and that the SUMO-1 binding 
activity of TDG resides within two separate motifs. 
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Figure 2.4.  SUMO-1 binding activity of TDG resides in amino-terminal and 
carboxy-terminal motifs. (A) Amino acid sequence alignments of the mouse (47), 
human (32), chicken (51), and Drosophila melanogaster (18) TDG orthologs showing 
putative SBMs. The coordinates for the mouse sequences are indicated. Complete 
sequences were aligned using Clustal W software, but only pertinent regions are shown 
(136 to 155 and 312 to 326 of mouse TDG). The location of the conserved DIVII and 
VQEV motifs (boxed) as well as the active site glycosylase motif (GINPGL) and the 
substrate recognition motif (VMPSSSAR) (19) are shown. Asterisks indicate identical 
residues, while colons indicate conserved residues. The different engineered substitution 
mutants of the DIVII and VQEV motifs are indicated. (B) Single amino acid substitutions 
within the conserved DIVII and VQEV motifs abrogate SUMO-1 binding. Radiolabeled 
in vitro-translated wild-type TDG and the indicated substitution mutants were analyzed 
for binding to GST-SUMO-1 in the presence of ethidium bromide. Binding was measured 
by phosphorimaging. (C) In vitro sumoylation of recombinant GST-p53. In vitro 
sumoylation reactions were performed by incubating GST-p53 with sumoylation enzymes 
(GST-SAE1, GST-SAE2, and UBC9) and SUMO-1. Reaction products were 
immunoblotted with p53 or SUMO-1 antibodies. (D) SBMs are required for optimal 
binding to conjugated SUMO-1. The products of the GST-p53 sumoylation and mock 
sumoylation reactions were bound to glutathione affinity beads and used for interaction 
assays with in vitro-translated TDG and SBM mutants (D144A and E321Q). Binding 
experiments were also carried out with sumoylation reaction mixtures lacking GST-p53 
to exclude interactions of TDG with GST-SAE1/SAE2. The results of three independent 
experiments are plotted, showing the mean percent binding of input proteins to beads 
containing sumoylated GST-p53. The standard error is shown.  
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To assess whether the amino- and carboxy-terminal SBMs are required for POD 
translocation, we expressed the SUMO-1 binding-deficient mutants (D144A, I147A, and 
E321Q) with YFP-PML and monitored cellular localization by immunostaining with an 
anti-FLAG antibody (Fig. 2.5A and B). This analysis showed that mutations within the 
amino-terminal SBM substantially reduced the number of transfected cells displaying 
POD accumulation of TDG; in contrast, the E321Q substitution completely abolished 
POD accumulation. These findings indicate that both SBMs in TDG are involved in POD 
targeting.  
Previous studies have demonstrated a potent stimulatory function of TDG on CBP-
dependent transcription (46). To assess whether the SUMO binding activity of TDG is 
involved in stimulating CBP-dependent transcription, we tested the activation potential of 
the D144A, I147A, and E321Q mutants using a chimeric fusion of CBP and the GAL4 
DNA binding domain on a GAL4-responsive reporter gene (Fig. 2.5C and D). The 
amounts of transfected expression vectors were adjusted to achieve approximately 
equivalent levels of expression of wild-type TDG and mutants. In accordance with the 
SUMO-1 binding and POD localization studies, the D144A, I147A, and E321Q mutants 
were found to be defective in CBP activation. Previous studies have shown that TDG 
interacts with the histone acetyltransferase and a carboxy-terminal domain (CH3) of CBP 
(46). Since the amino acid substitutions may affect interactions with CBP, we tested in 
vitro-translated wild-type, D144A, and E321Q proteins for binding to full-length 
recombinant CBP (see Fig. S.2.4 in the supplemental material). However, no differences 
in binding were detected, suggesting that abrogation of the CBP activation properties in 
the SBM mutants is likely due to loss of SUMO binding activity. We also investigated 
whether the previously reported sumoylation sites in CBP (14, 24) are required for 
activation by TDG. Accordingly, we examined the ability of TDG to activate a CBP 
mutant containing lysine-to-arginine substitutions at sumoylation sites K999, K1034, and 
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K1057. The transcriptional activity of this mutant was also robustly stimulated by TDG, 
indicating that CBP sumoylation is not essential for this effect (see Fig. S.2.5).  
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Figure 2.5.  SUMO-1 binding activity of TDG is essential for CBP activation and 
normal POD recruitment. (A) SUMO-1 binding mutants are defective in POD 
recruitment. FLAG-tagged wild-type TDG and the indicated mutants were coexpressed 
with YFP-PML, and POD recruitment was analyzed by indirect immunofluorescence 
using anti-FLAG antibody. Representative 0.5-µm optical sections are shown. (B) 
Incidence of POD accumulation for wild-type TDG and mutants coexpressed with YFP-
PML. An average of 120 cells were counted to determine POD accumulation of wild-type 
TDG or SUMO-1 binding mutants. Error bars represent standard deviations of 
determinations from three independent experiments. (C) Activation of CBP-dependent 
transcription is abrogated by E321Q substitution in the VQEV motif. (D) Mutations in 
DIVII motif also abrogate CBP activation. Expression vectors for GAL-CBP, wild-type 
TDG, and point mutants of TDG were cotransfected into MCF-7 cells. The luciferase 
reporter plasmid contains five copies of the GAL4 DNA binding site fused to the core ß-
globin promoter. The amounts of transfected TDG expression vectors were titrated to 
obtain approximately equal levels of protein expression (immunoblot, lower panel).  
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Sumoylation of TDG regulates association with CBP and subnuclear localization.  
Human TDG has been reported to be sumoylated at a single carboxy-terminal lysine 
residue (20). Consistent with this, we have observed a higher-molecular-weight band in 
immunoblots of mouse cell extracts and in transfected human cells expressing mouse 
TDG (Fig. 2.6 and data not shown). To determine whether the higher-molecular-weight 
band corresponds to sumoylated TDG, we cotransfected FLAG-TDG and HA-SUMO-1 
expression vectors into MCF-7 cells and analyzed cellular lysates by immunoblotting with 
anti-FLAG and anti-HA antibodies (Fig. 2.6A). This analysis indicated that the higher-
molecular-weight band detected with the anti-FLAG antibody corresponds to SUMO-1-
modified TDG, since it was also detected with the anti-HA antibody. The sumoylated 
form of TDG is not observed when lysine 341, located within the SUMO consensus 
conjugation site (VKEE), is mutated to arginine (Fig. 2.6B). 
In vitro sumoylation experiments, using recombinant TDG as a substrate, confirmed that 
the sumoylation machinery is present in both nuclear and cytoplasmic extracts (data not 
shown). We assessed whether TDG sumoylation occurred within the nucleus by 
expressing CFP-tagged amino-terminal deletions (CFP122-421, CFP157-421) of TDG 
defective in nuclear targeting and determining the level of sumoylation by 
immunoblotting cellular lysates with a TDG-specific antibody (Fig. 2.6C). The CFP157-
421 fusion protein that localized preferentially to the cytoplasm was not efficiently 
sumoylated, since a higher-molecular-weight band corresponding to sumoylated TDG 
was not readily detectable. A truncated form of TDG (CFP32-272) lacking the 
sumoylation site was also not sumoylated. These data suggest that TDG sumoylation takes 
place in the nuclear compartment and/or at the nuclear membrane. The observation that 
SUMO-1 binding mutants (E321Q, D144A, and I147A), defective in POD localization, 
were sumoylated efficiently in vivo indicates that noncovalent SUMO binding is not 
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required for sumoylation (Fig. 2.6D). Furthermore, these findings also suggest that 
sumoylation is likely not occurring within the PODs. 
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Figure 2.6.  TDG sumoylation occurs in the nucleus and does not require 
noncovalent SUMO-1 binding activity. (A) FLAG-TDG and HA-SUMO-1 expression 
vectors were cotransfected into MCF-7 cells, and lysates were analyzed by 
immunoblotting using anti-FLAG or anti-HA antibody. Sumoylated TDG (S-TDG), 
TDG, and nonspecific (NS) bands are indicated. (B) In vivo sumoylation occurs at lysine 
341 of mouse TDG. Expression vectors for TDG and K341R were transfected into MCF-
7 cells, and cellular lysates were blotted with TDG-specific antibody. (C) TDG is 
sumoylated predominantly in the nucleus. Whole-cell lysates of MCF-7 cells transfected 
with expression vectors for the indicated CFP fusions were analyzed by immunoblotting 
with TDG-specific antibody. CFP157-421 is localized preferentially in the cytoplasm 
(Fig. 2.2A). (D) SUMO-1-binding-deficient mutants are sumoylated efficiently in MCF-7 
cells. Cellular lysates from MCF-7 cells transfected with the indicated expression vectors 
were analyzed by immunoblotting with a TDG-specific antibody. 
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Sumoylation has been shown to regulate cellular partitioning of PML and other proteins 
(49); we therefore compared the subcellular localization of Renilla GFP fusions of the 
sumoylation-deficient mutant K341R and wild-type TDG. Notably, the K341R mutant 
protein was found to accumulate exclusively in PODs in approximately 30% of 
transfected cells, whereas wild-type TDG exhibited its characteristic nucleoplasmic 
distribution (Fig. 2.7A).  The enhanced ability of the K341R mutant to localize to the 
PODs suggests that sumoylation of TDG negatively regulates POD translocation.  
The conjugation of SUMO-1 to lysine 341 covalently links a bulky peptide to a region 
that has been previously shown to interact with CBP/p300 (46). Moreover, the presence of 
SUMO binding motifs within the amino- and carboxy-terminal regions suggests that 
sumoylation of TDG may promote intramolecular interactions that drastically alter the 
conformation of this protein. To investigate the functional consequences of sumoylation, 
we produced sumoylated recombinant TDG in vitro along with a mock-sumoylated 
control (Fig. 2.7B). Mock-sumoylated TDG and sumoylated TDG proteins were analyzed 
for DNA binding to a duplex oligonucleotide containing a single G:T mispair using the 
ABCD assay. As reported for the human ortholog, sumoylated mouse TDG failed to 
interact with DNA (Fig. 2.7C). We performed interaction studies with purified 
recombinant baculovirus-expressed CBP bearing a FLAG epitope tag. Protein complexes 
were captured using anti-FLAG affinity resin. While binding of mock-sumoylated TDG 
to CBP was readily observed, only weak interactions were observed with sumoylated 
TDG (Fig. 2.7D). Consequently, sumoylated TDG was not appreciably acetylated by CBP 
in the presence of 14C-AcCoA (Fig. 2.7E). To establish whether intramolecular SUMO 
binding in sumoylated TDG occludes both SBMs, we tested whether sumoylated TDG 
can interact with GST-SUMO-1 in vitro. In contrast to mock-sumoylated TDG, 
sumoylated TDG failed to interact with GST-SUMO-1 (Fig. 2.7F). To confirm that 
sumoylated TDG is enzymatically active, we performed DNA glycosylase assays using 
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radiolabeled duplex oligonucleotides containing a single G:U mispair. As previously 
reported (20), sumoylated TDG displayed enhanced G:U processing activity compared to 
unmodified TDG and mock-sumoylated TDG (see Fig. S.2.6). Therefore, abrogation of 
the interaction of sumoylated TDG with CBP is unlikely due to aberrant misfolding but 
likely involves sumoylation-induced conformational changes. 
 
  
111 
 
 
 
 
Figure 2.7.  Sumoylation of TDG abrogates interaction with CBP in vitro and 
negatively regulates POD translocation. (A) A sumoylation-defective TDG mutant 
localizes preferentially to PODs. Expression vectors for GFP-TDG or GFP-TDG(K341R) 
were transfected into MCF-7 cells, and subcellular localization was analyzed following 
immunostaining with PML-specific antibody. Representative 0.5-µm optical sections are 
shown. (B) In vitro sumoylation of TDG using recombinant SUMO-1 conjugation 
enzymes (UBC9, SAE1, and SAE2). Sixty nanograms of purified reaction products was 
analyzed by immunoblotting with TDG- and SUMO-1 specific antibodies. Mock-
sumoylated TDG was produced by performing sumoylation reactions without SUMO-1. 
(C) Sumoylated mouse TDG does not bind to DNA. Approximately 400 ng of either 
mock-sumoylated or sumoylated TDG was analyzed for DNA binding using the ABCD 
assay. Supernatants of each binding reaction mixture were also immunoblotted to 
demonstrate the stability of the modification during the assay (SUP-M and SUP-S). (D) 
TDG sumoylation abrogates CBP-TDG interactions. Mock or sumoylated TDG produced 
in vitro (400 ng) was incubated with recombinant FLAG-CBP (100 ng). Anti-FLAG resin 
was used to immunoprecipitate CBP, and the presence of TDG was detected by 
immunoblotting. Supernatants of each binding reaction mixture were also immunoblotted 
(SUP-M and SUP-S). (E) Sumoylated TDG is not acetylated efficiently by CBP.  Mock-
sumoylated or sumoylated TDG (400 ng) was incubated with CBP (100 ng) in the 
presence of 14C-acetyl-CoA. Reaction products were separated by electrophoresis, and 
acetylation was detected by autoradiography.  (F) Sumoylated TDG does not bind GST-
SUMO-1. Mock-sumoylated or sumoylated TDG was analyzed for binding to GST-
SUMO-1.  
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2.4 Discussion 
We have investigated the role of sumoylation and noncovalent SUMO-1 binding in the 
regulation of subcellular localization and biochemical properties of thymine DNA 
glycosylase. Our studies have mapped the regions of TDG necessary for non-covalent 
SUMO-1 interactions to two separate motifs (SBMs) located in the amino- and carboxy-
terminal regions that are essential for POD localization and activation of CBP-dependent 
transcription. The activities of the SBMs are regulated by DNA interactions, and 
uncoupling of TDG from DNA appears to be an essential step in POD translocation. In 
addition, we have established that TDG sumoylation regulates molecular interactions with 
CBP as well as translocation to PODs.  
PODs contain regulatory proteins involved in different nuclear processes, including DNA 
repair and transcription (9, 50). Diverse models of POD function have been proposed, 
including their potential role as sites of storage and modification of nuclear factors 
(reviewed in reference 26). For example, tumour suppressor p53 acetylation by CBP in 
PODs constitutes a critical step in p53 activation during RAS-induced premature 
senescence (38). Interestingly, there is evidence that PODs associate with 
transcriptionally active genomic loci, and transcription has been detected at the periphery 
of these structures (5, 48). We have established the presence of endogenous TDG in 
PODs using a TDG-specific antibody and demonstrated the SUMO-dependent 
recruitment of exogenously expressed TDG to these nuclear structures (Fig. 2.1). While 
recent studies have reported a direct interaction of mouse TDG with PML (45), we have 
not observed significant binding of these proteins in vitro. It is unlikely that the lack of 
interaction is due to misfolding of bacterially expressed PML, since we have obtained 
similar results with baculovirus-expressed FLAG-tagged PML (data not shown). 
Furthermore, no appreciable binding of sumoylated TDG with PML in vitro was observed 
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(data not shown). Our findings suggest that TDG may be recruited to PODs by 
sumoylated PML (30) and/or other sumoylated POD components. We base this assertion 
on the requirement of SUMO-1 binding activity of TDG for POD recruitment and the fact 
that mild hyperthermic stress, previously shown to cause rapid desumoylation of PML and 
SP100 (34), abrogates POD accumulation of TDG without affecting PML localization.  
Deletion analysis of TDG indicated the presence of two regions (residues 122 to 156 and 
308 to 346) essential for SUMO-1 binding in vitro, as well as a third region containing the 
LRD that exerted an inhibitory function (Fig. 2.2B). We have identified a novel SUMO-1 
binding motif (DIVII) within the 122-156 region conforming to the recently reported 
consensus SUMO-1 binding site (I/V-X-I/V-I/V) that mediates recognition of SUMO-
modified proteins (42). The observation that single amino acid substitutions within the 
DIVII motif (particularly D144A and I147A) substantially reduce SUMO-1 binding in the 
context of full-length TDG clearly demonstrates that this is a bona fide SBM (Fig. 2.4B) 
(see also Fig. S.2.3).  
Recent structural analysis of amino- and carboxy-terminal-truncated sumoylated human 
TDG identified a SUMO-1 binding motif (VQEV) located within the carboxy terminus 
near the SUMO conjugation site (1). Mutational analysis of mouse TDG revealed that 
both the amino- and carboxy-terminal SBMs (i.e., DIVII and VQEV) are required for 
stable interactions with both free and conjugated SUMO-1 (Fig. 2.4). Consequently, these 
observations suggest that SUMO-1 may bind concurrently to both SBMs. However, as 
both motifs have been reported to make nearly identical contacts (1, 42, 43) with residues 
on SUMO-1, we infer that there is considerable plasticity in these interactions. 
Accordingly, the I/V-X-I/V-I/V motif has recently been shown to interact bidirectionally 
with SUMO-1 (43). In contrast to a recent report (45), we have found that the SUMO-1 
binding activity of TDG is not required for covalent conjugation of SUMO-1 (Fig. 2.6). 
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This discrepancy could be explained by the reliance of previous studies on the analysis of 
a TDG mutant containing an 11-amino-acid deletion, whereas more subtle single amino 
acid substitutions were employed in our studies.  
The essential role of SUMO binding in POD translocation is demonstrated by the 
observation that single amino acid substitutions that decrease or abolish SUMO-1 binding 
also disrupt POD targeting (Fig. 2.4 and 2.5). Notably, both SBMs, in the context of full-
length TDG, appeared to be required for optimal POD translocation. In contrast, similar 
analysis of deletion mutants provided some discrepant results. Deletion of the 122-156 
region, containing the amino-terminal SBM, did not prevent POD localization in vivo. 
This may result from an inhibitory effect of the amino terminus (residues 1 to 121) on the 
carboxy-terminal SBM; removal of this region in the 157-421 deletion mutant may relieve 
inhibition and promote POD targeting. The TDG amino terminus (residues 1 to 121) is 
required for tight interaction with DNA and abasic sites (44) (Fig. 2.3C). Our findings 
suggest that uncoupling of TDG from DNA is necessary to unmask SUMO binding 
activity and promote POD translocation (Fig. 2.8). This may occur following excision of 
base mispairs via apurinic/apyrimidinic endonuclease (APE)-mediated displacement of 
TDG and/or following sumoylation of TDG (20). In the latter case, our findings suggest 
that sumoylation would prevent POD targeting by occluding the SBMs via intramolecular 
interactions; consequently, translocation to the PODs would require removal of SUMO-1 
by isopeptidases (22).  
A number of DNA repair factors have been shown to transit in PODs prior or following 
DNA damage (reviewed in reference 9), including enzymes involved in repair of double-
stranded DNA breaks (DSB). For example, MRE11 and NBS1 associate with PODs in 
unirradiated cells and relocate to sites of DNA damage following gamma irradiation (4, 
29). These observations suggest that PODs may act as sites of storage and/or assembly of 
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DNA repair protein complexes. Consistent with a role of PODs in genome maintenance, 
PML null mice display increased susceptibility to tumors following exposure to 
carcinogens (40). The association of PODs with transcriptionally active genomic loci (5, 
48) provides an attractive model for TDG function (Fig. 2.8). While DSB occur 
infrequently, it is estimated that several hundred DNA mispairs occur daily per cell as a 
result of cytosine deamination (27), suggesting that the DNA repair functions of TDG 
would be required more frequently to maintain genome integrity. The well-documented 
interactions of TDG with transcriptional coactivators and sequence-specific transcription 
factors suggest that the genome surveillance functions of this enzyme are linked to 
transcription (8, 46, 47). In vitro studies have demonstrated that CBP/p300 and TDG form 
stable ternary complexes with DNA containing G:T/U mispairs (46). The recruitment of 
CBP/p300 to repair sites in vivo may be required to promote local chromatin remodelling 
and/or regulate the functions of BER enzymes, such as TDG, APE, and DNA polymerase 
ß, previously shown to be acetylated by these factors (3, 21, 46). On the basis of the 
association of PODs with genomic loci (48), it is plausible that transient association of 
TDG with these nuclear structures is required to deliver this DNA repair enzyme to sites 
of active transcription, ensuring efficient repair of damaged CpG dinucleotides. 
Alternatively, as reported for p53 (38), POD localization of TDG may serve as a 
regulatory step to promote acetylation by CBP (46).  
Our studies indicate that the SUMO-1 binding activity of TDG is essential for activation 
of CBP-dependent transcription. Using reporter gene assays, we have demonstrated that 
SBM mutants (D144A, I147A, and E321Q), defective in SUMO-1 binding, do not 
mediate CBP activation (Fig. 2.5). Given that SUMO-1 binding is also required for POD 
recruitment, we are not able to resolve whether POD recruitment is required for CBP 
activation. However, this seems unlikely, since coexpression of TDG with PML does not 
produce greater levels of CBP activation despite increasing POD localization of TDG 
117 
 
 
 
(data not shown). Accordingly, we believe that SUMO-1 binding activity per se, and not 
POD targeting, is essential for CBP activation. The presence of a sumoylation-dependent 
transcriptional repressor domain in CBP/p300 that recruits histone deacetylases (14, 24) 
suggests a plausible role of TDG binding in promoting derepression by displacement of 
histone deacetylases. However, a CBP mutant containing lysine-to-arginine substitutions 
at characterized sumoylation sites (24) was also robustly activated by TDG (Fig. S.2.5), 
indicating that CBP sumoylation is not essential.  
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Figure 2.8.  Model for SUMO-1-dependent regulation of TDG subcellular 
localization and function. TDG associated with transcriptionally active euchromatin (46) 
initiates repair of G:T/U mispairs within CpG dinucleotides in a process that is likely 
linked to transcription. TDG-mediated repair may require CBP/p300 acetylase for local 
chromatin remodeling and/or regulation of repair enzymes via acetylation (3, 21, 46). 
Transcription has been detected in the periphery of PODs, and there is evidence for 
association of these structures with transcriptionally active genomic loci (5, 48). POD 
localization of TDG is dependent on its intrinsic SUMO binding activity and may be 
required to deliver this enzyme to transcriptionally active loci. For this purpose, TDG 
would require regulatory switches to control transit to PODs. Chromatin-associated TDG 
may not translocate to these nuclear structures due to DNA interactions that suppress 
SUMO binding activity. On the basis of our experimental findings, we propose that POD 
translocation is contingent upon uncoupling TDG from DNA, which may occur following 
base excision as a result of displacement by APE and/or sumoylation. Sumoylated TDG 
may not translocate to the PODs due to occlusion of the SBMs by intramolecular SUMO-
1 interactions. In this case, desumoylation would be required to permit POD 
translocation. Within these structures, TDG may be posttranslationally modified by CBP, 
as previously demonstrated for p53 (38), and/or assembled into functional complexes for 
delivery to transcriptionally active genomic loci. 
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TDG sumoylation has been shown to abrogate DNA binding activity and has been 
proposed as a mechanism to promote the turnover of TDG from abasic sites following 
base excision (20). We have confirmed that sumoylated mouse TDG is also defective in 
DNA binding. Our studies suggest that TDG sumoylation also plays an important role in 
regulating POD translocation and protein-protein interactions. Recent structural studies of 
sumoylated human TDG have revealed important insights on the conformational changes 
resulting from this covalent modification (1, 20). In addition, partial proteolysis studies 
have shown that sumoylation induces conformational changes involving interactions 
between the amino- and carboxy-terminal regions of human TDG (44). We have now 
identified a conserved amino-terminal SBM that in concert with a carboxy-terminal SBM 
may account for the observed sumoylation-induced conformational changes. Indeed, 
binding of the amino- and carboxy-terminal domains to SUMO-1 likely interferes with 
the DNA binding functions associated with the amino terminus (residues 1 to 121) (44). 
We have examined the effect of sumoylation on interactions with CBP and intermolecular 
SUMO-1 recognition in mouse TDG. Remarkably, TDG sumoylation abrogates both CBP 
interaction as well as intermolecular SUMO binding (Fig. 2.7). Based on these 
observations, loss of intermolecular SUMO binding should prevent POD translocation. 
Corroborating evidence for a role of sumoylation in regulating POD translocation comes 
from the analysis of the sumoylation-deficient mutant GFP-K341R, which displays 
exclusive POD localization in a subpopulation of cells. In view of our biochemical 
studies, we believe that loss of negative regulation (i.e., sumoylation) dramatically favors 
POD translocation. In view of the documented interactions of CBP/p300 with the TDG 
amino terminus and the resulting acetylation of the lysine-rich regulatory domain (46), we 
cannot exclude a role for CBP/p300 and acetylation in regulating POD targeting. 
Nevertheless, CBP is not likely to be a direct intermediary in POD recruitment since, 
when coexpressed with PML and TDG, it did not consistently accumulate with TDG in 
the PODs (data not shown).  
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In conclusion, we have elucidated the roles of sumoylation and noncovalent SUMO-1 
binding in regulating the subcellular localization and biochemical properties of TDG. 
Although the significance of POD localization remains to be established, our findings 
suggest a key role for these nuclear structures in regulating the functions of TDG in 
transcription and/or genome maintenance. 
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2.6 Supplemental information 
 
 
 
 
Figure S.2.1.  SUMO-1 binding does not interfere with DNA binding. Recombinant 
full-length TDG (500 ng) was preincubated with 2 μg of GST or GST-SUMO-1 prior to 
binding to biotin tagged duplex oligonucleotides (500 ng) containing either no mispairs 
(G:C) or a G:T mispair. DNA-protein complexes were isolated using streptavidin 
sepharose and analyzed by immunoblotting with an anti-histidine antibody. 
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Figure S.2.2.  Analysis of DNA glycosylase activity of in vitro translated TDG and 
SUMO binding motif point mutants.  The indicated in vitro translated proteins were 
incubated with radiolabelled duplex oligonucleotide containing a single G:T mispair. 
Excision of the mispaired thymine produces a 12-nucleotide fragment following alkali 
treatment and analysis by denaturing PAGE. The control reaction contained substrate 
only, while the reaction in lane 2 contained unprogrammed rabbit reticulocyte lysate. 
Phosphorimaging was performed on dried gels.  
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Figure S.2.3.  SUMO-1 binding activity of MCF-7 expressed TDG resides in amino- 
and carboxy-terminal motifs.  The D144A, I147A and E321Q mutant proteins as well 
as wild-type TDG were expressed in MCF-7 cells and whole cell extracts were bound to 
GST-SUMO-1.  Protein complexes were captured with glutathione sepharose, 
fractionated by SDS-PAGE and immunoblotted with a TDG-specific antibody. 
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Figure S.2.4.  SUMO binding motif mutants bind CBP in vitro. Recombinant CBP (1 
μg) was incubated with in vitro translated wild-type TDG, D144A and E321Q proteins.  
Protein complexes were isolated by immunoprecipitation with a CBP-specific antibody, 
fractionated by SDS-PAGE and visualized by autoradiography.  
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Figure S.2.5.  Sumoylation sites in CBP are not required for activation by TDG.  
Lysine residues in CBP previously shown to be sumoylated (K999, K1034, K1057) (24) 
were substituted with arginines.  This mutant also contained an arginine substitution at 
K1087. GAL DNA-binding domain fusions of wild-type CBP (GAL-CBP) and the above 
mutant (GAL-CBP4KR) were analyzed for transcriptional activation upon coexpression 
with TDG using a reporter plasmid consisting of five copies of the GAL4 binding site 
fused to the core β-globin promoter.  
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Figure S.2.6.  Sumoylated TDG possesses robust G:U processing activity.  DNA 
glycosylase assays were performed by incubating proteins with radiolabelled duplex 
oligonucleotide containing a single G:U mispair. Excision of the mispaired uracil 
produces a 12-nucleotide fragment following alkali treatment and analysis by denaturing 
PAGE. The control reaction contained substrate only.  
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Chapter 3: Opposing regulatory roles of phosphorylation and acetylation in DNA 
mispair processing by thymine DNA glycosylase 
3.1 Introduction 
Cytosine methylation in vertebrates is an important epigenetic mechanism regulating gene 
expression (24) that also contributes to CpG dinucleotide instability by promoting 
spontaneous base damage and increased susceptibility to endogenous and environmental 
mutagens (42).  Hydrolytic deamination of cytosine and 5-methylcytosine respectively 
generates uracil (U) and thymine (T) moieties mispaired with guanine (G) (29).  If these 
G:T/U mispairs remain unrepaired, they give rise to C to T transition mutations associated 
with oncogenic transformation and genetic diseases (43).  In fact, approximately 25% of 
all somatic mutations in the p53 tumor suppressor gene in human tumors involve C to T 
transitions at CpG and in some tumors this figure rises to almost 50% (41).   
Thymine DNA glycosylase (TDG) and methyl-CpG binding domain protein 4 (MBD4) 
mediate excision of mispaired thymine (G:T) and uracil (G:U) in the CpG context (20, 38, 
39) and also process various modified pyrimidines (5).  Excision of the aberrant base 
generates a cytotoxic abasic site that is subsequently processed by the coordinated action 
of other base excision repair (BER) enzymes, including apurinic/apyrimidinic 
endonuclease (APE) and DNA polymerase β (Polβ) (46).  MBD4 localizes predominantly 
to transcriptionally inactive heterochromatin while TDG is mostly excluded from these 
regions and associates with sequence specific transcription factors and cofactors (2, 3, 30, 
35, 50).  These findings suggest that TDG is targeted to transcriptionally active regions of 
the genome and that BER may be coupled to transcription.  Interestingly, overexpression 
of TDG was shown to reactivate a hormone regulated transgene silenced by CpG 
methylation, suggesting a role for TDG in epigenetic regulation (56).  Recent studies have 
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demonstrated that recruitment of TDG, in concert with other BER enzymes and DNA 
methyltransferases 3a/b, to the promoter regions of estrogen-responsive genes is essential 
to establish cyclic methylation/demethylation patterns in transcriptionally active 
chromatin (22).   
TDG contains a highly conserved central glycosylase domain flanked by divergent 
amino- and carboxy-terminal regions (12).  The amino-terminal region of mammalian 
TDG contains a hydrophilic lysine-rich region (residues 70-118) that is acetylated by 
CREB-binding protein and p300 (CBP/p300) while the carboxy-terminal region is 
modified by covalent conjugation of small ubiquitin-like modifier (SUMO) protein (17, 
50).  The amino-terminal region is essential for non-specific DNA interactions, as well as 
tight binding to abasic sites and processing of G:T mispairs (12, 36, 48).  The tight 
association of TDG to the abasic site following base excision prevents enzyme turnover 
thereby limiting mispair processing efficiency (48).  TDG contains two separate SUMO-
binding motifs located in the amino- and carboxy-terminal regions that mediate 
noncovalent binding to SUMO, which is required for translocation to PML oncogenic 
domains (PODs) (36). 
CBP/p300 and TDG form ternary complexes with DNA in vitro that retain the ability to 
mediate base excision and histone acetylation, suggesting that the recruitment of 
CBP/p300 in vivo may promote chromatin remodeling at the site of repair (50).  
Furthermore, TDG potentiates CBP-dependent transcription by means of intrinsic 
SUMO-binding activity (36).  Covalent SUMO conjugation to a carboxy-terminal lysine 
residue effectively abrogates DNA binding and association with CBP, while acetylation 
of the amino-terminal region may regulate interactions with accessory factors (36, 48, 
50).  The reported effects of CBP/p300-mediated acetylation on the activities of BER 
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enzymes (TDG, Polβ, flap endonuclease 1) (18, 19, 50), suggest an important role for 
CBP/p300 in coordinating BER.  
In light of the critical role of the amino-terminus in G:T processing, we have undertaken 
to identify additional covalent modifications in this region with potential regulatory 
functions.   Previous studies have shown that TDG is phosphorylated in living cells (52) 
and in silico analysis identified several putative protein kinase C (PKC) α/β/γ 
phosphorylation sites in the amino-terminal lysine-rich regulatory domain.  PKC 
comprises a family of 11 related signaling proteins with different tissue distributions and 
cofactor requirements that participate in diverse cellular processes such as proliferation, 
apoptosis, and differentiation (16).  PKC signaling is activated by oxidative stress (15) 
and there is evidence that Polβ and mismatch repair proteins Msh2 and Msh6 are 
regulated by PKC phosphorylation (4, 51).  In the present study, we identify a novel 
mechanism of crosstalk between CBP and PKCα that regulates the DNA mispair 
processing functions of TDG through mutually exclusive covalent modification of the 
amino-terminal region.  We demonstrate that acetylation of lysine residues not directly 
involved in DNA binding, selectively and potently abrogates G:T processing whereas 
phosphorylation of adjacent serine residues by PKCα may preserve this function by 
preventing CBP-mediated acetylation.  These findings highlight the importance of 
covalent modifications in regulating a DNA repair enzyme integral to the maintenance of 
CpG dinucleotides and epigenetic regulation. 
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3.2 Materials and Methods 
Plasmids 
pCMX-based mammalian expression vectors for FLAG epitope tagged TDG have been 
previously described (50).  Amino acid substitution mutants of TDG were constructed 
using the QuikChange mutagenesis kit (Stratagene) according to the manufacturer’s 
directions and were verified by sequencing.  Other expression vectors have been 
previously described (6, 36, 50). 
Antibodies and peptides 
TDG-specific rabbit polyclonal antibody has been previously described (36).  Human 
PKCα-specific polyclonal antibodies (sc-208, or sc-208-G) were obtained from Santa 
Cruz Biotechnology.   Anti-polyhistidine (HS1) and anti-FLAG monoclonal antibodies 
(M2) were obtained from Sigma-Aldrich.  TDG peptides obtained from GenScript 
Corporation were analyzed by mass spectrometry and quantified by reverse phase HPLC.   
Cell culture, and metabolic labeling 
NIH 3T3 fibroblasts were maintained in Dulbecco’s minimal essential medium (D-MEM) 
containing penicillin/streptomycin and supplemented with 10% fetal calf serum.  For 
subcellular localization experiments, cells were grown under serum-free conditions for 4 
hours and then treated with either 100 nM PMA or vehicle (DMSO) for 15 minutes in 
serum containing media. For metabolic labeling experiments, 150 mm dishes of NIH 3T3 
or HEK 293T cells were transfected with TDG expression vectors using the Polyfect 
transfection reagent (Qiagen).  Approximately 24 hours later, the culture medium was 
replaced with serum and phosphate-free D-MEM and the cells were incubated at 37° C 
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for 2 hours.  Subsequently, 32P-orthophosphate (200 μCi/ml) was added to the media 
followed by a 2.5-hour incubation at 37° C which included treatment with PMA or 
vehicle (DMSO) during the final 30 minutes.  Cells were then washed with PBS and 
whole cell extracts were prepared for immunoprecipitation as described below.  
Immunoprecipitates were separated by SDS-PAGE and incorporation of 32P was detected 
by phosphorimaging.  Equal loading of TDG was verified by immunoblotting.     
Preparation of whole cell extracts and immunoprecipitation 
Whole cell extracts for immunoprecipitation were prepared from 100 mm dishes of NIH 
3T3 cells stably expressing FLAG-TDG and control cells transduced with the empty 
expression vector (pLNCX).  Cells grown to 80% confluency were harvested by scraping, 
then pelleted by centrifugation and resuspended in 500 µl of Lysis buffer (50 mM Tris 
HCl pH 7.9, 300 mM NaCl, 1 mM EDTA, 1mM EGTA 10% glycerol, 0.5% Triton X-
100, 1 mM DTT, 50 mM sodium fluoride, 200 µM sodium orthovanadate and proteinase 
inhibitors - 20 μg/mL Pepstatin A, 10 μg/ml Aprotinin, 1 µg/ml Leupeptin, 0.5 mM 
PMSF) and incubated on ice for 30 minutes.  Subsequently, the cell lysate was diluted 
with 500 µl of dilution buffer (50 mM Tris-HCl pH 7.9, 1 mM EDTA, 1 mM EGTA, 10% 
glycerol, 1 mM dithiothreitol (DTT), 50 mM sodium fluoride,  200 µM sodium 
orthovanadate and proteinase inhibitors) and insoluble material removed by 
centrifugation.  Whole cell extracts were precleared twice with 50 µl (50% v/v) rabbit 
IgG-agarose (Sigma-Aldrich) for 30 minutes at 4° C and immunoprecipitated with 50 µl 
(50% v/v) anti-FLAG affinity resin (M2 agarose, Sigma-Aldrich).  Immunoprecipitated 
proteins were separated by SDS-PAGE and detected by immunoblotting.  In the case of 
immunoprecipitation of radiolabelled in vivo phosphorylated TDG, detection following 
SDS-PAGE was carried out by phosphorimaging and equal loading of TDG was verified 
by immunoblotting.   
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2D-PAGE 
Cell lysates and 2D-PAGE analysis was performed as previously described (7).  Cells 
were grown to 80-90% confluency in 150 mm dishes and treated with PMA as described 
above.  Approximately, 150 μg of cell lysate was fractionated by isoelectric focusing 
using a 7 cm Immobiline DryStrip gel (pH 6.2-7.5 – GE Healthcare).  Subsequently, 
proteins on the Immobiline Dry strip were fractionated by SDS-PAGE and TDG was 
detected by immunoblotting. 
Protein purification and in vitro interaction assays 
Protein purification, GST-based interaction assays, nickel-based pull-downs, and 
immunoprecipitation procedures have been previously described (36, 50).   
Base excision and electrophoretic mobility shift assays  
Base excision assays and electrophoretic mobility shift assays (EMSA) were performed 
as previously described using identical oligonucleotide substrates (36).  Either 25 or 12 ng 
of recombinant TDG was incubated at 30° C with 10 ng of radiolabeled duplex 
oligonucleotide (25 base pairs) containing a single G:U or G:T mispair in 20 µl of buffer 
(25 mM HEPES-KOH [pH 7.8], 1 mM EDTA, 0.1 mg/ml BSA, and 1 mM DTT).   
Reactions were carried out for 30 minutes followed by the addition of 2.5 µl 50% 
glycerol and 10 µl of the reaction was used directly for EMSA.  EMSA samples were 
fractionated using 6% polyacrylamide gels cast in 0.25xTBE and pre-run for 1.5 hours in 
0.5xTBE.  Protein-DNA complexes were detected by autoradiography or 
phosphorimaging.  The remainder of the reaction was treated with alkali to cleave the 
abasic sites generated by base release and subsequently the samples were analyzed by 
denaturing polyacrylamide electrophoresis as described by Hardeland et al (2002). 
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Avidin-biotin coupled DNA binding (ABCD) assays 
The ABCD assay was performed as described in Tini et al (2002) using identical 
biotinylated duplex oligonucleotides.  Briefly, streptavidin-coated paramagnetic beads 
(MagneSphere, Promega) were prepared by washing 0.6 ml (1 mg/ml) with ABCD assay 
buffer (50 mM Tris-HCl (pH 7.9), 150 mM NaCl, 10% glycerol, 5 mM MgCl2, 0.1% 
NP40, and 0.5 mM DTT) and resuspending in a final volume of 200 μl.  Approximately, 
250 to 500 ng of annealed oligonucleotide was incubated for 30 minutes at room 
temperature with 10 µl of the streptavidin-coated paramagnetic bead slurry and 100-500 
ng of purified bacterially expressed TDG in a total volume of 50 µl of ABCD buffer.  
Following incubation, beads were washed five times with 200 µl of ABCD buffer, and 
bound proteins were recovered by resuspending in 12 µl Laemmli buffer and incubation 
at 90° C for 5 minutes.  Proteins were fractionated by SDS-PAGE and detected by 
immunoblotting with an anti-polyhistidine antibody.  In experiments addressing the 
displacement of TDG from abasic sites, we first incubated TDG with DNA at room 
temperature for 10 minutes and subsequently GST-APE was added with a further 30-
minute incubation. 
Preparation of acetylated and phosphorylated TDG for biochemical studies 
Acetylated TDG was prepared by incubating recombinant TDG (750 ng) with 1 µg 
recombinant CBP and 1.25 mM acetyl coenzyme A (AcCoA) in acetylation buffer (20 
mM HEPES [pH 7.8], 1 mM EDTA, 1mM DTT, 10 mM sodium butyrate, and 10% 
glycerol) at 30° C for 90 minutes.   Subsequently, acetylation reactions were dialyzed for 
60 minutes against Nickel Binding Buffer (NiBB) (50 mM Tris-HCl [pH 8.0], 100 mM 
NaCl, 5% glycerol, 0.1% NP40, supplemented with 200 µM sodium orthovanadate, 50 
mM sodium fluoride, and 10 mM sodium butyrate).  NiBB (500 µl) and 60 µl (50% v/v) 
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Ni-NTA agarose were then added to the dialyzed reactions and they were incubated at 4° 
C for 90 minutes.  The Ni-ATA agarose was then washed three times with 200 µl NiBB 
and TDG was eluted 3 times with 50 µl of NiBB containing 1 M imidazole.  Eluted TDG 
was then dialyzed against NETN (50 mM Tris [pH 8.0], 100 mM NaCl, 1 mM EDTA, 
0.1% NP-40, 10% Glycerol, and 1 mM DTT) for 60 minutes.  The final concentration of 
TDG was determined by immunoblotting.  Phosphorylated TDG was prepared by 
incubating recombinant TDG (750 ng) with 50 mU recombinant PKCα (Calbiochem) and 
1 mM ATP in 50 µl PKC phosphorylation buffer (20 mM HEPES, pH 7.2, 1 mM sodium 
orthovanadate, 25 mM glycerol-3-phosphate, 1 mM dithiothreitol, 1 mM CaCl2, 15 mM 
MgCl2, 10 mg/ml 1,2-dioleyl-sn-glycerol, 100 mg/ml phosphatidylserine)  for 90 minutes 
at 30° C.  Mock reactions were performed in the absence of ATP.  Subsequently, TDG 
was purified as described above.   
Protein acetylation and phosphorylation assays 
Purified phosphorylated or mock-phosphorylated TDG (100 ng) was incubated with 
approximately 100 ng of purified, recombinant CBP in 30 µL of acetylation buffer in the 
presence of 1.5 µM 14C acetyl CoA (AcCoA) and incubated for 30 minutes at 30° C prior 
to stopping of the reaction by addition of 30 µl of Laemmli buffer and incubation at 95° C 
for 5 minutes.  Reaction components were then separated by SDS-PAGE.  After 
separation, the gel was fixed in a 30% methanol, 10% acetic acid solution and treated 
with amplifying solution (Amersham) prior to imaging by autoradiography or 
phosphorimaging.  Mock-acetylated or acetylated TDG were incubated with 0.25 mU of 
recombinant PKCα in phosphorylation buffer with 1 µl γ32P-ATP.  Reactions were 
incubated at 30° C for 30 minutes then stopped by addition of Laemmli buffer and 
incubation at 95° C for 5 minutes.  Reaction products were then separated by SDS-PAGE.  
The gel was fixed with a 30% methanol, 10% acetic acid solution and 32P incorporation 
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was detected by autoradiography.  To examine the effect of DNA on acetylation or 
phosphorylation, we preincubated TDG with DNA for 30 minutes on ice before 
proceeding with the reaction.   
Immunostaining and microscopy 
NIH 3T3 cells were fixed for 15 minutes with 4% formaldehyde in phosphate buffered 
saline (PBS) followed by a 10 minute incubation with 0.1 M glycine in PBS.  Cells were 
then permeabilized with 0.5% Triton X-100 in PBS for 10 minutes.  Immunostaining was 
performed with the appropriate primary antibodies and fluorophore-conjugated Donkey 
secondary antibodies (CY3, FITC) (Jackson ImmunoResearch Laboratories).  
Epifluorescence imaging was performed on an Axiovert 200M inverted microscope 
equipped with an Apotome (Carl Zeiss) using appropriate fluorophore-specific filter sets.  
Z-series images (63X magnification) were acquired at 0.5 µm intervals and processed 
with Axiovision software and Adobe Photoshop.  Fluorescence intensity plots were 
obtained by performing a line scan bisecting the cell using Axiovision software.   
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3.3 Results 
Phorbol ester-stimulated phosphorylation of TDG in living cells   
We have previously shown that TDG is acetylated by CBP/p300 at four lysine residues 
located within an amino-terminal region essential for DNA binding and G:T processing 
(Fig. 3.1A) (36, 48, 50).  In silico analysis using the Scansite algorithm (40) revealed 
several potential protein kinase C (PKC) α/β/γ phosphoacceptor residues flanking acetyl-
acceptor lysines, suggesting possible functional interplay between PKC and CBP/p300 
signaling in TDG regulation.  These residues are located within a short sequence motif 
(93SKKSGKS99) that is conserved in mouse, rat and human TDG.  We initially 
investigated whether endogenous TDG is phosphorylated in living cells in response to 
treatment with PKC agonist phorbol 12-myristate 13-acetate (PMA); serum-starved NIH 
3T3 mouse fibroblasts were treated for 15 minutes and whole-cell lysates were subjected 
to 2-dimensional polyacrylamide gel electrophoresis (2D-PAGE).  Fractionated cellular 
proteins were immunoblotted with TDG specific antibodies.  Theoretically, each 
phosphorylation event leads to a 78 Dalton gain in molecular weight and a 0.11-0.14 
decrease in isoelectric point.  We observed increases in apparent molecular weight and 
discrete changes in isoelectric point in response to PMA treatment consistent with 
phosphorylation of TDG in vivo (Fig. 3.1B).  We next verified that TDG is 
phosphorylated in living cells by metabolic labeling of NIH 3T3 cells transiently 
transfected with FLAG epitope tagged TDG.  Cells grown under serum free conditions 
were labeled with 32P inorganic phosphate for 2.5 hours which included a 30 minute 
treatment with either PMA or DMSO.  TDG was immunoprecipitated from cell lysates  
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Figure 3.1.  Phorbol ester-stimulated phosphorylation of TDG in living cells. (A) 
Illustration of the functional domains of mouse TDG and sites of posttranslational 
modification.  The central conserved glycosylase domain is sufficient for processing of 
G:U mispairs while a more divergent amino-terminal extension is required for tight DNA 
binding and G:T processing (36, 48).  Two SUMO binding motifs (SBM1, SBM2) and 
the sumoylation site (K341) are shown.  A lysine-rich regulatory region located in the 
amino-terminus is acetylated by CBP/p300 at four distinct lysines (K70, K94, K95, K98) 
(50).  Putative protein kinase C (PKC) α/β/γ phosphorylation sites (consensus [S/T-X-
[R/K]) within a sequence (boxed) conserved in mouse, rat and human TDG, are indicated 
by asterisks.  Complete sequence alignments and accession numbers are found in Figure 
S.3.1.  (B)  2D-PAGE analysis of cellular TDG demonstrating PMA-dependent 
alterations in apparent molecular weight and isoelectric point (pI).  Cell lysates were 
prepared from NIH 3T3 cells stimulated with PMA and then separated by 2D-PAGE.  
TDG was detected by immunoblotting with a TDG-specific antibody.  (C) In vivo 
metabolic labeling of transiently expressed TDG with 32P-orthophosphate.  Transfected 
NIH 3T3 fibroblasts were grown in serum-free media and metabolically labeled with or 
without PMA treatment.  One population of transfected cells was pretreated with a 
PKCα/β inhibitor (Gö6976, 100 nM) prior to PMA stimulation.  Immunoprecipitated 
TDG was fractionated by SDS-PAGE and analyzed by phosphorimaging (upper panel) 
and immunoblotting (lower panel).   
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with anti-FLAG resin and quantified by immunoblotting.  Subsequently, comparable 
levels of TDG were analyzed by SDS-PAGE and incorporation of 32P was detected by 
phosphorimaging.  We observed a basal level of phosphorylation which was enhanced by 
PMA treatment (Fig. 3.1C, top panel).  Pretreatment of cells with a PKCα/β specific 
inhibitor (Gö6976) (33) prior to PMA stimulation abolished phosphorylation.   Since the 
ubiquitous expression of PKCα (53) is more consistent with the wide tissue distribution 
of TDG, we focused our investigations on this isozyme.  To obtain corroborating 
evidence for a link between PKCα and TDG, we examined the subcellular distribution of 
the endogenous proteins in NIH 3T3 fibroblasts and undifferentiated P19 embryonal 
carcinoma cells by indirect immunofluorescence.  In NIH 3T3 cells cultured in the 
absence of serum, PKCα displayed predominantly cytoplasmic distribution while TDG 
was found almost exclusively in the nucleus (Fig. 3.2A panels I, III, V).  Treatment with 
PMA for fifteen minutes in the presence of serum, triggered nuclear translocation of 
PKCα as previously reported (47), and colocalization with TDG (Fig. 3.2C, panel II, IV, 
VI).  We observed mainly nuclear staining for PKCα (54) in untreated P19 cells and 
strong colocalization with TDG (Fig. 3.2B). These findings are consistent with numerous 
studies demonstrating phosphorylation of nuclear proteins by PKCα (32). 
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Figure 3.2.  Subcellular localization of TDG and PKCα in NIH 3T3 fibroblast and 
P19 EC cells.  (A) Subcellular localization of endogenous TDG and PKCα in NIH 3T3 
cells.  Serum starved cells were treated with PMA or DMSO and subsequently 
immunostained for TDG and PKCα.  (B)  Undifferentiated P19 embryonic carcinoma 
cells (not treated) were immunostained to detect endogenous TDG and PKCα. 
Representative optical sections generated by epifluorescence microscopy are shown.  The 
fluorescence intensity plot illustrates the coincidence of peak fluorescence for TDG 
(CY3, red) and PKCα (FITC, green).   
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PKCα interacts directly with TDG and phosphorylates the amino-terminal region 
To determine whether TDG and PKCα associate in living cells we carried out 
immunoprecipitations with anti-FLAG affinity resin on cell lysates derived from PMA 
treated NIH 3T3 fibroblasts stably expressing FLAG-tagged TDG.  The amount of full 
length FLAG-tagged TDG in these cells is comparable to that of endogenous TDG (Fig. 
3.3A, compare lanes 1 and 2). Immunoprecipitates were separated by SDS-PAGE and 
immunoblotted for TDG and PKCα.  PKCα was only detected in immunoprecipitates 
derived from FLAG-TDG expressing cells but not from control cells, consistent with the 
association of these proteins in living cells (Fig. 3.3A, compare lanes 3 and 4).  Similar 
results were obtained using transiently expressed epitope tagged proteins (Fig. S.3.2).  To 
examine whether these proteins interact directly, we carried out in vitro interaction 
studies using commercially available recombinant PKCα and poly-histidine tagged TDG 
or a truncated variant lacking the amino-terminal region (residues 1 to 121) (Fig. 3.3B)  
Following incubation of these proteins, nickel affinity resin was used to pull down TDG 
and PKCα was detected by immunoblotting (Fig. 3.3C).  PKCα was retained on the 
nickel affinity resin in the presence of full-length TDG but not with the amino terminal 
variant.  Coomassie staining of an aliquot of the binding reaction confirmed that both 
TDG and TDG(122-421) were bound to the affinity resin.  These findings establish a 
direct interaction between TDG and PKCα that is dependent on the amino-terminal 
region of TDG.  
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Figure 3.3.  PKCα associates directly with TDG.  (A)  PKCα coimmunoprecipitates 
with stably expressed TDG in NIH 3T3 fibroblasts.  Immunoprecipitations using anti-
FLAG affinity resin were carried out on whole-cell extracts prepared from PMA treated 
cells stably expressing FLAG- TDG or control cells transduced with the empty expression 
vector.  Aliquots of the cell lysates and immunoprecipitated proteins were immunoblotted 
for PKCα and TDG.  (B)  Coomassie staining of polyhistidine tagged TDG and 
TDG(122-421) used for in vitro protein interaction studies.  (C)   In vitro association of 
recombinant TDG and PKCα requires amino-terminal residues 1 to 121 of TDG.  
Approximately 1 μg polyhistidine-tagged TDG or TDG(121-421) were incubated with 10 
ng of PKCα and subjected to pull-down with nickel-affinity resin.  As a control, PKCα 
was also incubated with beads alone.  Bound proteins were subjected to SDS-PAGE and 
immunoblotting with a PKCα-specific antibody (upper panel).  Binding of poly-histidine 
tagged TDG and TDG(122-421) to the nickel-affinity beads was confirmed by Coomassie 
staining (lower panel).  
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We next assessed whether TDG is a direct substrate for PKCα phosphorylation in vitro, 
by incubating recombinant TDG or TDG(122-421) and PKCα in the presence of γ32P-
ATP and essential cofactors; subsequently, the reaction products were fractionated by 
SDS-PAGE and incorporation of  32P was measured by phosphorimaging (Fig. 3.4A).  
Incorporation of radioactivity was observed only with full-length TDG, indicating that the 
amino-terminal region is essential for phosphorylation by PKCα.  Considering that 
PKCα/β/γ consensus phosphorylation sites are located adjacent to acetyl-acceptor lysines 
94, 95 and 98 (see Fig. 3.1A), we employed two short peptides consisting of amino acid 
residues 68-91 and 91-107 in phosphorylation reactions to further delineate the location 
of phosphoacceptor serines or threonines.    Analysis of the reaction products by SDS-
PAGE and phosphorimaging revealed that the peptide containing residues 91-107 was 
robustly phosphorylated in vitro while the second peptide (residues 68-91) was not 
appreciably radiolabelled (Fig. 3.4B).  Phosphorylated residues were identified by 
examining the effect of alanine substitutions of potential phosphoacceptor residues in the 
context of the 91-107 peptide.  This analysis indicated that substitution of serine 96 (S96) 
and serine 99 (S99) substantially decreased 32P incorporation, thereby identifying these 
residues as the principal phosphoacceptor sites (Fig. 3.4C).  In the context of full length 
bacterially-expressed TDG, dual substitution of these residues with either alanine (S96-
99A) or aspartate (S96-99D) resulted in approximately 60% and 80% reduction in 
phosphorylation, respectively (Fig. 3.4D).  To assess whether these serines are 
phosphorylated in vivo, we transiently expressed FLAG-tagged wild-type TDG and 
TDG(S96-99D) in NIH 3T3 fibroblasts and carried out metabolic labeling with 
radiolabelled inorganic phosphate with and without PMA stimulation.  We observed that 
PMA treatment increased phosphorylation of wild-type TDG by approximately 80% but 
had no detectable effects on the S96-99D mutant (Fig. 3.4E, upper panel) confirming that 
these are the major phosphoacceptor sites.  Immunoblotting analysis indicated the 
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presence of comparable amounts of TDG in the different immunoprecipitates (Fig. 3.4E, 
lower panel).  These data confirm that phosphorylation of serine 96 and 99 of TDG is 
induced by phorbol ester stimulation in living cells.  
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Figure 3.4.  PKCα phosphorylates TDG on serines 96 and 99.  (A) PKCα-mediated 
phosphorylation of TDG requires the amino-terminal region.  In vitro phosphorylation 
reactions were performed in the presence of γ32P-ATP using 2 µg of TDG (lane 1) or 
TDG(122-421) (lane 2) and 0.3 ng (0.25 mU) of recombinant PKCα.  Reaction products 
were fractionated by SDS-PAGE and incorporation of 32P was detected by 
phosphorimaging.  (B) Delineation of the phosphorylated region using peptide probes.  
Equimolar amounts of TDG peptides (residues 68-91 and 91-107) and PKCα peptide 
substrate from glycogen synthetase (residues 1-8, designated GS 1-8) along with the 
FLAG peptide were reacted with PKCα and analyzed as indicated above.  (C) 
Identification of phosphoacceptor residues by alanine substitution.  In vitro 
phosphorylation of the TDG(91-107) (1 µg) peptide and alanine substituted derivatives 
was performed and analyzed by SDS-PAGE and phosphorimaging (top panel).  
Quantification of signal intensity is displayed in the bottom panel.  Lysines acetylated by 
CBP/p300 are indicated with asterisks.  (D) Dual alanine (lane 2) or aspartate (lane 3) 
substitutions of serine 96 and 99 reduces PKCα-mediated phosphorylation in full-length 
TDG.  Recombinant TDG and the indicated substitution mutants (2 µg) were 
phosphorylated in vitro and analyzed by SDS-PAGE and autoradiography. (E) In vivo 
metabolic labeling of transiently expressed TDG and S96-99D mutant with 32P-
orthophosphate.  Transfected NIH 3T3 fibroblasts grown in serum-free media were 
metabolically labeled for 2.5 hours which includes treatment with either vehicle or PMA 
during the final 30 minutes of labeling.  Proteins were immunoprecipitated with anti-
FLAG resin and then fractionated by SDS-PAGE and phosphorimaged (upper panel).  
Aliquots of the immunoprecipitates were analyzed by immunoblotting to ensure equal 
loading of TDG (lower panel).     
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Amino-terminal acetylation and phosphorylation are mutually exclusive.  
The proximity of the acetylated residues to the PKCα phosphorylation sites (see Fig. 
3.1A) suggested that each modification may affect the other by altering the effective 
charge in this region.  To investigate this, we established an assay whereby we initially 
acetylated or phosphorylated recombinant TDG in vitro and then used nickel-affinity 
chromatography to purify TDG from the modifying enzymes.  Following quantification 
by immunoblotting, we assessed whether acetylated TDG could be phosphorylated by 
PKCα and vice versa.  We found that acetylated TDG was not appreciably 
phosphorylated by PKCα (Fig. 3.5A) and similarly, when phosphorylated TDG was used 
as a substrate for CBP, acetylation was greatly reduced (Fig. 3.5B). Quantification by 
phosphorimaging revealed a 10-fold and 3-fold reduction in phosphorylation and 
acetylation, respectively.  The more moderate decrease in acetylation following 
phosphorylation is consistent with the presence of an additional acetyl-acceptor lysine 
(K70) which may not be affected by phosphorylation.   To determine whether loss of 
positive charges at acetyl-acceptor lysines was responsible for inhibition of 
phosphorylation we introduced charge neutralizing alanine substitutions at lysines 94, 95 
and 98 (K94-95-98A triple mutant), which constitute the major acetylation sites in vitro 
and carried out in vitro phosphorylation (Fig. 3.5C).  Reduced levels of phosphorylation 
were observed with the mutant consistent with lysine residues being essential for optimal 
phosphorylation by PKCα.  Serine to aspartate substitutions (S96 and S99) which mimic 
phosphorylation also reduced acetylation consistent with the mutually exclusive 
relationship (Fig. 3.5D). We next examined the relationship between these modifications 
in living cells by carrying out in vivo phosphorylation experiments in HEK 293T cells.  
This cell line was chosen due to the high transfection efficiency that can be routinely 
achieved and the fact that TDG acetylation can be readily observed by metabolic labeling 
(data not shown).  As with NIH 3T3 fibroblasts, we observed PMA-dependent 
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phosphorylation of TDG which could be attenuated by coexpression of CBP (60% 
reduction) (Fig 3.5E).  Furthermore, the TDG mutant with alanine substitutions at acetyl-
acceptor lysines was not phosphorylated in a PMA-dependent manner.  These findings 
are in agreement with the in vitro data and consistent with a mutually exclusive 
relationship between acetylation by CBP/p300 and PKC mediated phosphorylation.  
When we performed in vivo acetylation by metabolic labeling with 3H sodium acetate, we 
found surprisingly that both the S96-99D mutant and wild-type TDG were acetylated at 
comparable levels (data not shown).  These findings are consistent with our unpublished 
data indicating that TDG is acetylated by other acetylases in addition to CBP/p300,  
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Figure 3.5.  Acetylation and phosphorylation are mutually exclusive.  (A)  Acetylated 
TDG (acTDG) is refractory to phosphorylation by PKCα.  Recombinant polyhistidine-
tagged TDG was acetylated in vitro with CBP and then purified by nickel affinity 
chromatography.  Acetylated TDG was quantified by immunoblotting and approximately 
100 ng was used in phosphorylation reactions that included γ32P-ATP.  Reaction products 
were analyzed by SDS-PAGE and phosphorimaging.  (B) Phosphorylated TDG (pTDG) 
is refractory to acetylation by CBP.  Phosphorylated TDG was purified as indicated above 
and reacted with CBP and in the presence of 14C-acetyl coenzyme A (AcCoA).  (C) 
Reduced in vitro phosphorylation of the K94-95-98A mutant. (D) Reduced in vitro 
acetylation of the S96-99D mutant. Recombinant proteins (1 μg) were phosphorylated or 
acetylated in vitro as described above. (E) Inhibition of in vivo TDG phosphorylation by 
coexpression of CBP or substitution of positively charged acetyl-acceptor lysines.  HEK 
293T cells were transfected with the indicated expression vector and metabolically 
labeled with and without stimulation with PMA.  
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Divergent effects of TDG acetylation and phosphorylation on DNA mispair 
processing 
DNA binding has been reported to promote conformational changes in TDG (48).  In 
order to address whether TDG could be acetylated or phosphorylated when bound to 
DNA, we carried out acetylation reactions with CBP in the presence of increasing 
amounts of either normally paired or G:T mispaired duplex oligonucleotides (Fig. 3.6A).  
A considerable reduction in acetylation of TDG was observed in the presence of either 
oligonucleotide, while CBP autoacetylation was not significantly affected.  These 
findings suggest that in vivo TDG bound to DNA is unlikely to be acetylated by 
CBP/p300.  In contrast, the presence of DNA had little effect on the acetylation of GST-
p53 and SET/TAF1β/I2pp2A proteins (Fig. 3.6B).  Additionally, the presence of duplex 
oligonucleotides caused a more moderate reduction in PKCα mediated phosphorylation 
(Fig. 3.6C) suggesting that phosphorylation of TDG may occur on DNA.   
The marked reduction in acetylation following DNA binding suggests that the acetyl-
acceptor lysines may directly contact DNA.  To investigate this possibility, we compared 
the DNA binding activity of bacterially expressed recombinant wild-type TDG and the 
K94-95-98A mutant using the electrophoretic mobility shift assay (11),  We found that 
the alanine substitution mutant  displayed moderately enhanced binding to duplex 
oligonucleotides containing either  G:U or G:T mispairs (Fig. 3.6D).  Interestingly, we 
found that the mutant bound to an abasic site was resistant to displacement by APE 
compared to wild-type TDG (Fig. S.3.3).  These findings suggest that lysine 94, 95 and 
98 are critical determinants of the DNA binding properties of TDG and that these 
positively charged residues are not directly interacting with DNA but may be 
conformationally important.  
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Figure 3.6.  DNA binding prevents CBP-mediated acetylation of TDG. (A) Dose 
dependent inhibition of TDG acetylation by duplex oligonucleotides.  TDG (150 ng) was 
pre-incubated with the indicated duplex oligonucleotides for 30 minutes on ice and then 
acetylated in vitro with CBP (100 ng) and 14C-AcCoA.  Reaction products were analyzed 
by SDS-PAGE and autoradiography.  (B) DNA-dependent inhibition of CBP-mediated 
acetylation is specific to TDG.  In vitro acetylation was performed with TDG (150 ng), 
GST-p53 (150 ng), and SET/TAF-1β/I2pp2A (150 ng) recombinant proteins in the presence 
or absence of 200 ng of G:T mispaired oligonucleotide.  (C) Phosphorylation of TDG in 
the presence of duplex oligonucleotides.  In vitro phosphorylation reactions were 
performed as described in Figure 3.4 using TDG pre-incubated with 200 ng of the 
indicated oligonucleotides. (D) Alanine substitution of acetyl acceptor lysines enhances 
DNA binding. Electrophoretic mobility shift assay was carried out with radiolabeled 
duplex oligonucleotides bearing either a G:U or a G:T mispair with 25 ng of recombinant 
wild-type TDG or TDG(K94-95-98A).   
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In light of the critical role of the amino-terminal region of TDG in G:T processing and the 
observed inhibition of CBP-mediated acetylation by DNA, we investigated whether 
acetylation or phosphorylation could modulate DNA interactions.  To address this, we 
produced purified covalently modified (acetylated or phosphorylated) recombinant TDG 
in vitro using nickel affinity chromatography (see Fig. 3.5). As controls, we also carried 
out mock acetylation and phosphorylation reactions using heat-denatured CBP or by 
omission of ATP, respectively.  We assayed in vitro modified TDG for DNA-binding and 
G:T/U processing activity using asymmetrically radiolabelled duplex oligonucleotides 
containing the indicated DNA mispairs.  Remarkably, we observed that acetylated TDG 
retained robust G:U processing activity but displayed severely reduced G:T processing 
(Fig. 3.7A, compare lane 4 and 6).  Consistent with these findings, we observed using 
both the avidin-biotin coupled DNA (ABCD) binding assay (data not shown) and 
electrophoretic mobility shift  assay (EMSA) (Fig. 3.7B) that the binding of acetylated 
TDG to G:U mispaired oligonucleotides was comparable to that of mock acetylated TDG, 
whereas binding to G:T mispaired DNA was substantially reduced.  Therefore, these data 
indicate that acetylation of the amino-terminal region selectively abrogates the G:T 
processing functions of TDG.  In contrast, the DNA binding and mispair processing 
activities of phosphorylated TDG were found to be indistinguishable from mock 
phosphorylated protein (Fig. 3.7C and D).  To confirm that we achieved efficient 
phosphorylation of TDG in this experiment, we carried out an acetylation reaction with 
this material and observed a 3-fold reduction in incorporation of radiolabelled AcCoA 
(data not shown).  Therefore, although PKCα mediated phosphorylation does not appear 
to directly alter the processing functions of TDG it may prevent inhibition of G:T 
processing by preventing acetylation by CBP/p300.  
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Figure 3.7.  Divergent effects of acetylation and phosphorylation on DNA mispair 
processing.  (A) Acetylation of TDG selectively abrogates G:T processing.  Purified 
acetylated TDG (acTDG) (25 ng) was prepared as described in Figure 3.5 and base 
excision assays were carried out using asymmetrically radiolabelled duplex 
oligonucleotides (10 ng)  bearing either G:U or G:T mispairs.   Reaction products were 
treated with alkali to cleave the abasic sites and analyzed by denaturing PAGE and 
autoradiography.   (B)  Acetylated TDG does not stably bind oligonucleotides bearing a 
G:T mispair.  Aliquots of base excision reactions described above were subjected to 
electrophoretic mobility shift assays to determine binding to G:U or G:T mispaired 
oligonucleotides.  (C) Phosphorylation of TDG does not detectably alter G:T/U 
processing activity.  Phosphorylated (pTDG) and mock phosphorylated TDG (12 ng) 
were tested for ability to excise mispaired uracil and thymine.  (D) DNA-binding analysis 
of phosphorylated and mock phosphorylated TDG.   Aliquots of the base excision 
reactions were subjected to electrophoretic mobility shift analysis.  Figures S.3.4 and 
S.3.5 show images of EMSA gels that include unbound DNA probe.  
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3.4 Discussion 
We have elucidated a unique interplay between acetylation and phosphorylation in 
regulating the DNA repair functions of TDG.  We show that these posttranslational 
modifications occur on adjacent residues in the amino-terminus and are mutually 
exclusive.  Remarkably, acetylation by CBP/p300 selectively abrogates G:T processing 
while phosphorylation by PKCα may preserve this function in vivo by preventing CBP-
mediated acetylation.  Our findings suggest that the opposing regulatory roles of 
CBP/p300 and PKC may have profound effects on the functions of TDG in CpG 
maintenance and epigenetic regulation.  
We investigated a regulatory role for PKC in TDG-mediated base excision on the basis of 
the proximity of putative PKCα/β/γ phosphorylation sites and acetyl-acceptor lysines 
(K94, K95 and K98).  These residues are located within a sequence motif conserved in 
mouse, rat and human TDG (93SKKSGKS99).  Our studies indicate that in mouse 
fibroblasts PKCα translocates to the nucleus in response to PMA stimulation and 
phosphorylates residues in the amino-terminal DNA binding domain of TDG.  
Accordingly, we have shown that in NIH 3T3 cells, stably-expressed TDG 
coimmunoprecipitates with endogenous PKCα.  Furthermore, 2D-PAGE analysis and 
metabolic labeling indicate that TDG is phosphorylated in a PMA-dependent manner in 
vivo and this effect was abrogated by a PKCα/β-specific inhibitor.  Using recombinant 
bacterially expressed proteins we have shown that PKCα interacts directly with TDG and 
this association requires the amino-terminal region of TDG (residues 1-122).  The 
phosphorylation sites were mapped in vitro using peptides bearing alanine substitutions of 
potential phosphoacceptor residues.  We identified two serine residues (S96 and S99) that 
when mutated in the context of full-length TDG, substantially reduced phosphorylation 
by PKCα.  Consistent with this, in vivo PMA-dependent phosphorylation of transiently 
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expressed TDG was substantially reduced when the phosphoacceptor serines were 
substituted with aspartate.  Although we have focused on PKCα in our studies, these 
phosphoacceptor serines may be phosphorylated by other PKC subtypes.   We have used 
PMA to induce nuclear translocation of PKCα; however, it is well known that in 
fibroblasts this is a normal physiological response to growth factor (e.g. PDGF, EGF) 
stimulation (37).  Therefore, phosphorylation of TDG may be regulated by mitogenic 
signals.  Interestingly, in undifferentiated P19 EC cells, PKCα is mostly nuclear and 
colocalizes with TDG, consistent with a role in the regulation of nuclear processes.    
Considering the proximity of phosphoacceptor serines and acetyl-acceptor lysines and the 
different charge characteristics of these residues upon covalent modification, it should 
perhaps not be surprising that acetylation effectively prevents phosphorylation and vice 
versa.  We found that acetylation of recombinant TDG decreases subsequent 
phosphorylation by 10-fold while phosphorylation decreases acetylation by at least 3-
fold.  Furthermore, substitution of phosphoacceptor serines with aspartate, which mimics 
phosphorylation, reduced acetylation in vitro while replacement of positively charged 
lysines with alanine reduced phosphorylation.  Consistent with in vitro studies, PMA-
induced phosphorylation in vivo was abrogated by removal of acetyl-acceptor lysines and 
reduced by CBP overexpression.  Surprisingly, the phosphorylation mimic (S96-99D) 
was acetylated in vivo at similar levels to wild-type TDG.  This is most likely attributable 
to acetylation of TDG in vivo at other lysine residues by other acetylases.  The mutually 
exclusive nature of these adjacent modifications is reminiscent of the cross-talk observed 
on the amino-terminal KS dipeptide of histone H3; in this case, phosphorylation of S10 
blocks both K9 acetylation and methylation while K9 dimethylation antagonizes S10 
phosphorylation (8, 10, 28, 44).  Similar cross-talk as been suggested for non-histone 
proteins (27, 55). 
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In exploring the functional significance of these covalent modifications, we first 
established whether they could occur when TDG is bound to DNA as conformational 
changes in this context have been reported (17).  We found that DNA-bound TDG was 
very resistant to acetylation while CBP autoacetylation was not altered.  In contrast, 
phosphorylation by PKCα was much less affected by the presence of DNA.  These 
findings suggest that in vivo PKCα may phosphorylate DNA-bound TDG while 
acetylation by CBP/p300 requires uncoupling from DNA.  The observation that 
CBP/p300 mediated acetylation abrogates binding to duplex DNA and G:T processing 
may be relevant to both the  CpG maintenance functions of TDG as well as its recently 
postulated  role in gene-specific CpG demethylation (34).  Acetylated TDG retains the 
ability to process G:U mispairs in vitro, consistent with previous reports indicating that 
this function does not require the amino-terminal region (36, 48).  However, the reduced 
ability of acetylated TDG to bind DNA may interfere with the genome scanning functions 
attributed to DNA glycosylases, which could severely hinder detection of DNA mispairs 
and other DNA lesions in vivo.  G:U and G:T mispairs at CpG dinucleotides are generated 
by hydrolytic deamination of cytosine and methyl cytosine, respectively.  In order to 
restore cytosine methylation following repair of G:T mispairs, a mechanism is required to 
discern between mispairs arising from either the methylated or unmethylated cytosine.  
CBP/p300-mediated acetylation may provide a mechanism to discriminate between the 
two deamination products.  Recent studies employing chromatin immunoprecipitation 
(ChIP) assays, have shown that TDG transiently occupies the promoters of several 
estrogen responsive genes (2, 22) and it has been postulated that TDG and other BER 
enzymes are essential for the cyclical CpG demethylation patterns observed on these 
genes during transcription.  As the DNA binding activity and G:T processing functions of 
TDG are dramatically reduced by CBP-mediated acetylation, this may serve as a 
powerful mechanism to regulate CpG demethylation and/or the release of TDG from 
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promoters.  The finding that CBP/p300 mediated acetylation of Polβ reduces end 
trimming activity and impairs participation in BER (18) suggests that CBP/p300 may 
generally act as negative regulator of BER.  This is also in agreement with the role of 
acetylation in reducing the nuclease activity of another BER enzyme, flap endonuclease 1 
(Fen1) (19).  A recent study provided evidence for the direct excision of 5-methylcytosine 
by MBD4 and this activity is stimulated by PKC phosphorylation (23).  Therefore, PKC 
signaling likely plays a central role in regulating CpG demethylation by MBD4 and TDG.   
CBP/p300 as well as other protein acetylases respond to DNA damage and other cellular 
stresses by acetylating cellular proteins such as the tumor suppressor p53 (31, 45, 49).  
Covalent modification of key cellular regulatory proteins is an integral signaling 
mechanism in DNA damage response that leads to cycle arrest, apoptosis and cellular 
senescence.  Acetylation of TDG may serve to block DNA repair as part of an apoptotic 
response to cellular stresses such as excessive DNA damage.  In this context, it is 
interesting to note that both phosphorylation by PKC and acetylation by p300 have been 
shown to inactivate Polβ, while in this study we demonstrate that phosphorylation of 
TDG by PKCα may preserve G:T processing by preventing acetylation by CBP/p300.  
Altogether these findings suggest that the crosstalk between different signaling pathways 
could provide exquisite regulation of the different steps of BER in response to 
physiologic signals or stresses.  Although in this study we have focused on the classic 
functions of TDG in processing G:T/U mispairs, it also processes other damaged bases 
and may be important in cellular responses to oxidative stress.  Along these lines, since 
PKC isoenzymes are activated by reactive oxygen species (14, 25), TDG may be a crucial 
downstream target that would also be subject to opposing regulation by CBP/p300.   
The tight binding of TDG to abasic sites produced by base excision prevents enzyme 
turnover and limits processing efficiency (48).  It has been postulated that sumoylation of 
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mammalian TDG serves to promote release of the enzyme from abasic sites (17).  
Structural analysis of an amino- and carboxy-terminal deleted human TDG conjugated to 
SUMO revealed the presence of a protruding helix that interferes with DNA binding (1).  
However, analysis of sumoylated full-length human TDG by limited proteolysis 
suggested that sumoylation promotes conformational changes involving interaction of the 
carboxy- and amino-terminal regions (48).  We have shown previously that mouse TDG 
contains two separate conserved amino-terminal and carboxy-terminal SUMO-binding 
motifs that interact intramolecularly with the conjugated SUMO and may account for the 
sumoylation-induced conformational changes (36).  Interestingly, both sumoylation and 
acetylation by CBP/p300 abrogate DNA binding and processing of G:T mispairs (see Fig. 
3.8).  However, in contrast to sumoylation which can occur on DNA, we show that CBP-
mediated acetylation requires the uncoupling of TDG from DNA.  Furthermore, 
acetylated TDG retains the ability to form stable complexes with abasic sites as evidenced 
by the stable binding observed following the processing of G:U mispairs.  It is plausible 
that acetylation promotes limited conformational changes within the amino-terminus in 
contrast to the more extensive changes that are associated with sumoylation.   
Interestingly, substitution of lysines 94, 95 and 98 with alanines did not mimic the effects 
of acetylation on DNA binding and this mutant was resistant to displacement by APE 
when bound to abasic sites (Fig. S.3.3).   These findings suggest that these lysine residues 
play critical roles in DNA binding and mispair processing and the effects of acetylation 
are not strictly due to loss of positive charges.  
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Figure 3.8.  Cross-talk between TDG posttranslational modifications.  Previous 
studies have shown that sumoylation of human and mouse TDG induces a dramatic 
increase in G:U processing activity by promoting enzyme turnover (19,20).  In contrast, 
sumoylation (19,20) or acetylation by CBP (this study) abrogate DNA binding and G:T 
processing (17, 36).  TDG sumoylation also drastically reduces interactions with 
CBP/p300, thereby preventing efficient acetylation (20). The present studies reveal that 
phosphorylation of serine residues adjacent to acetyl-acceptor lysines by PKCα prevents 
acetylation by CBP and may preserve G:T processing in vivo.  
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We have provided biochemical evidence for the interplay of CBP/p300 and PKCα in 
modulating the DNA repair functions of TDG.  Our studies provide insights into the 
complex roles of posttranslational modifications in regulating genome maintenance and 
gene expression pathways.  The fact that both CBP/p300 and PKC signaling pathways are 
deregulated in oncogenesis (13, 16, 21)  suggests that TDG may be a downstream target 
that may be functionally compromised and contribute to the genomic instability 
associated with cancer.  Interestingly, TDG has recently been shown to efficiently excise 
5-fluorouracil from DNA and plays a role in cellular responses to this commonly used 
chemotherapeutic agent (9, 26).  Our studies indicate it may be possible to alter the DNA 
damage processing functions of TDG in vivo by targeting the signaling pathways that 
mediate acetylation and phosphorylation of this enzyme.  Future studies will establish the 
utility of our findings in this context and whether TDG is suitable target for cancer 
therapy. 
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3.6 Supplemental information 
Figure S.3.1.  Clustal W alignments of TDG orthologs.  Accession numbers: Mouse 
[Mus musculus], AAH10315; Rat [Rattus norvegicus], NP_446181; Human [Homo 
sapiens], NP_003202; Chicken [Gallus gallus], NP_990081; Xenopus [Xenopus laevis], 
NP_001084290 NP_001084291; Zebrafish [Danio rerio], NP_001018587 XP_688633; 
Drosophila [Drosophila melanogaster], AAD33588. Note that Drosophila TDG is 1095 
amino acids long and only part of the sequence is shown.  Alignments were performed on 
the European Bioinformatics Institute website (http://www.ebi.ac.uk/). 
CONSENSUS SYMBOLS:  
An alignment will display by default the following symbols denoting the degree of 
conservation observed in each column: "*" means that the residues or nucleotides in that 
column are identical in all sequences in the alignment. ":" means that conserved 
substitutions have been observed, according to the color table above. "." means that semi-
conserved substitutions are observed. 
AVFPMILW RED Small (small+ hydrophobic (incl.aromatic -Y)) 
DE BLUE Acidic 
RK MAGENTA Basic 
STYHCNGQ GREEN Hydroxyl + Amine + Basic - Q 
Others Gray   
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CLUSTAL 2.0.12 multiple sequence alignment 
TDG_Mouse           -MDAEAARSYS--LEQVQALYSFPFQQMMAEVPNMAVTTGQQVPAVAPNMATVTEQQV-- 
55 
TDG_Rat             ---------------------------MMAEAP---------------NMADVAGQQM-- 
16 
TDG_Human           -MEAENAGSYS--LQQAQAFYTFPFQQLMAEAP---------------NMAVVNEQQMPE 
42 
TDG_Chicken         -MEAEELGRYYAYLQQAQAFYTFPFHQMMTAPP---------------TMEAMTEQPTLE 
44 
TDG_Xenopus         -MEAQDPSSYY---QPAQPYYPFSYHQMMNVPS---------------NMDLGNEQQTLH 
41 
TDG_Zebrafish       -MDERLYGSLPHAPSEYLQQWVQSAQQHLQTLQAQYP-----------HMANGSAGFMME 
48 
TDG_Drosophila      MGEELHMHSPSHRHLDAVTTGPGRYGILVSNDTPECLSR---------EMYRHSQQSTTV 
51 
                                                :                    *           
 
TDG_Mouse           ------------------------------PADAPVQ--EPAPEAPKR-RKRKPRAAEPQ 
82 
TDG_Rat             ------------------------------PAEAPAQ--DPVPEAPKR-RKRKTRAAEAQ 
43 
TDG_Human           ----------------------------EVPAPAPAQ--EPVQEAPKG-RKRKPRTTEPK 
71 
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TDG_Chicken         ----------------------------GIPEPNLAQ--EPPKEVKKGGRKRKAKATEPK 
74 
TDG_Xenopus         PLTGVPAHELQAFSGMAANEPQVLHTLTGVPAQEPVNGEMPIPEMIPNPAEAEPTTGKRK 
101 
TDG_Zebrafish       GQREDAG----------------MQQMPVHPEDAAQLQPAAAQTAPAKGKRARQTNKEPK 
92 
TDG_Drosophila      ----------------------------LEQTDSSSCGINFKPMPKKRGRKKKLVAVNAD 
83 
TDG_Mouse           EPVEPKKPATSKKSGKSTKS------KEKQEKITDAFK-VKRKVDRFNGVSEAELLTKTL 
135 
TDG_Rat             DPVEPKKPAASKKSGKSTKS------KEKQEKITDTFK-VKRKVDRFNGVSEAELLTKTL 
96 
TDG_Human           QPVEPKKPVESKKSGKSAKS------KEKQEKITDTFK-VKRKVDRFNGVSEAELLTKTL 
124 
TDG_Chicken         Q---PKKPAAKKE--KATKS------KGKQEKITDTFK-VKRKVDRFNGVSEAELLTKTL 
122 
TDG_Xenopus         RGKAPSEPKPKKPAAKSAKAPK----SGKQEKITDAFK-VKRKVNRFNGVSEAELLTKTL 
156 
TDG_Zebrafish       PKGEPKPRAKPGPKPKKAKEDKEAPPAEGQEKIDETFKKVKRKVDRFKGMSEEEVMKRTL 
152 
TDG_Drosophila      TSQMTTPVDQQKVSAGRADCE-----DGGGDQAAKPKE--RKKHDRFNGMSEEEVIKRTI 
136 
                        ..           :.           ::  .. :  ::* :**:*:** *::.:*: 
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TDG_Mouse           PDILTFNLDIVIIGINPGLMAAYKGHHYPGPGNHFWKCLFMSGLSEVQLNHMDDHTLPGK 
195 
TDG_Rat             PDILTFNLDIVIIGINPGLMAAYKGHHYPGPGNHFWKCLFMSGLSEVQLSHMDDHTLPGK 
156 
TDG_Human           PDILTFNLDIVIIGINPGLMAAYKGHHYPGPGNHFWKCLFMSGLSEVQLNHMDDHTLPGK 
184 
TDG_Chicken         PDILTFDLDIVIIGINPGLMAAYKGHHYPGPGNHFWKCLFMSGLSNEQLNHMDDHTLPHK 
182 
TDG_Xenopus         PDILTFNLDIVIIGINPGLMAAYKGHHYPGPGNHFWKCLFLSGLSDKQLNHLDDHSLPEK 
216 
TDG_Zebrafish       PDILIPNLDYVIIGINPGLMAAYIGRWFPGPGNHFWKCLFLSGFTEKLLNHMDDQSLPEK 
212 
TDG_Drosophila      PDHLCDNLDIVIVGINPGLFAAYKGHHYAGPGNHFWKCLYLAGLTQEQMSADEDHKLIKQ 
196 
                    ** *  :** **:******:*** *: :.**********:::*:::  :.  :*:.*  : 
TDG_Mouse           YGIGFTNMVERTTPGSKDLSSKEFREGGRILVQKLQKYQPRIAVFNGKCIYEIFSKEVFG 
255 
TDG_Rat             YGIGFTNMVERTTPGSKDLSSKEFREGGRILVQKLQKYQPRIAVFNGKCIYEIFSKEVFG 
216 
TDG_Human           YGIGFTNMVERTTPGSKDLSSKEFREGGRILVQKLQKYQPRIAVFNGKCIYEIFSKEVFG 
244 
TDG_Chicken         YGIGFTNMVERTTPGSKDLSSKEFREGGRILMQKLQKYKPRIAAFNGKCIYEIFSREVFG 
242 
TDG_Xenopus         YGIGFTNMVERTTPGSKDLSSKEFREGGRILLEKLQKYKPRIAVFNGKCIYEIFSKEIFG 
276 
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TDG_Zebrafish       YGIGFTNMVARATPGSKDLSSKELREGGKILVEKIKQFKPLIAVFNGKCIYEMFCRELFG 
272 
TDG_Drosophila      G-IGFTNMVARATKGSADLTRKEIKEGSRILLEKLQRFRPKVAVFNGKLIFEVFS----- 
250 
                      ******* *:* ** **: **::**.:**::*:::::* :*.**** *:*:*.      
 
TDG_Mouse           VKVKNLEFGLQPHKIPDTETLCYVMPSSSARCAQFPRAQDKVHYYIKLKDLRDQLKGIER 
315 
TDG_Rat             VKVKNLEFGLQPHKIPDTETLCYVMPSSSARCAQFPRAQDKVHYYIKLKDLRDQLKGIER 
276 
TDG_Human           VKVKNLEFGLQPHKIPDTETLCYVMPSSSARCAQFPRAQDKVHYYIKLKDLRDQLKGIER 
304 
TDG_Chicken         IRVKNLEFGLQPHKVPETETLCYVMPSSSARCAQFPRAQDKVHYYIKLKDLRDQLKGIAP 
302 
TDG_Xenopus         VKAKKIDFGIQPHRIPETDTICYLMPSSSARCAQFPRAQDKVHHYIKLKELRNQLRGVET 
336 
TDG_Zebrafish       KKPKTLEFGLQPHKIPDSDTALYLMPSSSARCAQFPRAQDKVHFYIKLRELRDQLKGVIK 
332 
TDG_Drosophila      -GKKEFHFGRQPDRVDGTDTFIWVMPSSSARCAQLPRAADKVPFYAALKKFRDFLNGQIP 
309 
                       * :.** **.::  ::*  ::**********:*** *** .*  *:.:*: *.*    
TDG_Mouse           NTDVQEVQYTFDLQLAQEDAKKMAVKEEKYDPGYEAAYGGAYGE----NPCNGEPCGIAS 
371 
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TDG_Rat             STDVQEVQYTFDLQLAQEDAKRTAVKEEKYDPGYEAAYGGACGE----NPCNGEPCGFAS 
332 
TDG_Human           NMDVQEVQYTFDLQLAQEDAKKMAVKEEKYDPGYEAAYGGAYGE----NPCSSEPCGFSS 
360 
TDG_Chicken         NTEVQEVQYTFDLQLAQEDAKKMAVKEEKYDPGYEAAYGGAYCDR---APYESEQCNFSS 
359 
TDG_Xenopus         NREIQEVQYTFDLQLAQEDAKRQAIKEEKYDPGYNSALGEQFNEQT--TSGESGMCNFST 
394 
TDG_Zebrafish       QKEVEEVNYTFDLGLAKEDAKRIAVKEEQYDPGYEAAFGGAYGEAAPEGGQSNGICNFSA 
392 
TDG_Drosophila      HIDESECVFT-DQRIRLCSAQQQVDIVGKINKTHQPPLGDHPSSLTVVSNCSGPIAGDAE 
368 
                      : .*  :* *  :   .*:: .    : :  ::.. *    .       ..  .. :  
 
TDG_Mouse           NGLTAHSAEPRGE-----------ATPGDVPNGQ--WMAQSFAEQIPSFNN-CGTREQEE 
417 
TDG_Rat             NGLTANSAELGGE-----------SAPSDVPNGQ--WMAQSFAEQIPSFNN-CGTGEQEA 
378 
TDG_Human           NGLIES-VELRGE-----------SAFSGIPNGQ--WMTQSFTDQIPSFSNHCGTQEQEE 
406 
TDG_Chicken         NGTAPSNPQYCEG-----------SSFGEVPNGQ--WMTQSFADQIPEFSA--GMTQERE 
404 
TDG_Xenopus         DATVPSNAEFNG----------------QAQNGQ--WIPQPIAEQMSTYNH--SGDQQQG 
434 
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TDG_Zebrafish       SEENANTAEKAPTK---------PSDVGQVQDGQ--WMTQSFADQIPDIGS--SSQAQNW 
439 
TDG_Drosophila      CGIVAEESDQVQSEKMIPQMDPTVPSSSNATDGKSFSYTAENTPLLPVSNHNPSINENNY 
428 
                            :                      :*:    .   :  :.  .   .   :.  
TDG_Mouse           ESHA-------------------------------------------------------- 
421 
TDG_Rat             GSHAGSHA---------------------------------------------------- 
386 
TDG_Human           ESHA-------------------------------------------------------- 
410 
TDG_Chicken         GSSA-------------------------------------------------------- 
408 
TDG_Xenopus         GSNA-------------------------------------------------------- 
438 
TDG_Zebrafish       GV---------------------------------------------------------- 
441 
TDG_Drosophila      LSVMGSQQPLSQQPLEKKKRGRPKKIKGQDIIDHSVGGKASIAGQHIPSHDFNNILNLSV 
488 
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Figure S.3.2.  Coimmunoprecipitation of transiently overexpressed TDG and PKCα.  
The indicated expression vectors (7.5 mg per 10 cm culture plate) were transfected in 
NIH 3T3 cells and lysates were immunoprecipitated using a FLAG-affinity matrix.  
Captured protein complexes were separated by SDS-PAGE and analyzed by 
immunoblotting.  
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Figure S.3.3.  Alanine substitution of acetyl acceptor lysines enhances DNA binding.  
TDG(K94-95-98A) bound to a G:T mispair-bearing oligonucleotide is refractory to 
displacement  by GST-APE. TDG or TDG(K95-95-98A) (100 ng each) were pre-
incubated with a biotinylated oligonucleotide bearing a G:T mispair and then 1 or 2  μg of 
GST-APE was added to the reaction and incubated for 30 minutes.   The DNA-protein 
complexes were captured using streptavidin coated paramagnetic beads.  Bound TDG was 
detected by immunoblotting (upper panel).   Signal volume is shown in the lower panel.   
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Figure S.3.4.  DNA-binding analysis of acetylated and mock acetylated TDG (acTDG 
and mock acTDG).   Aliquots of  base excision reactions (Fig 3.7A) were analyzed using 
EMSA.   
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Figure S.3.5.  DNA-binding analysis of phosphorylated and mock phosphorylated 
TDG  (pTDG and mock pTDG).   Aliquots of base excision reactions (Fig 3.7C) were 
analyzed using EMSA.   
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Chapter 4: Subnuclear localization of TDG is regulated by posttranslational 
modifications. 
4.1 Introduction 
Methylation of cytosine within CpG dinucleotides is an important modification in 
vertebrates used to regulate transcription.  While an effective mechanism for repression of 
transcriptional activity, cytosine and 5-methylcytosine are prone to spontaneous 
hydrolytic deamination, generating uracil and thymine mispairs respectively.  Left 
unrepaired, these mispairs will result in C to T transition mutations upon replication.  
These mispairs are major contributors to mutations in tumor genomes which alter CpG 
content and CpG methylation patterns (55-57).  For example, examination of the IARC 
p53 mutation database indicates that C to T mutations at CpGs may be found in the p53 
gene in almost half of all human tumor samples analyzed (53).  These mutations are also 
major contributor to genome instability on an evolutionary time scale as evidenced by a 
loss of methylated CpG sequences over time resulting in approximately 1/5th the expected 
frequency of CpG within the genome (7, 33, 34).   
Performing a critical role in safeguarding CpG dinucleotides from degradation, DNA 
glycosylases TDG and MBD4 are able to excise mispaired uracil and thymine bases 
within CpG sequences, thereby initiating the base excision repair (BER) pathway.  Repair 
of the product abasic site is completed by APE, Polβ and DNA ligase β, which comprise 
the remainder of the BER pathway (26).   
TDG possess an unusually large hydrophobic catalytic pocket (4) which allows 
processing of various bases damaged as a result of alkylation (22), halogenation (47), and  
other environmental toxins (72).  In NIH 3T3 mouse fibroblasts, MBD4 associates 
primarily with heterochromatin, whereas TDG preferentially associates with 
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transcriptionally active euchromatic regions (66).  However, overexpression of Dnmt3a in 
these cells promotes TDG localization to heterochromatic regions (35).  A small fraction 
of TDG has also been shown to localize to heterochromatic regions in P19 mouse 
embryonic carcinoma cells in a Dnmt3b-dependent manner (8).  TDG interacts with a 
number of sequence-specific transcription factors including c-Jun (14), thyroid 
transcription factor 1(TTF-1) (44), retinoic acid receptor (RAR), retinoid X receptor 
(RXR) (68), estrogen receptor α (ERα), and several other nuclear receptors (13), as well 
as transcriptional coactivators SRC1 (38), and cyclic AMP response element binding 
protein (CREB) binding protein (CBP)/p300 (66), suggesting that TDG and BER may 
play a role alongside these important coregulators of transcription in facilitating gene 
expression.   
The links between transcription and BER were further strengthened in recent studies by 
Metivier at al. demonstrating that TDG and BER proteins APE, Polβ and DNA ligase, 
participate in the cyclical demethylation of the transcriptionally active, estrogen 
responsive pS2/TFF1 and Wisp-2 promoters.  When TDG, along with DNA 
methyltransferases Dnmt3a and Dnmt3b bind these methylated promoters, the 
methyltransferase can promote deamination of methylated cytosines, producing G:T 
mispairs.  The mispair is recognized and corrected by TDG and BER, resulting in 
replacement of the methylated cytosine with an unmethylated base.  The 
methyltransferases in turn, remethylate the previously methylated cytosines, silencing the 
promoter until the next signal for gene expression is received (43).   
Deregulation of gene methylation patterns, including hypermethylation of tumor 
suppressor genes (eg. p16, RASSF1A and RUNX3) (48) or hypomethylation of oncogenes 
(eg. WNT5A, CRIP1 and S100P) (70), has been associated with promoting carcinogenesis 
(27, 31, 67).  The TDG gene has also been shown to be hypermethylated and partially 
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silenced in multiple myeloma cell lines suggesting that decreased cellular levels of this 
enzyme contributes to genome instability and cellular transformation (52). 
TDG functionally associates with the transcriptional coactivators CREB binding protein 
and its homologue p300 (CBP/p300).  These essential cellular proteins are 
acetyltransferases and function as transcriptional coactivators (20, 30).  CBP/p300 and 
TDG have been shown to form stable complexes on DNA which are competent for 
excision of mispaired bases.  Additionally, TDG synergistically co-activates CBP-
mediated transcription and is also a substrate for CBP/p300-mediated acetylation on 
amino terminal lysine residues 70, 94, 95, and 98 (66).  Recently, we have shown that 
acetylation at these sites selectively abrogates TDG G:T processing activity while G:U 
processing is unaffected (45).  Furthermore, we were able to infer from studies of an 
alanine substitution mutant (K94-95-98A) of TDG that the effect of acetylation was likely 
mediated by conformational changes in the amino terminus of TDG and not through 
disruption of direct TDG-DNA interactions. 
As shown in the previous chapters, TDG is phosphorylated on serines 96 and 99 by 
PKCα (45) and is also modified by covalent attachment of small ubiquitin-like modifier 
(SUMO) (sumoylation) on lysine 341 (46).  We have shown that sumoylation of TDG 
induces allosteric changes in TDG which are mediated by amino and carboxy terminal 
SUMO binding motifs (SBM1 and SBM2, respectively).  These changes prevent 
sumoylated TDG from stably binding DNA, resulting in a loss of G:T processing, but not 
G:U processing function.  Additionally, sumoylation of TDG prevents interactions with 
CBP and prevents CBP-mediated acetylation.  PKCα-mediated phosphorylation of TDG 
was also shown to prevent CBP-mediated acetylation and reciprocally, acetylation 
prevented phosphorylation, making these modifications mutually exclusive on TDG.  
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This complex interplay between PTMs may cooperate in vivo to regulate TDG function 
and subcellular localization. 
 Considering the evidence that the incidence of C to T mutations at CpG is dramatically 
increased in ageing tissues (5, 12, 15, 26, 49), we investigated whether changes in TDG 
subcellular localization and sumoylation occur in senescent cells.  Cellular senescence 
defines a normal biological response to DNA damage, and other stresses, which results in 
cell-cycle arrest.  This mechanism can block cellular transformation by preventing the 
proliferations of cells that have incurred excessive DNA damage (49).  We found that in 
normal diploid mouse and human fibroblast, replication- and drug-induced senescence 
was associated with redistribution of TDG from the nucleus to the cytoplasm.  
Additionally, there was also a dramatic increase in the fraction of high-molecular weight 
TDG in senescent cells consistent with increased sumoylation.  Similar changes in TDG 
were also elicited by oxidative stress induced by hydrogen peroxide treatment.  Our 
studies also revealed that in MCF-7 breast carcinoma cells a point mutant of TDG which 
could not be sumoylated was excluded from nucleoli while wild-type TDG could be 
driven into these non-membrane-bound organelles upon overexpression of SUMO.  
Finally we examined the effect PKC activation, using the agonist PMA, on the subcellular 
localization of TDG.  We found that PMA treatment decreased colocalization of TDG 
with sites of active transcription and promoted entry into heterochromatic regions from 
which TDG is otherwise largely excluded.  Collectively, these findings suggest that post-
translational modification may play an important role in regulating TDG function in 
response to cellular stress.   
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4.2  Materials and Methods 
Plasmids 
pCMX-based mammalian expression vectors for CFP-TDG and TDG(K341R) have been 
previously described (46, 66).  The pCMX-based mammalian expression vector for YFP-
SUMO was constructed by Marc Tini. 
Antibodies 
TDG-specific rabbit polyclonal antibody has been previously described (46).  Human 
PKCα-specific polyclonal antibodies were obtained from Santa Cruz Biotechnology (sc-
208, or sc-208-G).   Monoclonal (H14) antibody to phosphorylated RNA polymerase II 
was obtained from Abcam (ab24759). 
Cell culture and transfections 
NIH 3T3 fibroblasts were maintained in Dulbecco’s minimal essential medium (DMEM) 
containing penicillin/streptomycin and supplemented with 10% fetal calf serum.  IMR-90 
cells were maintained in DMEM containing penicillin/streptomycin and supplemented 
with 2.5% fetal calf serum and 7.5% fetal bovine serum.  Mouse embryonic fibroblast 
(MEF) and MCF-7 cells were maintained in DMEM containing penicillin/streptomycin 
and supplemented with 10% fetal bovine serum.  For subcellular localization 
experiments, cells were grown under serum-free conditions for 4 hours and then treated 
with either 100 nM PMA or vehicle (DMSO) for 15 minutes in serum containing media. 
For overexpression studies, 6-well plates were seeded with MCF-7 cells on coverslips and 
grown to approximately 80% confluency.  Cells were then transfected with the indicated 
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YFP-SUMO, and CFP-TDG fusion expression vectors using the Polyfect transfection 
reagent (Qiagen).   
Preparation of whole cell extracts for immunoblotting 
Whole cell extracts for immunoblotting were prepared from 100 mm plates of the 
indicated cells.  Cells were grown to approximately 80% confluency and treated as 
indicated.  Cells were then harvested by scraping, pelleted by centrifugation at 300xG for 
2 minutes.  Cell pellets were then washed with PBS before being resuspended in 500 µl of 
Laemmli buffer containing 100 units Benzonase (Roche) and incubated at 95° Celsius for 
5 minutes.   
Immunoprecipitations 
Whole cell extracts for immunoprecipitation were prepared from 100 mm dishes of 
NIH3T3 cells stably expressing FLAG-TDG and control cells transduced with the empty 
expression vector (pLNCX).  Cells grown to 80% confluency were harvested by scraping, 
then pelleted by centrifugation and resuspended in 500 µl of Lysis buffer (50 mM Tris 
HCl pH 7.9, 300 mM NaCl, 1 mM EDTA, 1mM EGTA 10% glycerol, 0.5% Triton X-
100, 1 mM DTT, 50 mM sodium fluoride, 200 µM sodium orthovanadate and proteinase 
inhibitors - 20 μg/mL Pepstatin A, 10 μg/mL Aprotinin, 1 µg/ml Leupeptin, 0.5 mM 
PMSF) and incubated on ice for 30 minutes.  Subsequently, the cell lysate was diluted 
with 500 µl of dilution buffer (50 mM Tris-HCl pH 7.9, 1 mM EDTA, 1 mM EGTA, 10% 
glycerol, 1 mM dithiothreitol (DTT), 50 mM sodium fluoride,  200 µM sodium 
orthovanadate and proteinase inhibitors) and insoluble material removed by 
centrifugation.  Whole cell extracts were precleared twice with 50 µl (50% v/v) rabbit 
IgG-agarose (Sigma-Aldrich) for 30 minutes at 4o C and  immunoprecipitated with 50 µl 
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(50% v/v) anti-FLAG affinity resin (M2 agarose, Sigma-Aldrich).  Immunoprecipitated 
proteins were separated by SDS-PAGE and detected by immunoblotting. 
Immunostaining and microscopy 
NIH 3T3 cells were fixed for 15 minutes with 4% formaldehyde in phosphate buffered 
saline (PBS) followed by a 10 minute incubation with 0.1 M glycine in PBS.  Cells were 
then permeabilized with 0.5% Triton X-100 in PBS for 10 minutes.  Immunostaining was 
performed with the appropriate primary antibodies and fluorophore-conjugated Donkey 
secondary antibodies (CY3, FITC) (Jackson ImmunoResearch Laboratories) diluted with 
1% BSA/PBS solution.  Epifluorescence imaging was performed on an Axiovert 200M 
inverted microscope equipped with an Apotome (Carl Zeiss) using appropriate 
fluorophore-specific filter sets.  Z-series images (63X magnification) were acquired at 0.5 
µm intervals and processed with Axiovision software and Adobe Photoshop.  
Fluorescence intensity plots were obtained by performing a line scan bisecting the cell 
using Axiovision software.  
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4.3 Results 
TDG is responsible for repairing an array of toxic base lesions which contribute to 
mutations which have been found to accumulate in aging tissues.  We therefore decided 
to examine whether alterations in TDG regulation may occur in ageing cells.  IMR-90 
diploid fibroblasts are derived from a 16-week female fetus and are capable of 
approximately 50-60 population doublings before entering senescence.  The cellular 
distribution of TDG in low (LP) and high passage (HP) fibroblasts was examined by 
indirect immunofluorescence using an antibody that recognizes both mouse and human 
TDG (46).  We found that in high-passage number IMR-90 cells TDG may be found in a 
punctate pattern in the cytoplasm and nucleus (Figure 4.1A).  We next examined LP cells 
treated with the histone deacetylase inhibitor (HDACi) sodium butyrate which has been 
shown to induce alterations in cells similar to senescence (64).  In these cells we found 
that TDG underwent a similar redistribution to that seen in IMR-90 cells naturally 
entering senescence (Figure 4.1B).  To corroborate these findings, we performed the same 
analysis in sodium butyrate-treated mouse embryonic fibroblasts (MEFs) and found that 
TDG underwent a similar redistribution in these cells (Figure 4.1C).  These observations 
suggested that TDG may undergo redistribution in aging cells and furthermore, that a 
similar pattern of relocalization may be stimulated by treatment with histone deacetylase 
inhibitors. 
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Figure 4.1.  Redistribution of TDG to cytoplasm in senescent and sodium butyrate 
treated cells.  (A)  TDG undergoes redistribution from the nucleus to cytoplasm in high-
passage IMR-90 cells.  IMR-90 cells were passaged until they were no longer dividing, 
then fixed in 4% formaldehyde and TDG was detected by indirect immunofluorescence 
with a TDG-specific antibody. Cells were imaged using a Carl Zeiss Axiovert 200M 
microscope equipped with Apotome at 60x magnification.  Using appropriate filters, 0.5 
μm sections were taken.  High passage number (HP) and low passage (LP)  number cells 
are indicated.  (B)  Treatment of IMR-90 cells with sodium butyrate causes redistribution 
of TDG from the nucleus to cytoplasm. LP IMR-90 cells were treated with 10 mM 
sodium butyrate for 48 hours, and TDG localization was detected as in Figure 4.1.  (C)  
Treatment of mouse embryonic fibroblasts (MEFs) with 10 mM sodium butyrate causes 
redistribution of TDG from the nucleus to cytoplasm.  MEFs were treated with 10 mM 
sodium butyrate and analyzed as described above. 
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In order to assess the sumoylation status of TDG after HDACi treatment we fractionated 
cellular lysates by SDS-PAGE and detected TDG by immunoblotting.  Sumoylated TDG 
is approximately 10 kD greater in mass than unmodified TDG although the modified and 
unmodified proteins resolve at an apparent size of approximately 60 and 80 kD 
respectively when resolved by SDS-PAGE.  By comparing the relative intensities of the 
immunoreactive TDG bands we were able to approximate the proportion of TDG which 
was sumoylated in the lysate.  Interestingly, we noted that in lysates prepared from 
untreated IMR-90 cells TDG migrated similarly (~ 80 kD) to sumoylated TDG in lysates 
prepared from NIH 3T3 cells (Figure 4.2A).  When we examined IMR-90 lysates treated 
with 1 μM TSA or 10 mM butyrate for 48 hours, we found that TDG from HDACi-
treated cells migrated at approximately 90 kD, while control lysates showed bands at both 
80 and 90 kD.  These observations are consistent with the modification of TDG by 
conjugation of either SUMO-1 or SUMO-2/3 (3) and SUMO-2/3 may then be sumoylated 
by SUMO-1 (40).  This suggested that redistribution of TDG in HDACi-treated cells may 
be related to further sumoylation of TDG. 
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Figure 4.2.  Cellular redistribution of TDG may be associated with changes in 
posttranslational modification.  (A)  Cellular lysates from immortalized NIH 3T3 
mouse fibroblasts and human IMR-90 fibroblasts were prepared in Laemmli buffer and 
immunoblotted for TDG.  The expected relationship between a presumptive sumoylated 
(S-TDG) and TDG normally seen in NIH 3T3 cells is indicated.  (B)  IMR-90 cells were 
treated with either trichostatin A (TSA) (1 μM) or sodium butyrate (10 mM) for 48 hours 
and lysates were prepared and analyzed as in (A).  The putative sumoylated TDG band is 
indicated. 
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We have shown that crosstalk between acetylation and phosphorylation and between 
acetylation and sumoylation in the regulation of TDG functions (45, 46).  In order to 
determine whether phosphorylation or acetylation of TDG could alter sumoylation in 
response to cellular stress, we serum-starved NIH 3T3 cells stably transfected with 
FLAG-TDG expression vector (NIH 3T3-TDG) or empty vector (NIH 3T3-FLAG) for 
four hours then treated with phorbol ester PMA, which promotes phosphorylation of TDG 
(45), the biologically inactive phorbol ester 4αPMA, sodium butyrate, or various 
concentrations of hydrogen peroxide (H2O2).  The latter is a natural signaling molecule 
causes oxidative damage to cells, and has also been shown to activate PKCα (32).  
Additionally, H2O2 has been shown to alter sumoylation through regulation of SUMO 
conjugating enzymes, causing a decrease in global sumoylation at low concentrations, 
and increase at high concentrations (9).  We prepared whole cell lysates from treated cells 
and immunoprecipitated FLAG-TDG using FLAG-specific M2 agarose.  After 
fractionation of immunoprecipitates by SDS-PAGE, we detected TDG by 
immunoblotting with a TDG-specific antibody.  This analysis showed that although 
phorbol esters do not alter sumoylation as detected by this method (Figure 4.3, lanes 4 
and 5), peroxide (compare lane 2 to lanes 6-9) and HDACi treatment (compare lane 2 to 
lane 3) strongly promotes a shift in TDG mobility consistent with its sumoylation (46).    
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Figure 4.3.  Oxidative stress and sodium butyrate treatment alter post-translational 
modification of TDG.  NIH 3T3 cells stably expressing FLAG-TDG were starved in 
serum-free DMEM media then treated with the indicated stimuli for one hour (overnight 
for sodium butyrate (NaBut) treatment).  FLAG-TDG was then captured by 
immunoprecipitation of lysates prepared from these cells using FLAG-specific M2 
agarose.  Immunoprecipitates were then fractionated by SDS-PAGE and TDG was 
detected by immunoblotting with a TDG-specific antibody. 
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These studies suggested that sumoylation of TDG occurs in response to oxidative 
stress while previous studies also indicate that TDG sumoylation prevents localization to 
the PODs (46).  Therefore, we were interested in further investigating the role of 
sumoylation in regulating the cellular localization of TDG.  Analysis of cellular lysates by 
immunoblotting with a TDG-specific antibody indicates that the percentage of TDG 
sumoylated varies between 5 and 50% depending on which cell type is examined [(Tini, 
unpublished)(45, 46)].  Specific detection of S-TDG in cells is problematic as there is no 
immunological method for distinguishing S-TDG from TDG.  In order to determine the 
subcellular localization of S-TDG we carried out a comparative analysis of the cellular 
distribution of cyan fluorescent protein (CFP) fusion proteins of wild-type TDG and the 
sumoylation-deficient mutant TDG(K341R) cotransfected with yellow fluorescent protein 
(YFP)-SUMO.  This approach allowed us to identify differences in the colocalization of 
YFP-SUMO and CFP-TDG(K341R) compared to CFP-TDG.  The subcellular regions 
where CFP-TDG(K341R) does not appear to colocalize with YFP-SUMO  may represent 
cellular compartments where localization is dependent on sumoylation of TDG.  This 
approach did not allow us to specifically identify areas where only unmodified TDG 
localized or where both unmodified and S-TDG colocalized. Using this approach we 
found that YFP-SUMO and CFP-TDG colocalized extensively within the nucleus, 
including in nucleolar regions, from which TDG is normally excluded (46).  CFP-
TDG(K341R) however, did not colocalize with SUMO in the nucleoli, and rather 
accumulated around these non-membrane bound structures (Figure 4.4, compare panels 
IV and VIII).  When we coexpressed FLAG-promyelocytic leukemia protein (PML) with 
YFP-SUMO we observed accumulation of SUMO within the PML oncogenic domains 
(PODs) (42, 46).  Interestingly, in these cells neither exogenous TDG or TDG(K341R) 
localized to the nucleoli, suggesting that PML can regulate the nucleolar localization of 
TDG.  We did observe accumulation of YFP-TDG and -TDG(K341R) in the PODs, 
suggesting that SUMO interactions were important for regulation of TDG localization to 
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these subnuclear compartments (Figure 4.4, compare panels XII and XVI).  Interestingly, 
YFP-TDG(K341R) localized more readily to the PODs compared with YFP-TDG, 
suggesting that sumoylation of TDG negatively regulates POD targeting.  Previously, 
TDG(K341R) was shown to accumulate within the PODs in the absence of SUMO 
overexpression (46).  Additionally, sumoylated TDG was shown to be deficient in 
intermolecular SUMO-binding ability.  Together with observations that selective 
desumoylation of PML within the PODs results in a loss of accumulation of TDG to the 
PODs (46), these observations suggest that sumoylation of TDG in concert with 
intracellular trafficking of SUMO may contribute to regulation of TDG subcellular 
localization which is dependent on TDG SUMO binding activity.  
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Figure 4.4.  Sumoylation of TDG may promote nucleolar localization.  Expression 
vectors for the indicated proteins were cotransfected into MCF-7 cells using 
Lipofectamine 2000 transfection reagent.  After allowing 24 hours for expression, cells 
were fixed in 4% formaldehyde/PBS and fluorescent fusion proteins were detected by 
epifluorescence microscopy using an Axiovert microscope (Zeiss) and the appropriate 
filters.  Representative 0.5 μM sections are shown.  Arrows indicate nucleoli, or 
promyelocytic leukemia (PML) oncogenic domains (PODs) where appropriate. 
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We were intrigued by the observed cytoplasmic redistribution of TDG in senescent 
fibroblasts and hypothesized about the possible consequences this may have on genome 
maintenance and transcriptional regulation.  To further explore the association of TDG 
with active transcription we investigated the extent of TDG colocalization with nuclear 
transcription sites.   In order to minimize the effects of the observed alterations in TDG 
regulation related to passage number in standard MEF cells or from the IMR-90 cells 
lines we utilized P19 mouse embryonic carcinoma stem cells for this purpose.  We 
immunostained P19 cells with antibodies specific for TDG to detect endogenous TDG 
and phosphorylated RNA polymerase II (p-polII) to detect sites of active transcription 
(54).  When we examined the localization of endogenous TDG and p-polII we found a 
dramatic colocalization of the two proteins consistent with a role for TDG in active 
transcription and the coupling of BER to transcription (Figure 4.5, panel V).  
Interestingly, treatment with PMA reduced the extent to which TDG and p-polII 
colocalized (Figure 4.5, compare panels V and X), suggesting that phosphorylation events 
control either directly or indirectly the cellular functions of TDG.   
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Figure 4.5.  Colocalization of TDG with nuclear transcription sites in P19 embryonic 
carcinoma cells: Influence of PKC activation.  TDG associates with sites of active 
transcription, but dissociates upon treatment with phorbol ester PMA.  P19 embryonic 
carcinoma cells were treated with 100 nM PMA for 20 minutes before fixation with 4% 
formaldehyde.  Endogenous TDG and phosphorylated RNA polymerase II (p-polII) were 
detected in by immunostaining with specific antibodies and 0.5 μm sections were 
obtained as described above.  Arrows indicate heterochromatic regions. 
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We also immunostained endogenous TDG and PKCα in P19 cells treated with PMA.  In 
untreated P19 cells, the majority of PKCα was detected throughout the nucleus excluding 
the nucleoli, and no gross changes in PKCα localization were detected after PMA 
treatment.  However, a fraction of TDG relocalized to heterochromatic regions and 
showed an increased localization with PKCα (Fig 4.6, compare panels V and X.  Arrows 
indicate heterochromatic regions.).  This was not accompanied by a drastic loss of 
localization of TDG with euchromatic areas of the nucleus.  These results suggest that 
PKC activation promotes localization of with transcriptionally inactive heterochromatic 
regions.    
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Figure 4.6.  Nuclear colocalization of TDG and PKCα is altered by phorbol ester 
treatment.  IMR-90 cells were treated and analyzed as in Fig. 4.5 using antibodies 
toward endogenous TDG and PKCα.  Arrows indicate heterochromatic regions. 
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4.4 Discussion 
We have shown that in senescent mouse and human fibroblasts TDG is found in both the 
nuclear and cytoplasmic compartments in contrast to the strictly nuclear localization 
observed in proliferating fibroblasts.   The cytoplasmic localization coincides with altered 
posttranslational modification consistent with increased sumoylation or ubiquitination.   
Interestingly, exposing asynchronously cycling fibroblasts to oxidative stress also induced 
sumoylation of TDG.  When we examined the localization of sumoylated TDG in breast 
carcinoma cells however, we found that sumoylation was associated with entry into 
nucleoli.  We also found that TDG associates with sites of active transcription and that 
activation of PKC, previously shown to phosphorylate TDG, resulted in decreased 
association with sites of active transcription and increased association with 
heterochromatin.  Our findings suggest that TDG PTMs are important regulators of TDG 
subcellular localization and that the effects PTMs on TDG may be cell-type and/or cell-
cycle dependent.  Importantly, we have shown that external agents may be used to alter 
TDG PTM in cells.    
Cells may enter senescence in response to extended proliferation, telomere loss, oncogene 
activation, or oxidative damage (39).  It has been proposed that cells in culture undergo 
senescence due to exposure to super-physiological concentrations of oxygen as opposed 
to the lower oxygen concentration found in vivo, suggesting that senescence is likely 
caused by oxidative stress.  Furthermore, some evidence suggests that cells grown in low 
oxygen conditions may grow indefinitely (11).  The most obvious sign of senescence is 
growth arrest caused by failure to progress from G1 to S phase (59) also termed G0.  
Analysis of aging mouse tissues has revealed that they are deficient in base excision 
repair (BER) (21) and accumulate oxidative DNA damage (2, 17, 24, 28, 29, 61) 
suggesting that these cells sustain genomic damage over time which may contribute to 
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evasion of protective cell cycle arrest mechanisms and carcinogenesis.  For example, 
telomerase has been found to be activated in over 90 percent of human tumors and cancer 
cells (10, 23).  Extensive evidence for misregulation of p53 and p21 or Rb mediated cell 
cycle arrest pathways has also been demonstrated in transformed cells (1, 16, 19, 25, 60, 
65).  BER is the predominant DNA repair pathway for repair of oxidative lesions in cells 
(37, 58) and so we chose to examine regulation of the essential protein (M. Tini, 
unpublished) and BER enzyme TDG, in senescent IMR-90 diploid cells.  We found that 
TDG underwent a dramatic relocalization from nucleus to cytoplasm in these cells.  
Interestingly, there is a concomitant alteration in TDG distribution from being smoothly 
distributed within the nucleus, to forming distinct foci throughout the cell.  Similarly, 
misregulation of BER protein subcellular localization to both nuclei and mitochondria has 
been observed with oxoguanine DNA glycosylase (OGG1) and AP endonuclease (APE) 
(62).   
To exclude that extended culture had resulted in selection of aberrant cells, we also 
induced senescence by treating IMR-90 and mouse embryonic fibroblast (MEF) cells 
with histone deacetylase inhibitor (HDACi) sodium butyrate which induces a senescent 
phenotype (51).  We found that this treatment induced dramatic redistribution of TDG 
from nucleus to cytoplasm similar to that seen in high passage number IMR-90 cells.  
This raised the intriguing possibility that TDG localization was regulated by post-
translational modification (PTM) in cells and that this regulation may be altered as cells 
age.  The BER protein APE, also a substrate for CBP-mediated acetylation, has been 
shown to be highly-acetylated and in aging cells (62) and this modification enhances APE 
binding to negative calcium response elements in the parathyroid hormone promoter (6).  
Although extended treatment with sodium butyrate induces numerous changes which 
result in a state similar to senescence (71), if an increased percentage of TDG is 
acetylated in aged cells this may predispose them to accumulating G:C to A:T transition 
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mutations since acetylated TDG does not excise thymine from G:T mispairs (45).  This is 
supported by evidence showing an accumulation of these mutations in aging tissues (17) 
although a comparative measure of the G:T-mispair processing capacity of young and 
aged tissues has yet to be done.  Furthermore, evidence indicates that senescence may act 
as a tumor suppressor, yet paradoxically correlative evidence suggests that because 
senescent cells are still susceptible to DNA damage and rely on maintenance of an 
elaborate senescence program mediated by the p53 and Rb pathways, which have been 
shown to be commonly misregulated in tumors, senescence may also contribute to 
carcinogenesis through reestablishment of cell division after transforming DNA damage 
(11).  While the chance of incorporating DNA lesions such as mispairs may be offset by a 
lack of cell division, spontaneous DNA damage continues even after an organism has 
ended its natural life as a result of the inherent instability of the molecule  (36).     
Immunoblotting analysis of TDG in IMR-90 cells treated with sodium butyrate or 
trichostatin A (TSA) by immunoblotting identified a shift in mobility consistent with 
sumoylation of TDG, suggesting that acetylation promotes sumoylation.  This could 
possibly be occurring in the cytoplasm, where we observe an increase in TDG 
localization.  While sumoylation of TDG reduces acetylation of the protein in vitro (46), 
the effect of acetylation on sumoylation has not yet been investigated.  Sumoylation likely 
prevents acetylation through steric hindrance of the acetylase (46), but such a mechanism 
does not preclude sumoylation of acetylated TDG.  Previous studies indicate that 
phosphorylation and acetylation are mutually exclusive (45) yet treatment with PMA did 
not reduce sumoylation.  It is possible that phorbol ester treatment may also promote 
sumoylation of TDG since both modifications reduce the charge of residues within the 
hydrophilic TDG amino terminus.  Metabolic labeling experiments indicate that 
sumoylated TDG is indeed phosphorylated (45), although it is not clear which 
modification occurs first, nor whether there is an interplay between the modifications, or 
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what the nature of such an interplay may be.  TDG was originally identified as a 
phosphoprotein based upon observations of differential mobility of TDG species in whole 
cell lysates fractionated by SDS-PAGE.  These differences in mobility could be 
eliminated by pretreatment of lysates with calf thymus intestinal phosphatase (68).  In this 
report, the authors observed TDG species around 60 kD and just over 84 kD.  TDG, 
despite being a 45 kD peptide, normally resolves at about 60 kD when fractionated by 
SDS-PAGE.  Interestingly, sumoylated TDG normally migrates at approximately the 
same position as the phosphatase-sensitive band in these experiments (68).  If this were 
the case, it may mean that phosphorylation of TDG stabilizes TDG sumoylation while 
phosphatase treatment acts to destabilize TDG sumoylation.     
Hydrogen peroxide has been shown to affect multiple signaling pathways and is itself a 
signaling molecule (18).  Acting through CBP, peroxide treatment has been shown to 
cause acetylation of the FOXO4 transcription factor, reducing its transcriptional activity 
(69).  PKCα is a classical PKC isozyme that normally requires calcium and 
diacylglycerol for activation.  Some evidence suggests that PKCα, and perhaps other 
PKC isoforms, may be activated in the absence of these cofactors by hydrogen peroxide 
(32).  Hydrogen peroxide stress has also been shown to modulate sumoylation of proteins 
negatively at low concentrations and positively at high concentrations (9).  When we 
treated NIH 3T3 cells stably transduced with FLAG-TDG, with concentrations of 
hydrogen peroxide ranging from 10-500 μM we found a large increase in the proportion 
of S-TDG from concentrations beginning as low as 50 μM.  The exact concentrations of 
hydrogen peroxide required to effect such changes is likely dependent on the culture 
conditions and cell type as previous studies performed in HeLa cells show that simply 
doubling the concentration of peroxide over a shorter treatment period may result in an 
overall decrease in sumoylation of cellular proteins, which is mediated by modulating the 
interactions between SUMO conjugating enzymes Uba2 and Ubc9 (9). 
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Considering the evidence that TDG sumoylation may be regulated in response to 
oxidative stress, we wanted to specifically determine the subnuclear localization of S-
TDG.  We found that when coexpressed with YFP-SUMO-1, CFP-TDG accumulates in 
nucleolar regions whereas CFP-TDG(K341R) was excluded, and instead accumulated 
around these non-membrane bound structures.  In both cases, YFP-SUMO localized to 
the nucleoli.  Coexpression of PML, a major component of the heavily sumoylated PML 
oncogenic domains (PODs), caused YFP-SUMO to accumulate in the PODs instead of 
nucleoli.  Interestingly, both YFP-TDG and YFP-TDG(K341R) preferentially localized to 
the PODs in these cells.  The lack of YFP-TDG(K341R) localization to nucleoli suggests 
that sumoylation is a dynamic process which can regulate TDG subcellular localization.  
Since TDG(K341R) is not defective in SUMO-binding,  the differences in nucleolar 
localization are attributable to lack of sumoylation and not noncovalent SUMO 
interactions.  Therefore, sumoylation appears to be a requisite step for entrance into these 
regions.  SUMO proteases exist in the nucleolus and it is possible that sumoylated TDG 
crosses into the nucleoli where it is promptly desumoylated (63, 73).  We have previously 
shown that SBMs in TDG are necessary for POD translocation and that TDG sumoylation 
negatively regulates this process (46).  The observation that localization of YFP-SUMO 
to the PODs upon overexpression of PML causes a corresponding accumulation of TDG 
and TDG(K341R) to these structures indicates that SUMO binding is a critical 
determinant of the localization of TDG within the nucleus.  Our current findings suggest 
that transient sumoylation may permit access into certain subcellular compartments such 
as the nucleoli and PODs.   Interestingly, inhibition of proteasomal degradation by 
treatment with the peptide inhibitor MG132 in MCF-7, HeLa, and IB-4 cells causes a 
redistribution of PML and SUMO, as well as another POD constituent sp100, from the 
PODs to the nucleoli.  Subsequent removal of MG132 allowed reconstitution of the PODs 
(41).  This indicates that POD components, including SUMO, traffic to nucleoli in a 
process related to proteasomal degradation.  These observations suggest that TDG 
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trafficking with SUMO to nucleoli may promote degradation of TDG by the proteasome, 
and that sumoylation may play an important role in permitting progression of this 
pathway in degrading TDG.      
Senescence and oxidative stress have been associated with dramatic changes in chromatin 
structure and transcriptional programs (50, 74).  These changes to the transcriptional 
program are associated with euchromatinization of some previously heterochromatic 
regions.  There is an overall increase in heterochromatic regions in senescent nuclei 
compared to early passage cells (50), and this chromatin remodeling may act as a 
mechanism for silencing a portion of the numerous genes downregulated to create the 
senescence gene signature (74).  TDG has been shown to associate preferentially with 
transcriptionally active euchromatic regions and act as a coactivator for multiple 
transcription factors in actively dividing cells and we were therefore interested in 
quantifying the extent to which TDG may be involved with transcriptional activity in 
cells.  When we examined this at a gross level by immunostaining P19 cells with 
antibodies specific for endogenous TDG and transcriptionally active phosphorylated 
RNA polII (p-polII), we observed extensive colocalization of these proteins throughout 
the nucleus.  Interestingly, treatment of cells with PMA caused reduced p-polII-TDG 
localization but increased TDG localization to heterochromatic foci which also contained 
PKCα.  Examination of the effect this had on TDG-PKCα colocalization demonstrated an 
increase in colocalization similar to that seen between nuclear TDG and PKCα in NIH 
3T3 fibroblasts (45).  It is possible that phosphorylation of TDG in cycling cells serves to 
target TDG to heterochromatin without drastically decreasing the levels of TDG acting in 
euchromatic regions, while redistribution of TDG in senescent cells may serve to reduce 
the amount of TDG within the nucleus, thereby reducing the amount of TDG-mediated 
transcription occurring in these quiescent cells.  
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These observations suggest that the subcellular localization of TDG is altered in senescent 
fibroblasts, concurrent with alterations in TDG PTM.  Additionally, we have shown for 
the first time that alterations in TDG PTM may induced by oxidative damage to proteins 
and DNA that promote cellular senescence or growth arrest.  Interestingly, we have also 
demonstrated that TDG may be extensively associated with sites of active transcription in 
actively cycling cells, suggesting that BER mediated by TDG may play a more general 
role in transcriptional regulation than previously understood, and that modification of 
TDG and relocalization of the protein may contribute to the senescent transcriptional 
program.   
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Chapter 5: Conclusion 
TDG plays a role in maintaining genome stability through BER and also participates in 
transcriptional regulation.  Consequently, TDG is predicted to play a role in diverse 
aspects of cellular function.  The TDG protein possesses a central, highly conserved core 
region which is sufficient for excision of uracil from G:U mispairs within a CpG context.  
Less conserved are amino- and carboxy-terminal regions.  Of these, the lysine and serine-
rich amino terminus is of particular interest because it mediates numerous protein-protein 
interactions as well as tight DNA interactions necessary for excision of thymine from G:T 
mispairs within CpGs.  Numerous TDG PTM have been characterized, and a majority are 
directed toward the amino terminus.  We therefore hypothesized that PTM of the amino 
terminus may act to regulate TDG function.  Accordingly, the aim of this thesis was to 
examine how TDG PTM may alter TDG subcellular localization, protein-protein 
interactions, and enzymatic function.  The findings presented in this thesis and their 
implications are discussed in the following sections.  
5.1 Summary 
In Chapter 2 we examined the role of covalent attachment of SUMO (sumoylation) and 
non-covalent SUMO binding in regulating TDG subnuclear localization, protein-protein 
interactions, DNA binding, and enzymatic function.  Initially, we undertook an 
examination of TDG subnuclear localization which indicated that TDG may localize to 
PODs by binding to SUMO conjugated to PML.  Subsequent experiments revealed a 
novel amino-terminal SUMO binding motif  145IVII148 (SBM1) which was conserved in 
various TDG orthologs and corresponded to a SUMO binding motif consensus sequence 
I/V-X-I/V-I/V (35) which could be recognized in both forward and reverse orientations 
(36).  Mutation analysis showed that SBM1 was required for TDG-SUMO interactions 
and also for activation of CBP-mediated transcription.  Analysis of in vitro sumoylated 
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TDG (S-TDG) showed that S-TDG did not bind stably to DNA and was deficient in 
excision of thymine from G:T mispairs, yet capable of excising uracil from G:U mispairs.  
Protein-protein interaction studies showed that sumoylation of TDG also prevented 
binding to free SUMO and abrogated interactions with CBP, including CBP-mediated 
acetylation of TDG. 
In Chapter 3 we took a closer look at the TDG amino terminus and discovered the 
existence of PKCα phosphorylation sites on amino acid residues proximal to acetylated 
lysines 94, 95, and 98.  The close proximity of the substrate residues for acetylation (K95, 
95, and 98) to these acetylated serines (S96, 99) led us to investigate a potential 
relationship between these modifications.  Remarkably, we found that acetylation and 
phosphorylation were mutually exclusive on TDG.  Analysis of the functional 
consequences of these modifications on TDG substrate interactions showed that 
acetylated TDG lacked the ability to excise thymine from G:T mispairs, and was unable 
to bind an oligo bearing the same mispair while phosphorylated TDG retained these 
functions.  Interestingly, while it appeared that sumoylation and acetylation of TDG both 
led to a loss of tight DNA interactions – resulting in a loss of G:T mispair processing 
ability, sumoylated TDG actually displayed an enhanced ability to process G:U mispairs 
while we did not observe the same with acetylated TDG.   
In Chapter 4 we examined whether TDG regulation is altered in ageing cells.  We 
examined the localization of endogenous TDG in IMR-90 and MEF cells approaching 
senescence and found that TDG is differentially localized in aging cells.  Interestingly, we 
also found that inhibition of histone deacetylases may contribute to this process.  
Exposure of cells to oxidative stress, which is thought to contribute to ageing and has 
been shown to activate PKC as well as CBP, in addition to modulating cellular levels of 
sumoylation through targeting of SUMO conjugating enzymes, led to similar changes in 
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TDG mobility.  An analysis of the consequences of TDG sumoylation suggested that this 
modification, may regulate TDG localization to nucleoli – normally sparsely populated by 
TDG.  Interestingly, we also found that PML may play a role in coordinating SUMO-
based regulation of TDG localization.  To conclude Chapter 4, we examined 
colocalization between endogenous TDG and sites of active transcription in cells by 
immunostaining P19 embryonic carcinoma stem cells with TDG- and phosphorylated 
RNA polymerase II (p-polII)-specific antibodies and found extensive colocalization 
between TDG and p-polII which could be decreased by treatment of cells with the PKC-
stimulating agent PMA, resulting in increased TDG association with heterochromatic 
regions from which TDG is otherwise largely excluded. 
5.2 Significance and Conclusions 
Together these data show that TDG is subject to multiple PTM including acetylation, 
phosphorylation, and sumoylation.  Additionally, TDG has been shown to be 
polyubiquitinated during S-phase, leading to degradation of the protein  (9).  Furthermore, 
we demonstrate that these PTM are involved in an interplay which can regulate all aspects 
of TDG function including susceptibility to further PTM (Figure 5.1).  It is important to 
note that many of these findings are novel observations.  Accordingly Chapters 2 and 3 
have been published in the journal of Molecular and Cellular Biology, and Nucleic Acids 
Research respectively.  Although a complete understanding of how TDG participates in 
pathways mediating cellular processes is still unclear, these findings serve to show that 
TDG PTM can be a powerful regulator of TDG function. 
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Figure 5.1.  Cross-talk between TDG posttranslational modifications.  Previous 
studies have shown that sumoylation of human and mouse TDG induces a dramatic 
increase in G:U processing activity by promoting enzyme turnover (10, 28).  In contrast, 
sumoylation (10, 28) or acetylation by CBP (this study) abrogate DNA binding and G:T 
processing (16, 41).  TDG sumoylation also drastically reduces interactions with 
CBP/p300, thereby preventing efficient acetylation (28). Phosphorylation of serine 
residues adjacent to acetyl-acceptor lysines by PKCα prevents acetylation by CBP and 
may preserve G:T processing in vivo (27).  This regulation may occur over rapid or 
extended time periods, in response to external stimuli and pharmacological agents, 
resulting in altered TDG function, localization, and interaction with DNA substrates or 
protein partners.   
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We began our investigations into TDG PTM by examining the roles of sumoylation and 
SUMO binding in regulation of TDG.  In early studies examining TDG sumoylation, it 
was proposed that sumoylation of TDG occurred primarily on DNA and was a 
mechanism for facilitating conformational changes in TDG which promote its 
disassociation from abasic sites (10, 37).  Here we present a number of observations 
which suggest that sumoylation may occur in other contexts as well.  Our first indication 
that sumoylation may not be exclusively associated with DNA repair activities came from 
observations that glycosylase deficient point mutant TDG(N151A) was sumoylated as 
readily as wild-type TDG.  Despite being unable to excise mispaired bases, TDG(N151A) 
was able to bind abasic sites, although it seemed unlikely that this could account for the 
degree of sumoylation observed.  Furthermore, we showed in Chapter 3 that APE could 
effectively displace TDG from abasic sites in the absence of sumoylation in vitro and 
endogenous levels of APE should suffice to do the same in vivo (27).  Other observations 
outlined in Chapter 4 pointed to a number of potential roles for sumoylation in TDG 
function.  For example, we showed that co-expression of YFP-TDG and CFP-SUMO 
resulted in nucleolar localization for TDG, but sumoylation-minus mutant TDG(K341R) 
was excluded from these non-membrane-bound subnuclear compartments, indicating that 
sumoylation may play a role in facilitating entry into these areas.   Interestingly, when we 
examined TDG regulation in senescent cells we noted an apparent increase in sumoylated 
TDG in addition to a dramatic relocalization of the protein, suggesting that sumoylation 
may facilitate passage into the cytoplasm or alternatively that TDG may be subject to 
increased sumoylation within the cytosol.  With respect to the senescence program, it is 
unclear whether sumoylation of TDG is necessary for establishing senescence or if it is a 
product of the process.   
Once sumoylated, TDG displays altered biochemical properties.  In Chapter 2 we propose 
that this is due to changes in TDG conformation attributable to intramolecular SUMO-
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binding mediated by the dual SUMO binding motifs SBM1 and SBM2.  Consequently, S-
TDG no longer excises thymine from G:T mispairs, or binds free SUMO.  Additionally, 
sumoylation of TDG reduces interactions with CBP as well as CBP-mediated acetylation 
of TDG.  We were also able to replicate experiments performed with human S-TDG 
using mouse S-TDG to show that sumoylated TDG is more efficient than unmodified 
TDG in excision of uracil from CpGs due to increased turnover on the product abasic site 
(28, 37).  This seemingly implies that S-TDG may also be more efficient at processing 
mispairs in vivo, however the base-flipping mechanism of glycosylase function requires 
that TDG systematically scan the genome, flipping out each base until an aberrant base is 
detected and excised.  It seems unlikely that S-TDG, with its reduced DNA-binding 
ability would serve such a function efficiently.  Interestingly, we also found an increase in 
TDG sumoylation in cells exposed to oxidative stress.  This observation may be 
interpreted in two ways; if sumoylation of TDG is simply a switch to produce a more 
efficient glycosylase, then it would be predicted that increased S-TDG would promote 
cell survival.  If not, then it would promote genome instability and apoptosis or 
senescence.   
We have also presented evidence indicating that the SUMO binding activity of TDG 
plays an important role in regulating TDG function.  For example, we show that TDG can 
bind to SUMO conjugated to p53.  This observation opens the door to an entirely new set 
of interacting proteins for TDG as it could potentially interact with any number of 
sumoylated proteins and is an important consideration for future studies.  For example, 
after purification of a putative TDG cellular complex it may be tempting to dismiss an 
interaction mediated through a sumoylated protein as artefact if it cannot be verified in 
vitro with unmodified proteins.  Interestingly we also found that mutants of TDG 
deficient in SUMO binding were unable to activate CBP-mediated transcription on a 
reporter gene (28).  Although the nature of the requirement for SUMO binding activity in 
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this context is unclear, it suggests sumoylation of TDG may also reduce activation of 
CBP-mediated transcription by preventing SUMO binding.  Such a prediction is 
supported by our observation that sumoylation of TDG reduces direct interactions with 
CBP.  These findings may have a broader effect on transcriptional regulation in addition 
to affecting pathways directly regulated by TDG.  This is because CBP/p300 transcription 
is partially regulated through competition between transcription factors for a limited 
number of CBP/p300 molecules in the nucleus (3, 18, 32).  In Chapter 4 we show that 
senescence is accompanied by a concurrent increase in TDG sumoylation and dramatic 
subcellular redistribution which excludes approximately half of the cellular compliment 
of TDG from the nucleus.  This may serve to reduce TDG-associated activation CBP 
while allowing other factors access to this important mediator of transcription.  Hundreds 
of genes are differentially regulated in senescence and such a redistribution of 
transcription-associated factors would contribute to effecting these changes (43).   
Acetylation of TDG by CBP/p300 was first observed by Tini et al who identified the 
acetylated lysine residues and showed that acetylation of TDG promotes dissociation of 
TDG-CBP complexes and reduces interactions with APE in vitro (39).  In Chapter 3 we 
show that acetylation of TDG is inhibited by DNA interactions and that acetylation of 
TDG reduces stable DNA binding and processing of thymine from G:T mispairs (27).  
The latter observation is of particular interest because it provides a mechanism for 
regulating pathways that utilize thymine glycosylase activity such as BER and cyclical 
demethylation of methylcytosine on transcriptionally-active promoters.  With respect to 
transcription, analysis of a glycosylase deficient mutant of TDG (mouse TDG N151A) 
has indicated that this activity is dispensable for activation of some transcriptional 
pathways as it was able to activate CBP-mediated transcription on a reporter gene (39).  
Similarly, glycosylase activity was found to be dispensable for ER-mediated transcription 
in reporter gene assays (5).  However, glycosylase activity was shown to be required for 
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participation in cyclical demethylation of the transcriptionally active estrogen responsive 
pS2 and Wisp-2 gene promoters (25).    This suggests that acetylation of TDG could 
selectively inhibit glycosylase-dependent transcription while leaving glycosylase-
independent pathways active and potentially provide an additional level of transcriptional 
control to the cell in response to nuclear receptor ligands such as estrogen.  Use of PTM 
to regulate TDG participation in transcriptional processes would be consistent with 
observations that interactions between CBP and some transcription factors may be 
regulated by upstream PTM (17).  For example, phosphorylation of cyclic-AMP response 
element binding protein (CREB) at serine 133 by protein kinase C (PKC) facilitates 
interaction with CBP allowing transcriptional activation (15). 
Another possibility includes use of TDG acetylation as a mechanism for discriminating 
between damaged methylated or unmethylated cytosine residues (26).  Because the 
product of cytosine deamination and 5-methylcytosine deamination are uracil and 
thymine respectively acetylated TDG would permit determination of the undamaged state 
of the lesion because it discriminates between the products of cytosine deamination 
whereas unmodified TDG processes both lesions.  In fact, Metivier et al employed a 
similar principle to distinguish between the products of cytosine or 5-methylcytosine 
deamination in an in vitro assay designed to demonstrate that Dnmt3 deaminates 5-
methylcytosine.  They compared base excision by TDG to that of UNG, a glycosylase 
capable of excising uracil but not thymine mispaired with guanine, on a defined template 
bearing either methylated or unmethylated cytosine residues and were able to show that 
abasic sites were created on methylated templates only when pre-treated with Dnmt3 
catalytic fragments followed by treatment with TDG, indicating that 5-methylcytosine 
had been deaminated and the resulting thymine residue excised (25).  In vivo, acetylated 
TDG could take the place of UDG to facilitate discrimination between formerly 
methylated or non-methylated cytosines.  In this scenario one would expect that TDG 
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would associate with cellular machinery which is competent for methylation of cytosine 
and it was been shown that TDG associates with cytosine methyltransferases Dnmt3a and 
3b (2, 20, 25).  While it remains to be determined whether acetylation of TDG alters this 
interaction our investigations into the properties of acetylated TDG, described in Chapter 
3, show that acetylation of TDG induces conformational changes in the protein which 
alter DNA interactions and these conformational changes may also promote differential 
association with protein complexes in vivo (27).   
In Chapters 3 and 4 we firmly establish phosphorylation as an important PTM in 
regulation of TDG.  Interestingly, we showed in Chapter 4 that treatment of P19 cells 
with PKC agonist PMA increased TDG localization to heterochromatic foci.  Previously, 
separate studies showed that TDG localizes to heterochromatic regions in complex with 
both Dnmt3a and 3b.  TDG was shown to recruit Dnmt3a to DNA in vitro and colocalize 
with Dnmt3a in heterochromatic foci in untreated NIH 3T3 cells (20).  Dnmt3b was 
shown to be necessary for association with heterochromatic minor and major 
periocentromeric repeats in untreated P19 cells (2).  In Chapter 3 we show that 
phosphorylation of TDG reduces acetylation of the protein, preventing loss of G:T 
processing activity (27).  This suggests that phosphorylation would be favorable for TDG 
participation in establishing patterns of cyclical cytosine demethylation on 
transcriptionally active promoters along with Dnmt3a and 3b because it would prevent 
acetyltransferases from stalling transcription by neutralizing TDG before excision of the 
mutagenic mispaired thymine residue.  There is much still to be learned about the 
consequences of TDG phosphorylation and its role in regulating TDG function beyond 
inhibiting acetylation of TDG. 
During analysis of TDG in lysates prepared from P19 embryonic stem cells and mouse 
embryonic fibroblasts by SDS-PAGE fractionation and immunoblotting with a TDG-
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specific antibody we observed a novel shift in TDG mobility consistent with near 
complete sumoylation of the protein.  Interestingly, when we analyzed lysates prepared 
from these cells after entry into senescence, we noted a further discrete alteration in TDG 
mobility similar to that which might be seen upon conjugation of another SUMO peptide 
to TDG (Chapter 4).  Although dual sumoylation of TDG in vivo has not yet been 
described and the TDG peptide contains only one SUMO conjugation consensus site, 
TDG has been shown to be sumoylated by SUMO-3 in vitro (1), and SUMO-3 may be 
sumoylated by SUMO-1 which might explain the two discrete alterations in mobility 
(24).  While only a few proteins are known to be modified by both SUMO-1 and SUMO-
2/3, sumoylation of TDG with either SUMO-1 or -2/3 has been shown to result in similar 
biochemical properties for the sumoylated protein (1).  SUMO-1 and -2/3 do however, 
localize differently within cells (44) and we observed concomitant modification and 
redistribution of TDG in senescent cells suggesting that the second sumoylation event 
may be a signal for relocalization (Chapter 4).  Alternatively, TDG has been shown to be 
polyubiquitinated (9) and it is possible that the observed alterations in mobility may be a 
result of monoubiquitination [see Hardeland et al. (2007) figure 5b lane 4 right panel (9)].  
Further study is required to elucidate this novel mechanism of TDG regulation. 
The findings reported in this thesis, within the context of previous studies done to 
investigate TDG function, have highlighted the amino terminus as a hotspot for PTM and 
protein-protein interactions in addition to being a critical mediator of TDG enzymatic 
function.  Sequence analysis shows that the amino terminus is more evolutionarily 
divergent than the central core of the protein and it appears that function conferred by this 
divergent region correlate with mechanisms of genome regulation being utilized within 
the organism in question.  For example, mammalian TDG is much more efficient at 
excising thymine from G:T mispairs than its Drosophila ortholog which surveys a 
genome possessing almost no DNA methylation (23) and excises thymine mispairs at a 
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physiologically irrelevant rate (8).  Accordingly, discovery of a role for TDG thymine 
glycosylase activity in the process of cyclical demethylation of cytosine indicates that the 
amino terminus plays an important role in facilitating the complex regulatory mechanisms 
of higher organisms.  To date most insights into the structure-function relationship of the 
TDG amino terminus have been gained through indirect evidence based upon partial 
proteolysis and functional assays performed with truncated proteins (10, 28, 37).  Only 
one study describes an NMR-based examination of the TDG amino terminus and the 
authors show that the amino terminus assumes different conformations when examined in 
the presence or absence of the entire TDG peptide (33), suggesting that it is not feasible 
to study this region outside the context of the full molecule.  Furthermore, our 
investigations show that the amino terminus is neither a modular DNA binding domain 
(28), nor sufficient for interactions with PKCα outside of the context of full-length TDG 
(27).  Therefore, the findings outlined within this thesis represent important insights into 
the regulation of TDG and should provide a strong basis for future studies into TDG 
function in cellular and animal models, potentially leading toward use of TDG as a target 
for future therapeutics.  
5.3 Research Impact and Future Directions 
Cancer is a leading cause of death in affluent countries and the number of cases and 
deaths due to cancer are expected to double to over 26 million new cases and 17 million 
deaths per year by 2030 (38).  The etiology of this disease is complex and many factors 
have been found to contribute to carcinogenesis.  This poses a hurdle for 
chemotherapeutics as tumors have proven to be heterogeneous and cells within 
millimeters of each other may react to therapy differently.  Compounding this problem, 
the tumor microenvironment has also been shown to foster carcinogenesis and tumor 
survival (6).  Despite these therapeutic hurdles, there are common traits or hallmarks of 
255 
 
 
 
cancer cells which permit their identification and selective targeting by 
chemotherapeutics.  For example, cancer cells commonly exhibit a tendency toward 
genomic instability and it is thought that as few as two mutations may destabilize the 
delicate balance of homeostasis and facilitate carcinogenesis.  Once transformed, 
malignant cells undergo a number of genomic rearrangements which shuffle the genome, 
contributing to tumor heterogeneity and permitting evasion of normal processes that 
allow apoptosis and necrosis.  For example, sampling of human tumors shows that one of 
the most often damaged genes is that of the p53 DNA damage response protein (30).  
Dysfunction of p53 and other cell cycle arrest genes is significant because they permit 
cell cycling to continue without first repairing damaged DNA, further promoting an 
accumulation of damage (31).  This drastic loss of genomic stability displayed in all 
cancers means that the malignant cells become increasingly reliant on remaining DNA 
repair pathways to prevent complete genomic disintegration.  This has led to the 
widespread use of chemotherapeutics which promote DNA damage to induce apoptosis in 
cancer cells.     
The cancer therapeutic 5-fluorouracil 5-FU is widely used in combination therapy with 
other agents to treat a number of human cancers (21).  In vivo, 5-FU produces metabolites 
such as fluorodeoxyuridine monophosphate (FdUMP), fluorodeoxyuridine triphosphate 
(FdUTP), and fluorouridine triphosphate (FUTP) (21).  FUMP may be incorporated into 
RNA, disrupting RNA metabolism at multiple levels (13) while FdUMP  may be directly 
incorporated into DNA during synthesis, creating A:5-FU or G:5-FU mispairs.  FdUMP 
also causes nucleotide pool imbalances by inhibiting thymidylate synthase (11), which 
produces dTMP from dUMP, thereby increasing production of dUTP at the expense of 
dTTP.  The increasing pools of U and 5-FU are incorporated into DNA and their active 
removal causes fragmentation of the genome as futile cycling of BER creates abasic sites 
which are susceptible to becoming double-stranded breaks (14).  It has been shown that 
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TDG excises 5-FU with high efficiency from G:5-FU and A:5-FU DNA mispairs as well 
as from single stranded DNA in vitro (8).  TDG was also shown to mediate 5-FU toxicity 
in cells (19).   
In light of the important role TDG plays in effecting the cytotoxicity of this widely used 
chemotherapeutic, it may be useful to supplement 5-FU treatment with compounds which 
alter regulation of TDG PTM to favor apoptosis or cell cycle arrest.  Studies are currently 
underway to gauge the effectiveness of agents generally targeting acetylation or 
phosphorylation to treat cancers by use of HDACi or kinase inhibitors alone or in 
combination have shown promise (4, 7, 29, 42).  Previous findings indicating that TDG is 
a major mediator of 5-FU cytotoxicity (19) as well as the findings outlined within this 
thesis suggest that combining 5-FU treatment with pharmacological agents to selectively 
alter TDG PTM and promote 5-FU glycosylase activity may increase effectiveness of 5-
FU-based therapy. 
There has recently been a burst of important findings about TDG function however large 
gaps still exist about how these functions may be regulated and ultimately manipulated in 
vivo.  Significantly, we have described here the existence of novel phosphorylation sites 
on TDG, and the only known examples of stimuli which alter TDG sumoylation and 
association with chromatin.  Additionally, we have shown for the first time that TDG may 
be localized to the cytoplasm in senescent cells and in response to HDACi treatment.  In 
order to most effectively employ TDG PTM-targeting therapeutics to compliment current 
cancer therapy strategies, more must be known about the mechanism by which TDG 
functions and the biological processes which would be affected by such interventions. 
A largely neglected aspect of TDG function is its association with RNA.  In previous 
studies TDG was purified as part of a putative demethylase complex from chick embryos 
and this complex included an RNA component which was assigned no specific role in the 
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demethylation process.  TDG was also found to be present in a complex with Dnmt3a/b 
containing an RNA component.  Although it has been suggested that the CpG-rich 
composition of these RNAs may promote targeting of the complex to CpG islands, the 
nature of any TDG-RNA interaction remains unclear and it has not yet been shown that 
the glycosylase interacts directly with RNA.  Interestingly, TDG residues 94KKSGK98 
resemble an RNA binding motif identified in adenosine deaminases acting on RNA 
(ADAR) 1 and 2 KKXXK (40).  Substitution of lysine residues within the KKXXK motif 
to EAXXA has been shown to abrogate RNA binding in ADAR1 and 2 (40) and may be a 
useful tool to further investigate putative TDG-RNA interactions within these complexes.  
Intriguingly, these conserved residues are also substrates for CBP/p300-mediated 
acetylation which we have shown in chapter 3 to also be regulated by PKC 
phosphorylation.  
Future investigations should be directed toward completing our understanding of how 
TDG PTM regulate TDG function and subsequent PTM.  For example, we have shown 
that sumoylation of TDG reduces acetylation of the protein through allosteric changes in 
the TDG peptide (28), but evidence presented in Chapter 4 indicate that acetylation may 
promote TDG sumoylation.  Based upon the findings of Chapter 4, and close examination 
of previously published data which is discussed above (9), further investigation into the 
possibility that TDG is monoubiquitinated is also required.  Monoubiquitination is a 
widely used PTM regulating diverse cellular processes including gene expression and 
may play a role in regulating TDG function as well (12).  Finding answers to these 
questions is possible using the methods described in this thesis although it would be 
useful to develop antibodies or mass spectrometry methods which are able to detect TDG 
PTM in samples isolated from cells.  Mass spectrometry-based methods would allow the 
detection of modified residues, and can be used to further verify crosstalk between 
modifications.  For example, mass spectrometry of samples isolated from differentially 
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treated cells could be used to verify the mutual exclusivity of acetylation and 
phosphorylation on the amino terminus in vivo (27).   
Modification-specific antibodies could be used to purify modification-specific TDG 
complexes from cells and to examine the subcellular localization of modified TDG.  It 
will be important to capture these complexes and analyze their components in order to 
gain insight into the role TDG PTM play in regulating cellular functions.  Since it is not 
possible to raise antibodies toward sumoylated TDG, we may use TDG(K341R) to 
identify proteins interacting with sumoylated TDG by comparing proteins in complex 
with TDG to those in complex with TDG(K341R) and identifying any not interacting 
with the sumoylation-minus mutant protein.  These may be interacting specifically with 
sumoylated TDG.  However, due to the small amount of S-TDG in most cells, this 
strategy may not be effective.  We have already shown that sumoylation of TDG reduces 
interactions with CBP in vitro and that the SUMO binding activity of TDG is necessary 
for activation of CBP-mediated transcription.  Therefore, we are confident that isolation 
and comparison of various TDG complexes would identify differences in the protein 
complexes formed by TDG and TDG SBM mutants or between TDG and sumoylated 
TDG in vivo. 
Considering the increasing body of evidence for the transcriptional cofactor role of TDG, 
it is essential to identify target genes to gain further insights into its biological functions.  
As described in this thesis, both SUMO-binding and DNA glycosylase activities of TDG 
have been shown to be important for transcriptional regulation (25, 28).  Determining the 
overall compliment of genes activated or repressed by targeting TDG may be achived 
using techniques such as chromatin immunoprecipitation - sequencing (ChIP-Seq) (22) to 
determine which promoters TDG associates with, followed by quantitative PCR (qPCR) 
using cells stably transfected with defined mutants of TDG in order to determine whether 
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loss of TDG function affects gene expression.  Classification of these genes into 
subgroups dependent on specific TDG activities would provide a useful guide for future 
studies into potential therapeutics targeting TDG.  These investigations are now routine 
and may be performed using either modification-specific TDG antibodies or stable cell 
lines transduced with TDG modification mimics for analysis by ChIP-seq and qPCR (22, 
34).  
5.4 Perspective 
As discussed in this thesis, TDG is a critical cellular protein involved in multiple 
physiological processes including maintenance of genomic integrity and transcriptional 
regulation, including removal of epigenetic marks.  Abberant regulation of any of these 
processes has been shown to contribute to disease and carcinogenesis.  Here we have 
shown that TDG is subject to multiple PTM which can dramatically alter TDG function in 
vitro and in vivo.  Furthermore, we describe a unique interplay between PTM of TDG in 
which modified TDG displays differential susceptibility to further PTM.  Interestingly, 
we also show that TDG is differentially regulated in senescent cells and importantly, we 
identify pharmacological agents which can alter TDG PTM in cells.  A useful way to look 
at our findings is that we have identified biochemical switches controlling TDG and that 
future studies will attempt to identify how these switches can be pharmacologically 
regulated to potentially enhance the efficacy of cancer chemotherapy.   
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